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Abstract 
 
Induced pluripotent stem (iPS) cells have the potential to generate a wide array of cell types 
from multiple lineages that enable us to explore the mechanisms that are involved in the 
conversion of cell states. The reprogramming process that generates iPS cells is complex, but 
since its discovery, technical advancements and improvements in the methodology have 
improved the speed and efficiency of generating integration-free, clinically relevant iPS cells. 
However, despite improvements, the mechanisms of reprogramming are not fully 
understood and so the process remains largely inefficient and slow. It has been reported 
that reprogramming mediated through the delivery of exogenous mRNAs encoding OCT4, 
SOX2, KLF4 and cMYC is a fast and efficient method for generating integration-free iPS cells. 
Here we show that mRNA reprogramming can be enhanced further by employing an mRNA 
dose-ramping approach that provides greater control of the dose of mRNA that is introduced 
into the target cells. This improvement upon existing methods promotes the viability of the 
target cells during reprogramming which in turn improves the efficiency, speed and success 
of generating iPS cells. We also show that an optimisation to the reprogramming factor 
cocktail, replacing OCT4 with a fusion between OCT4 and the transcriptional activation 
domain of MYOD1 – called M3O, further improves the kinetics of reprogramming.    
 
Reprogramming disease cells is also possible in that several iPS cell-disease models have 
been established that have successfully modelled aspects of disease development in vitro. 
Here we show the applicability of using the mRNA approach we have developed, on 
neuroblastoma cells and the characterisation of iPS cells reprogrammed from 
neuroblastoma cells using OCT4, SOX2, KLF4 and cMYC delivered using Sendai viral vectors. 
Finally, we demonstrate how human fibroblasts introduced to a vector encoding MYOD1 
causes them to transdifferentiate in to myoblast-like cells without a genomic footprint.  
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Together this data demonstrates how integration-free mRNA can be used to control gene 
expression to direct cell fate through reprogramming and transdifferentiation. This mRNA 
approach provides proof of concept that warrants the testing of other genes to explore their 
function in reprogramming and other pathways that govern cell fate. 
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  Chapter 1. 
General Introduction. 
 
1.1. Human embryonic stem cells  
 
Human embryonic stem cells (hESCs) were first derived in 1998 by Thomson and colleagues and 
represent a unique cell type that can give rise to every cell type in the body as well as possessing 
the capacity for indefinite self-renewal [1]. This pluripotent state is achieved predominantly 
through increasing transforming-growth factor βeta (TGFβ)/Activin/Nodal and FGF signalling 
while repressing BMP signalling that causes hESCs to differentiate [2] (Figure. 1.1). The 
TGFβ/Activin/Nodal pathway signals through SMAD2/3/4 proteins [2] that help to induce the 
transcription of three key transcription factors, OCT4, SOX2 and NANOG, by regulating the 
accessibility of the surrounding chromatin [3]. As chromatin binding sites become accessible, the 
SMAD2/3/4 proteins recruit epigenetic modifiers that modify the binding affinity between 
histones and DNA to allow or restrict transcription of target loci [4]. In addition, the FGF pathway 
uses MEK/ERK signalling to activate gene expression of OCT4, SOX2 and NANOG [4]. These genes 
support the maintenance of hESCs in a pluripotent state by promoting the transcription of genes 
typically expressed in undifferentiated hESCs, by regulating their own expression through an auto 
regulatory feedback loop and by repressing differentiation-inducing genes activated through the 
BMP pathway [5-7]. The BMP pathway signals through SMAD1/5/8 proteins that repress 
pluripotency by inducing the transcription of differentiation-inducing genes [4]. However, the 
activity of SMAD1/5 is repressed via SMAD2/3 from the TGFβ/Activin/Nodal pathway and 
through self-renewal signals from the FGF signalling pathway [8]. This combination of signalling, 
gene repression and activation is tightly regulated and provides the core basis that enables hESCs 
to continuously divide in an undifferentiated state. 
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Figure 1.1: TGFβ/Activin/Nodal signalling utilises SMAD2/3/4 proteins to promote the transcription 
of OCT4, SOX2 and NANOG that support the maintenance of hESCs in an undifferentiated state. 
FGF signalling supports pluripotency through MEK and ERK signalling while repressing BMP 
signalling that uses SMAD1/5/8 with SMAD4 to induce hESCs to differentiate. The pluripotency 
factors OCT4, NANOG and SOX2 regulate themselves and one another in a coordinated way that 
enables the cells to remain in an undifferentiated state and self-renew. 
Figure 1.1. Signalling pathways that support 
pluripotency and self-renewal in hESCs 
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HESCs are derived from the inner cell mass of pre-implantation blastocysts (Figure. 1.2) and once 
explanted can be induced to undergo tri-lineage differentiation i.e. differentiation to the three 
germ layers; endoderm, mesoderm and ectoderm, in vitro or in vivo after injection into severe 
combined immunodeficient mice [1]. Mice injected with hESC lines produce teratomas that 
contain multiple cell types derived from more than one germ layer [1]. Histological analysis of 
teratomas is used to determine the presence of each of the three germ layers to confirm the 
pluripotency status of the injected cells. Alternatively, pluripotency can be assessed in vitro by 
differentiating hESCs in non-adherent cultures to form hESC aggregates called embryoid bodies 
(EBs) [9]. These EBs can be dissociated and analysed by qPCR to detect gene expression levels 
that are characteristic of all three developmental germ layers.  
 
The derivation procedure for hESCs was based on Thomson’s previous work on primate ES cells 
[10]. ES cells derived from rhesus monkey provided a valuable and relevant tool for studying 
primate development being more closely related to humans than ES cells derived from other 
mammals such as rabbits [11], sheep [12], pigs [13] and mice [14]. Primate ES cells and hESCs are 
similar in many aspects including: morphology, cell surface marker expression, differentiation 
capacity and culture conditions required for long-term maintenance of established ES cell lines.  
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Figure 1.2. Derivation of human              
Embryonic Stem cells  
Figure 1.2: Schematic of hESC derivation. The inner cell mass is isolated from the blastocyst and 
plated on to an inactivated mouse embryonic fibroblast (MEF) feeder layer. After 9-15 days the 
inner cell mass is dissociated and re-plated on MEFs as cell clumps for a further 7-10 days to 
establish hESC colonies. 
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Undifferentiated hESCs, like primate ES cells, morphologically resemble flat, epithelial colonies with 
defined colony borders. Both cell types also express Stage Specific Embryonic Antigen (SSEA)-3 [15] 
and SSEA-4 [16] as well as high molecular glycoproteins TRA-1-60 and TRA-1-81 [17] in an 
undifferentiated state and SSEA-1 in response to differentiation [18]. HESCs are routinely passaged 
in clumps of cells as they have poor survival when dissociated as single cells [19] and like primate ES 
cells cannot be maintained in culture as undifferentiated cells without additional attachment factors 
such as a mouse embryonic feeder layer [1]. These characteristics are dissimilar to undifferentiated 
mouse embryonic stem cells (mESCs) and it is possible that hESCs correspond to a state later in 
embryonic development similar to mouse-derived epiblast stem cells [20]. Brons and colleagues 
demonstrated that deriving cells from the epiblast layer of mouse embryos possessed the 
morphological characteristics, capacity to differentiate and cell surface expression profile similarly 
displayed in undifferentiated hESCs [21]. As a result, it is considered that hESCs correspond to a 
primed pluripotent state while mESCs correspond to a ‘naïve’ pluripotent state. In contrast to mouse 
epiblast stem cells mESCs are characteristically different in that they form tightly-packed dome-
shaped colonies and express SSEA-1 in an undifferentiated state [22]. Self-renewal is regulated in 
mESCs via LIF and bone morphogenetic proteins (BMPs) [23] while hESCs require fibroblast growth 
factors and transforming-growth factor βeta (TGFβ) signalling [2].  
 
There are, however, similarities with respect to key genes required for self-renewal of pluripotent ES 
cells. The pluripotent status of both hESCs and mESCs is facilitated by the upregulation of key genes 
OCT4, SOX2 and NANOG which work in synergy to regulate one another [7, 24]. When these genes 
are not expressed in the cells of the inner cell mass during embryo development, pluripotency can-
not be established and instead the cells are trapped in a non-viable, intermediate state [25]. These 
genes, OCT4, NANOG and SOX2, are therefore critical for establishing and maintaining pluripotency 
in ES cells and are equally important in the establishment of iPS cells from somatic cells through 
reprogramming [26]. 
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1.2. Reprogramming to induce pluripotency 
 
Cellular reprogramming refers to the process whereby a somatic cell, such as a fibroblast, is 
artificially induced to become a different cell type through the erasure and remodelling of 
epigenetic marks, such as histones, that result in a shift in the cells gene expression profile [26, 
27]. Yamanaka found that overexpressing four exogenous transcription factors: OCT4, SOX2, 
KLF4 and cMYC in fibroblasts (Figure. 1.3), is sufficient to reprogramme their epigenetic status to 
that of a pluripotent stem cell [26]. Cells generated in this way are called induced pluripotent 
stem cells (iPS cells).  
 
The identity of a cell is stabilised through epigenetic marks that act like switches turning genes 
on or off without affecting the underlying DNA code [28]. These epigenetic marks prevent 
aberrant cell fate changes by maintaining an epigenetic state appropriate to the cell type [29]. 
For example, a fibroblast cell will naturally promote the transcription of sections of DNA that can 
be translated into fibroblast proteins to keep the cell a fibroblast while repressing the 
transcription of non-fibroblast genes by configuring the chromatin structure in a way that makes 
transcription factor binding sites inaccessible. The accessibility of DNA is regulated by the 
chromatin structure which comprises multiple nucleosomes that form when DNA wraps around 
protein molecules called histones [30]. Chromosomes are made up of thousands of nucleosomes 
that are joined together by linker DNA to form chains [31]. The chains of nucleosomes are 
subsequently folded through higher order structures to compact the DNA so that it can fit inside 
the nucleus of a cell [31]. When chromatin becomes loosely packaged, genes can be actively 
transcribed. Conversely when the chromatin structure is tightly packaged, transcription is 
repressed [30]. The opening and closing of chromatin can be facilitated by epigenetic 
modifications such as DNA and histone methylation, acetylation and deacetylation [32]. These 
processes involve the recruitment of transcription activators and repressors such as histone 
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acetyltransferases and histone deacetylases respectively [32]. The accessibility of chromatin 
represents one of several limiting factors to reprogramming [33]. Other limiting factors to 
reprogramming include: 
 
Limiting factor: The epigenetic status of the starting population 
Reprogramming is predominantly an epigenetic process, and epigenetic modifiers have 
fundamental roles in remodelling chromatin in somatic cells so that repressed genes can be 
actively transcribed [33], which facilitates the conversion of cell states. Efficiencies of 
reprogramming in to distinct cell types, for example neurons (~20%)[34] and cardiomyocytes 
(20%)[35] are reportedly higher than reprograming to iPS cells (~0.1%)[36]. Variance in 
reprogramming efficiencies may be attributable to epigenetic barriers, for example transcribing 
genes in areas of inaccessible chromatin, that need to be overcome in order to execute 
reprogramming.  
 
Limiting factor: The NuRD complex 
During somatic cell reprogramming, the gene Zfp281 functions to repress Nanog expression in 
mice by directly recruiting the NuRD repressor complex to the Nanog promoter to inhibit its 
reactivation [37]. In addition, the depletion of ZFN281, the human orthologue to Zfp281, was 
shown in human cells to improve the reprogramming of pre-induced pluripotent stem cells to 
iPS cells [38]. Overexpressing NANOG during somatic cell reprogramming has been shown to 
improve the efficiency of generating iPS cells [39].  However, the NuRD complex represses the 
expression of NANOG and thus represents a barrier to reprogramming. 
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Limiting factor: p53 signalling pathway 
In mouse embryonic fibroblasts (MEFs), p53 can cause apoptosis, promote differentiation and 
induce cell cycle arrest [40]. The p53 pathway is activated in MEFs following the individual and 
collective introduction of the reprogramming factors Oct4, Sox2, Klf4 and cMyc.  Activation of 
the p53 pathway has also been shown to inhibit the reprogramming of human somatic cells [41]. 
Several studies have demonstrated that the p53 pathway acts as a barrier to both human and 
mouse cell reprogramming and that reprogramming kinetics and efficiencies can be improved 
10<100-fold following its suppression [42-44].  
 
Reprogramming of somatic cells in vitro was first demonstrated in 2006 by Yamanaka and 
colleagues in mouse [36] and in 2007 in human [26, 45]. In addition to fibroblasts several other 
human cell types have been shown to be amenable to reprogramming to an ES cell-like state 
including retinal-pigmented epithelial cells [46] pancreatic islet β cells [47] and human neural 
stem cells [48].  
 
The first evidence of reprogramming, however, dates back to the 1960’s [49]. In this study by 
Gurdon [49], differentiated somatic cell nuclei in Xenopus were shown to contain genetic 
information that had an unrestricted capacity for multi-lineage differentiation. This was 
demonstrated by transplanting differentiated intestinal epithelium cell nuclei into enucleated 
frog eggs [49] that gave rise to feeding-tadpoles. While Gurdon demonstrated that a somatic cell 
nucleus can be reprogrammed in a host egg cell via somatic cell nuclear transfer, Yamanaka 
demonstrated that somatic cell reprogramming can be achieved by resetting the epigenetic 
status of a somatic cell through the overexpression of exogenous transcription factors. 
 
Originally, a combination of 24 genes that are highly expressed in mouse ES cells were 
constitutively expressed using a retrovirus to generate iPS cells. It was eventually found that just 
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four factors, Oct4, Sox2, Klf4 and cMyc, were sufficient to reprogramme mouse embryonic 
fibroblasts to iPS cells [36]. Generating iPS cells from human somatic cells is achievable using the 
same four factors [45]. Using lentiviral vectors, Yu et al. showed that a combination of OCT4, 
SOX2, LIN28 and NANOG, substituting KLF4 and cMYC with LIN28 and NANOG, was similarly able 
to reprogramme human fibroblasts to iPS cells [45]. The addition of LIN28 was shown to have a 
modest effect on reprogramming and has been demonstrated to inhibit the let-7 micro-RNA 
(miRNA) that promotes differentiation [50]. The inclusion of NANOG as a reprogramming factor 
was shown to increase the survivability of emerging iPS cells as well as increase the efficiency of 
reprogramming [39, 45]. Generating iPS cells without using cMYC and KLF4 has clinical relevance 
as it may prevent the risk of tumour formation as a result of oncogene reactivation [51]. 
However, the creation of iPS cells involves inducing somatic cells to transition from a 
mesenchymal to an epithelial phenotype, which KLF4 facilitates [52] and is thus important for 
reprogramming. A study by Papapetrou identified that reprogramming MEFs using a three-fold 
relative increase of Oct4 compared to the other reprogramming factors: Sox2, Klf4 and cMyc 
significantly improved the speed and efficiency of reprogramming [53].  
 
IPS cells are characteristically very similar to human embryonic stem cells, possessing the ability 
to undergo tri-lineage differentiation in vitro and by in vivo teratoma forming assays [1]. 
Morphologically iPS cells resemble flat, epithelial colonies much like hESCs and express similar 
cell surface markers SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 that characterise an 
undifferentiated cellular state [1, 26]. There are, however, two benefits to using human iPS cells 
over hESCs. Firstly the ethical dilemma associated with using cells derived from human embryos 
is circumvented. Secondly iPS cells are patient specific therefore issues with donor availability 
and immunological rejection are alleviated, which facilitates their use in autologous therapies. 
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Reprogramming mechanisms and roles of the reprogramming factors  
In general, the efficiency of reprogramming is low in that <1% of somatic cells become fully 
reprogrammed iPS cells whether using lentiviral, episomal, Sendai-viral or RNA methods [54]. 
Initially the perception was that only a small fraction of cells within the starting cell population 
possessed stem or progenitor characteristics that made them amenable to reprogramming, and 
that these cells solely contributed to the generation of iPS cells [55]. However, it has been shown 
through clonal reprogramming assays that cells at different differentiation stages can all give rise 
to daughter cells that form iPS cells [56]. The reason for low reprogramming efficiencies is more 
likely due to the complexity of the process, involving many events and states that cells must go 
through in order to become iPS cells. Reprogramming can either be a stochastic or deterministic 
process in that following the commencement of reprogramming, all somatic cells proceed 
through various cell states at different times or at the same time respectively [56-58]. The stages 
that a fibroblast cell passes through in order to become an iPS cell is summarised below.  
 
Initial sustained overexpression of the four reprogramming factors: OCT4, SOX2,KLF4 and cMYC 
induces local epigenetic changes [28]. The first change that occurs is the repression of 
mesenchymal genes induced by the overexpression of OCT4, SOX2 and cMYC [59]. The 
generation of iPS cells requires somatic cells to undergo a mesenchymal-to-epithelial transition 
(MET), therefore the suppression of genes that support an epithelial-to-mesenchymal transition 
(EMT) is required [28]. To achieve this, OCT4 and SOX2 repress the transcriptional regulator 
SNAIL that represses the promoter region of epithelial genes such as E-cadherin (CDH1) [60] 
while cMYC represses TGFβ1 and TGFβ receptor 2 that also support the EMT [52].  
 
This is followed by the acceleration of the cell cycle mediated by cMYC through enhancing the 
production of elongating forms of RNA polymerase II to facilitate the transcription of cell cycle 
associated genes [61]. The cell cycle can also be accelerated by overexpressing LIN28, a non-
 
22 
essential reprogramming factor that has been shown to improve reprogramming kinetics 
through enhanced translation of cell cycle associated proteins [62]. A further role of cMYC is to 
cooperatively work with the OCT4, SOX2 and KLF4 reprogramming factors to improve overall 
chromatin accessibility [58]. Initially cMYC engages accessible chromatin which opens up 
transcription factor binding sites on target loci for OCT4, SOX2 and KLF4 to bind which in turn 
permit cMYC to bind to target loci in previously inaccessible chromatin [63]. Improving 
chromatin accessibility permits the binding of exogenous transcription factors that facilitate the 
establishment of an endogenous pluripotency network [59].   
 
The suppression of the EMT alleviates the repression of epithelial genes which allows KLF4 to 
directly induce expression of epithelial genes such as E-cadherin (CDH1) to support the MET [52]. 
At this point, iPS cell intermediates begin to emerge that are dependent on sustained 
overexpression of the reprogramming factors [64]. In the later stages of reprogramming the cells 
become less reliant on the reprogramming factors to induce pluripotency as they begin to 
establish their own endogenous pluripotency network [65]. Finally, epigenetic modifications 
associated with pluripotency are re-established while DNA methylation patterns associated with 
somatic cells are erased [59]. The resultant iPS cells display characteristics and morphology 
specific to pluripotent stem cells including the capacity to differentiate to derivatives of all three 
germ layers.  
 
As a result of the complex reprogramming process, most cells do not become fully 
reprogrammed iPS cells and the resultant reprogramming efficiency is low [54]. It has been 
shown that overexpression of NANOG can enhance the efficiency of reprogramming [39, 45], 
potentially by improving the ability for iPS colonies to form at very low cell densities [66]. The 
role of NANOG may also be important during the late stages of reprogramming in supporting iPS 
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cells to maintain a pluripotent state through signalling mechanisms previously described and 
illustrated in Figure 1.1.  
 
1.2.1 Improving the methodology and efficiency of reprogramming 
 
The process of reprogramming is very inefficient. In original protocols only 0.01% of 
fibroblasts were reprogrammed [45]. Considering iPS cells can be aberrantly, partially or fully 
reprogrammed with fully reprogrammed cells being the only type capable of multi-lineage 
differentiation [64], low efficiencies reduce the chance of generating high quality, fully 
reprogrammed iPS cells. This impacts their use in clinical applications hence, researchers 
have tried to enhance reprogramming through for example, using non-integrating methods, 
reducing the number of factors, use of cell permeable proteins and by using small molecules 
[67]. 
 
Relaxing the chromatin structure in somatic cells has also been shown to increase 
reprogramming efficiency [68].  There are two forms of chromatin, heterochromatin and 
euchromatin that function to silence or enable gene transcription respectively and can be 
remodelled by chromatin modifying proteins [69]. It has been shown that a fusion protein 
between OCT4 and MYOD (called M3O) more effectively recruits chromatin modifying 
proteins, than OCT4 alone, to pluripotent loci during reprogramming [68]. This allows for 
genes such as OCT4, NANOG and SOX2 that are not endogenously expressed in somatic cells 
to be more actively transcribed.  
 
In addition to making reprogramming more efficient, researchers have also tried to simplify 
the process and reduce the number of transcription factors to less than the original four. For 
example, human neural stem cells have been reprogrammed using OCT4 alone that is made 
 
24 
possible as human neural stem cells endogenously express SOX2 and cMYC [48]. The study 
demonstrated that less than the original four reprogramming factors (OCT4, SOX2, KLF4 and 
cMYC) could efficiently reprogramme cells that already endogenously express one or more 
of the reprogramming factors.  
 
Coupled with broadening the range of reprogrammable cell types and factor combinations, 
advances in the development of integration-free reprogramming methods [70-72] have 
been the focus of intense research with the aim of generating integration-free iPS cells that 
can be used in therapeutic applications. Initially, reprogramming methods relied on highly 
efficient gene transfer using genome-integrating retroviral and lentiviral vectors [1, 26]. 
These integrating vectors randomly integrate into the host genome and can cause 
insertional mutagenesis, potentially activating proto-oncogenes which can lead to the 
formation of tumours [73]. As a result, the risk of insertional mutagenesis and oncogene 
activation in iPS cells derived using viral delivery methods renders the method unsuitable for 
generating clinically relevant cell types.  
 
Non-integrating viruses such as the Sendai virus [70] or DNA-based methods such as 
episomal vectors [72] plasmids [74] or protein transfection [75] and also mRNA transfection 
[76] have been successfully used for reprogramming. DNA-based episomal vectors are virus 
free and operate extra-chromosomally avoiding the possibility of genomic integration. The 
reported reprogramming efficiencies, however, are extremely low, ~0.0003% [28], possibly 
due to the low establishment efficiency of colonies containing stably introduced episomes 
(~1% of transfected cells) [77]. With respect to plasmids and other DNA-based strategies to 
reprogramming, the risk of integration is ever-present [78-81] and these methods suffer 
from low efficiencies. Sendai virus and mRNA based integration-free reprogramming are the 
most efficient ways of reprogramming [54], both devoid of any DNA and hence removing the 
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risk of genomic integration. The Sendai virus contains a sequence-sensitive RNA replicase 
[81, 82] that catalyses the replication of RNA in the cytoplasm of transduced cells. However, 
mutations within this sequence can occur, conferring temperature sensitivity to the virus 
resulting in defective transcription and viral replication [70, 82, 83]. It is also very difficult to 
remove Sendai viral vectors from iPS cells derived using the Sendai virus [81], making 
informative analyses on such cells difficult without performing extensive genetic screening. 
While the use of Sendai virus vectors requires a P2 safety laboratory that may not be 
available in all facilities, Sendai virus reprogramming is now a standard method in many 
reprogramming laboratories, due to its commercial availability, high efficiency and 
reproducibility. 
 
Besides the Sendai virus method, a further advanced mRNA-based approach reported by 
Warren et al [34] provides a virus-free, integration-free, faster and highly efficient way of 
generating human iPS cells. This mRNA reprogramming method involves introducing 
exogenous mRNAs encoding pluripotency factors in to somatic cells to induce pluripotency 
with high efficiency and speed [76]. One of the previous barriers to using in vitro transcribed 
mRNAs for reprogramming was the inability to sustain high levels of ectopic expression over 
time. This was partially attributable to the fact that single stranded mRNAs elicit an 
intracellular interferon immune response [76, 84] that involves the active transcription of 
over 300 immunosuppressant genes [85] which have been reviewed to cause widespread 
cell death via RNA cleavage [86]. In order to overcome this, Warren et al [34] modified 
mRNAs by substituting conventional triphosphates CTP and UTP for 5-methylcytidine (5M-
CTP) and pseudouridine (pUTP) respectively (Figure. 1.4) during in vitro transcription 
reactions. Modified nucleotides have altered chemical structures compared to their normal 
counterparts to confer resistance against nucleases that rapidly degrade mRNAs [87]. To 
further prevent the intracellular interferon response the transfection medium was 
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supplemented with B18R (Figure. 1.4), a recombinant protein that binds interferon [88]. 
Warren found that by incorporating modified nucleotides in mRNAs and supplementing 
reprogramming medium with B18R sufficiently mitigates cell death, induced by the repeated 
addition of mRNAs, to enable levels of exogenous mRNA to be sustained for a length of time 
required to generate iPS cells. In this study, the reprogramming efficiency of mRNA-
mediated reprogramming was ~ 1% and offers a quick and efficient, integration-free method 
for generating iPS cells [39]. 
 
Warren et al further showed through hierarchical clustering analysis that mRNA-
reprogrammed iPS cells more closely relate to the transcriptional profile of hESCs than 
virally-mediated iPS cells [76], potentially owing to the absence of transgenes. Sendai-
derived transgenes can be diluted from the reprogrammed cells over multiple cell divisions 
offering an advantage over retroviral and lentiviral methods [89]. Both the mRNA-based 
reprogramming method and the Sendai virus method negate the risk of genomic integration 
as post-transcriptionally modified mRNAs operate in the cytoplasm outside of the nucleus. 
Furthermore mRNAs are rapidly degraded owing to deadenylation [90] and endonuclease-
mediated mRNA decay [91] which is advantageous over other methods that require excision 
of viral vectors and extensive genetic screening to purge the cells after reprogramming. In 
summary, mRNA-mediated reprogramming offers an efficient and safe way for generating 
iPS cells, however the methodology is technically demanding and requires optimisation 
compared to Sendai virus reprogramming.  
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Figure 1.3. A simplified process for creating iPS 
cells through mRNA-mediated reprogramming 
Figure 1.3: Schematic of iPS cell derivation using mRNA. Reprogramming is typically performed 
by introducing exogenous mRNAs encoding OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG into 
somatic cells. The entry of mRNA into somatic cells is facilitated by a lipofectamine-based 
transfection reagent, Stemfect (Stemgent, 00-0069). Repeated delivery and sustained 
overexpression of mRNAs in somatic cells induces epigenetic changes that lead to the 
establishment of an endogenous pluripotency network, resulting in the generation of iPS cells.  
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Figure 1.4. Preventing mRNA degradation via 
transcriptional modifications and B18R 
Figure 1.4: mRNA modifications and proteins that prevent mRNA degradation. mRNA can be 
modified to prevent premature degradation through (i) the incorporation of modified  
nucleotides, (ii) mRNA capping at the 5’ end and (iii) the addition of a PolyA tail. (iv) B18R, a 
protein that contains a mimic IFN-1 receptor, can be added with mRNAs to repress the 
induction of an intra-cellular interferon immune response by specifically binding to IFN-1 
molecules. 
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1.3. Disease modelling 
 
Disease models provide a platform that allows for the initiation and development of diseases to 
be assessed both in vivo and in vitro. Disease models created in animals are often used to 
recapitulate aspects of human diseases as Homo sapiens share interspecies genomic similarities 
with animals such as mice [92], zebrafish [93] and Drosophila [94]. Such disease models provide 
a platform for both drug screening and research into the pathogenesis of a disease so that a 
greater understanding of how the disease develops can lead to the generation of therapies and 
cures. Disease models are often used for screening drugs as their effect on disease-affected cell 
types can be assessed, as reviewed by Hackam and Redelmeier [95] and Perel et al [96], with the 
intention of translating successful results into human clinical trials. The hope is that positive 
results obtained from in vivo studies will similarly induce a desirable effect in humans and thus 
generate novel therapeutic agents. However, on the majority of occasions clinical trials that 
were based on results translated from successful in vivo studies have proved unsuccessful [97, 
98]. A recent review summarises that less than 8% of animal models have translated successfully 
into phase I clinical trials [99]. The failure rate may be attributable to physiological and 
molecular differences that exist between animals and humans, which ultimately limit the 
number of aspects of human biology that can be modelled through in vivo studies. While animal 
models without question remain an essential pre-clinical assessor of drug safety, the differences 
in pharmacokinetics, drug metabolism and excretion, mean that caution should be exercised 
when extrapolating data from animal models to understand human disease.  
 
The discovery of hESCs and the generation of patient-specific pluripotent stem cells [26, 45] has 
improved our ability to model aspects of human disease development in vitro. Disease models 
can be created by reprogramming the somatic cells of a diseased patient to a cellular state that 
precedes that associated with the disease [100-102]. The subsequent differentiation of these 
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cells to the cell of origin from which a disease develops provides an in vitro system that allows 
for the assessment of the consequences of forcing the genome to operate in the context of a 
distinct lineage. Disease models also provide a drug-screening platform that facilitates the 
identification of novel therapeutic targets [103]. IPS cells lend themselves well to disease 
modelling for a few reasons. Firstly, the creation of iPS cells is not limited by the availability of 
donors and in vitro disease models can be created from a patients fibroblasts [26], retinal-
pigmented epithelial cells [46] pancreatic islet β cells [47] or neural stem cells [48]. Secondly, iPS 
cells can generate an abundance of cellular material unlike somatic cells that have a reduced 
capacity to proliferate because of low telomerase activity [104]. Thirdly, genetic mutations 
harboured in the somatic cells of a patient with a genetic disease carry over in to iPS cells 
following reprogramming [100], which allows for drug screening and the pathophysiology of 
diseases to be studied.  
 
Currently disease models for several diseases have successfully been established including those 
for spinal muscular atrophy (SMA) [100], Down’s syndrome [101], several gastrointestinal 
cancers [105], schizophrenia [106] and long QT syndrome [107]. While SMA and long QT 
syndrome are associated with single mutations in the SMN1 and KCNQ1 genes respectively, 
some diseases such as schizophrenia and cancer involve a more complex interplay between 
genetic and epigenetic events [102]. When this is the case, disease models can help elucidate 
the effect of inducing and inhibiting disease related genes to gain insights into the mechanisms 
that govern disease development. Importantly it has been demonstrated that key genes involved 
in schizophrenia such as NRG1 are not ubiquitously expressed in all host-derived cell types [106] 
stressing the importance of analysing phenotypic changes on the cell type relevant to the 
disease and not necessarily the iPS cells from which they were derived. This can often be a 
problem when the method to differentiate an iPS cell to the relevant cell type is unknown.  
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An additional problem with in vitro disease models is that diseases often affect multiple cell 
types and tissues that interact with one another to contribute to the pathogenesis and effects of 
a disease [108, 109]. Recapitulating these interactions in vitro is complex and therefore iPS cell 
disease models tend to focus on modelling a small aspect of a disease, such as modelling in the 
context of a distinct lineage, rather than the disease as a whole [52]. Epigenetic and aberrant 
genetic changes may also contribute to the pathogenesis of a disease. While it is difficult to 
transfer the epigenetic status of a disease cell to an iPS cell, owing to the erasure of the 
epigenetic landscape following reprogramming, there is evidence to suggest that transcription-
factor derived iPS cells can harbour an epigenetic memory that is characteristic of their somatic 
cell of origin [110]. The inheritance of an epigenetic memory may influence an iPS cell’s ability to 
differentiate because, for example, DNA methylation signatures drive the iPS cells to 
differentiate along pathways related to the parental cells [110].  
 
Many of the currently established disease models including those aforementioned (SMA, Down’s 
syndrome, several gastrointestinal cancers, schizophrenia and long QT syndrome) were 
generated through the use of integrating viruses. Whilst disease models do provide a valuable 
platform to study disease development, informative disease models rely on accurately analysing 
the functional effect that disease specific mutations have on normal development, a feature 
which is compromised by the presence of transgenes created by genomic integrations [111]. 
Transgenes undesirably affect the developmental potential and differentiation capacity of iPS 
cells, demonstrated by injecting transgene-containing iPS cells into murine blastocysts that 
formed embryos that displayed severe morphological abnormalities attributable to an inhibited 
ability to undergo tri-lineage differentiation [111]. A further undesirable effect of integrating 
methods is the possibility for oncogenic transgene reactivation which can occur if viral particles 
integrate downstream of nearby gene promoters [73]. As mRNA-derived iPS cell lines are 
advantageously footprint free and circumvent issues relating to insertional mutagenesis, it 
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suggests that disease models can be made more informative when generated using techniques 
that maintain genomic integrity, such as mRNAs. 
 
1.4. Neural Crest 
 
In normal development, neural crest cells are derived during neurulation (Figure. 1.5) following 
the formation of the three germ layers. Inductive signals, specifically the inhibition of bone-
morphogenetic protein, specify a portion of the ectoderm to thicken to become neuroectoderm 
[112]. The neuroectoderm is separated from the non-neural ectoderm by neural plate borders 
which exhibit intermediate levels of BMP signalling [113]. This is in contrast to the devoid and 
elevated levels of BMP found in the neural plate and non-neural ectoderm respectively [113]. 
Ultimately, a BMP gradient is established across the neural plate that specifies different neural 
fates dependent on the dose of BMP [114]. The neural plate border is further distinguishable via 
elevated levels of fibroblast growth factors (FGFs) [115] and activation of canonical WNT 
signalling [116, 117] induced by the adjacent epidermis and paraxial mesoderm. After ectoderm 
specification the neural plate converges as a result of inductive signals from the notochord [118] 
and via apical constriction which is regulated by the expression of SHROOM [119]. The neural 
plate borders subsequently fuse together forming the neural tube that separates from the 
overlying ectoderm. The neural plate borders now reside as a population of neural crest cells on 
the most dorsal part of the neural tube. As the neural tube fuses, the neural crest cells 
delaminate and migrate along specific pathways to peripheral targets. A study on focal labelling 
of migrating neural crest cells showed that delamination tends to be directed in streams along 
rostrolateral and caudolateral trajectories [120]. Within this study and one follow up study [121] 
migration to and from the dorsal midline, wandering between rhombomere boundaries and 
attractions to neighbouring cells suggests that neural crest cell migratory pathways are at least 
partially controlled by cell-to-cell contacts. Differences in migration pathways between 
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populations of neural crest cells from different regions along the anteroposterior axis and from 
the same region suggest a level of heterogeneity with regard to guidance cues [120, 121]. Neural 
crest cells that populate the anterior end of this axis differentiate into derivatives different from 
those positioned more posteriorly. As the geographical location correlates with the type of 
neural crest derivatives formed, subcategories of neural crest populations; cranial, trunk, vagal 
or sacral are used to identify the various phenotypes [122]. During migration the neural crest 
cells develop integrin receptors that interact with extracellular matrices and trophic factors such 
as neural growth factor (NGF) to permit continued proliferation and migration [123, 124]. Upon 
reaching the final migratory destination, the neural crest cells differentiate into derivatives 
appropriate to the target site. A surplus of neural crest cells are available for differentiation into 
target cell types to ensure that sufficient physiological development can occur [125]. Excess 
neural crest cells that are surplus to requirement for differentiation into target cell types are 
then targeted for apoptosis via the withdrawal of NGF [125, 126].  
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Figure 1.5: Neural crest cells reside in the neural plate border (NPB) that sits between the 
neuroectoderm (NE) and the non-neural ectoderm (NNE). These tissues are separated by a 
BMP gradient: NE = BMPlow, NPB = BMPmed and NNE = BMPhigh. Inductive signals from the 
notochord induce the neuroectoderm layer to thicken and form the neural plate. As the neural 
plate is drawn downwards, neural folds converge and pinch together to form the neural tube. 
Neural crest cells reside at the uppermost part of the neural tube and are specified by 
numerous genes: SHROOM, FOXD3, SLUG/SNAIL, cMYC, SOX9, Id and SOX10. Closure of the 
neural tube causes the neural crest cells to detach from the overlying epidermis allowing them 
to migrate and differentiate into specialised cells. 
Figure 1.5. Neurulation and the                
formation of the neural crest 
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1.5. Neuroblastoma 
 
Recently we have generated a set of iPS cells from a neuroblastoma cell line called SK-N-SH, 
using lentivirus and Sendai virus reprogramming methods (unpublished work by Christian 
Unger). Neuroblastoma is the most common, extracranial, solid childhood tumour that can arise 
anywhere along the sympathetic nervous system chain although most commonly in the adrenal 
medulla [127]. While the underlying mechanisms for neuroblastoma initiation and progression 
are largely unknown, in vivo mouse models have begun to identify genes and factors that 
predispose neuroblastoma tumorigenesis [128]. In humans, genetic mutations in genes that 
regulate neural crest development including MYCN [129], PHOX2B [130] and ALK [131] 
contribute to an array of neurocristopathies including Hirschsprung disease [130, 132], 
congenital central hypoventilation syndrome [133] and neuroblastoma [134-137]. Modelling the 
effects of these mutations on neural crest cells within in vitro models may provide further 
insights into the development of neuroblastoma. These models could provide a platform for 
drug discovery and further insight into the aetiology and possible prevention of this malignant 
disease. 
 
Neuroblastomas arise from cells that originate from the neural crest, a population of 
multipotent cells that can differentiate into a wide array of derivatives including craniofacial 
bones, melanocytes, chromaffin cells of the adrenal medulla and neurons and glia of the 
sensory, sympathetic and parasympathetic nervous system [138]. Normal development of neural 
crest cells is perturbed following the acquisition of mutations, for example in the mouse, somatic 
mutations in Myc-n [134] and germline mutations in Phox2b [135, 136] have been found to 
contribute to the abnormal development of cells derived from the neural crest, such as 
sympathetic ganglion cells, as has ALK mutations in humans [137]. Phox2b is functionally 
associated with regulating sympathetic neuronal differentiation [130]. Knockdown of 
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endogenous Phox2b has been functionally demonstrated in mouse, chick [135] and zebrafish 
models [136] to impair neuronal differentiation while neuroblastoma Phox2b variants have been 
shown to enhance sympathetic neuron proliferation and dedifferentiation [135]. Overexpression 
of Myc-n under the control of a tyrosine hydroxylase promoter in transgenic mice has been 
shown to initiate neuroblastoma pathogenesis [134] and is considered a primary oncogenic 
abnormality. In this study, the transgenic mice formed tumours after a period of latency 
indicating the involvement of other contributing factors in neuroblastoma development. One 
contributing factor is the resistance of neuroblastoma precursor cells to NGF withdrawal [139]. 
In SW-13 epithelial cells this is mediated through pleiotrophin-binding to ALK receptors [140]. 
Resistance to NGF withdrawal within the latent period after MYCN overexpression [141] 
indicates the role of ALK in tumour progression rather than tumour initiation. The 
overexpression and missense mutations of ALK have also been demonstrated to enhance the 
proliferation of cells that harbour these abnormalities [137, 142]. The survival of neuroblastoma 
cells in the absence of NGF is aided by further oncogenic changes such as the overexpression of 
BCL-2 [143]. 
 
1.6. mRNAs as a tool for directing cell fate 
 
Creating differentiated cell types that can be used to model aspects of disease development can 
be achieved by differentiating iPS cells that have been reprogrammed from a diseased somatic 
cell. An alternative way of obtaining differentiated cell types directly is through 
transdifferentiation. Transdifferentiation is the process whereby a somatic cell directly converts 
to a cell of a different lineage without passing through an intermediate pluripotent state. 
Transdifferentiation of fibroblasts has been extensively reported to lineages including neurons 
[144, 145], cardiomyocytes [35] and striated muscle cells [146] highlighting the amenability of 
fibroblasts to be reprogrammed to an altered cell fate. While iPS cells are beneficial for creating 
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endless supplies of cellular material, transdifferentiation offers a quicker more high-throughput 
alternative for isolating differentiated cell types. Transdifferentiation was first discovered in the 
1970’s whereby 5-azacytidine or Decitabine (5-aza-2’-deoxycytidine)-treated C3H10T1/2 mouse 
embryonic fibroblasts directly converted to adipocytes, chondrocytes and contractile striated 
muscle cells [146]. Decitabine is a drug that acts as an epigenetic modifier by remodelling 
chromatin through the inhibition of DNA methyltransferase, an enzyme that methylates gene 
promoters to repress gene expression [147]. Typically, exposing cells to Decitabine induces 
hypomethylation that causes repressed genes to become active. It has been shown that mouse 
embryonic fibroblasts exposed to Decitabine causes them to transdifferentiate to a myoblast 
phenotype at a conversion frequency of around 25% attributable to either a single or a select 
few demethylation events [148]. Weintraub went on to show that transfecting the DNA of 
transdifferentiated myoblasts into normal mouse embryonic fibroblasts mediated myogenic 
conversion [149]. Weintraub and colleagues compared myocyte-related gene expression 
between proliferating mouse embryonic fibroblasts and myoblasts revealing three candidate 
genes responsible for myogenic conversion. Upon cDNA transfection of the three candidate 
genes into normal mouse embryonic fibroblasts they identified demethylation at the MYOD1 
locus as a master regulator for myogenic conversion [150].  
 
Transdifferentiation of mouse embryonic fibroblasts to myoblasts has been achieved using a 
single defined factor, MyoD1, by cDNA transfection [150], lentivirus [151] and retrovirus [152]. 
In these studies, adding exogenous MyoD1 to mouse embryonic fibroblasts activated 
endogenous MyoD1 gene expression resulting in the formation of myoblasts. This is attributable 
to MyoD1 being a transcription factor that regulates the transcription of other muscle related 
genes, for example, Myogenin and Cx43, that are required for myoblast conversion from non-
muscle cells [151]. Transdifferentiating fibroblasts to myoblasts has been established in several 
systems with high conversion frequencies compared to the low efficiencies when converting 
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fibroblasts to, for example, cardiomyocytes (16% conversion frequency) [35] or neural crest (3% 
conversion frequency) [93]. The reported myoblast conversion frequencies from mouse 
embryonic fibroblasts when delivering MyoD1 by lentivirus was ~50% [111], by retrovirus ~5% 
[112] and following transfection of MyoD1 cDNA, ~50% [87]. To date there is no report of 
transdifferentiation of specifically human fibroblasts to myoblasts using mRNA encoding 
MYOD1. However, very recently a study demonstrated an mRNA method that successfully 
transdifferentiated C3H10T1/2 mouse embryonic fibroblasts to myoblasts through the repeated 
addition of murine MyoD1 mRNA [153]. In that study, the conversion of fibroblasts to myoblasts 
occurred within eight days, comprising a three-day transfection phase and a five-day 
transdifferentiation phase. However, the conversion frequency and the capacity of the 
myoblasts to form multinucleated myotubes was not reported.  
 
Warren et al [76] demonstrated that iPS cells, but not fibroblasts, could be differentiated to an 
intermediate cell type that would transdifferentiate to myoblasts following the repeated 
introduction of human MYOD1 mRNA. In that study, a validated mRNA-reprogrammed iPS cell 
line was differentiated for 28 days under conditions whereby fibroblast growth factor (FGF) had 
been removed, serum added and the cells were plated directly onto gelatine-coated dishes. 
After 28 days, mRNA encoding MYOD1 was introduced into the cells daily for three days 
followed by three days culture in a low serum medium. At the end of the 34-day process, cells 
expressed myoblast-associated markers, myosin heavy-chain (MyHC) and Myogenin. 
 
In addition to the transdifferentiation study performed by Warren et al involving MYOD1, 
several other experiments have utilised alternative factors, all delivered via lentiviral vectors, to 
convert somatic cells into alternative cell types. These experiments include using combinations 
of Brn2, Ascl1 and Myt1l together to convert mouse fibroblasts into functional mouse neurons 
[144, 145], Gata4, Mef2c, and Tbx5 together to convert mouse post-natal cardiac and dermal 
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fibroblasts into mouse cardiomyocytes [35] and OCT4 in combination with a specific cytokine 
treatment to convert human dermal fibroblasts into human hematopoietic cells [154].  
 
Recently, the overexpression of SOX10 in human fibroblasts in the presence of epigenetic 
modifiers and growth factors was found to be sufficient to induce a neural crest phenotype 
[155]. Initially, the fibroblasts were differentiated from a hESC line containing a doxycycline 
regulated inducible system for SOX10-eGFP. After 14 days of SOX10 induction in the presence of 
growth factors, laminin / fibronectin and/or the addition of 5-azacytidine, the culture was sorted 
for green fluorescing cells with varying frequencies of neural crest conversion. Utilising 
combinations of the aforementioned parameters resulted in conversion frequencies to putative 
neural crest cells ranging from 0.01% to 0.5%. These induced neural crest cells showed 
immunoreactivity to neural crest markers P75, HNK1 and AP2α, exhibited a morphology 
characteristic of neural crest cells and could be further differentiated to peripheral neurons, 
Schwann cells and melanocytes. This study highlights that the introduction of a single gene can 
convert fibroblasts to neural crest cells and postulates that other lineages may be derived 
following the introduction of lineage-specific master regulatory genes.  
 
The vast majority of transdifferentiation experiments have utilised viruses as a means of 
delivering transdifferentiation factors into cells. These factors are often combined with 
epigenetic modifiers such as 5-azacytidine, Decitabine or enhancers of virus-mediated gene 
transfer such as polybrene, which incorporate into the DNA of the host cells. However due to the 
risk of viral-based methods introducing undesirable mutations it is more beneficial to generate 
differentiated cell types using non-integrating techniques, such as the use of transient 
transfections with mRNA, that maintain genomic integrity.  
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1.7. Aims and Objectives 
 
AIM 1 
 
To develop a reproducible mRNA-based reprogramming method with improved efficiency and 
kinetics that generates fully reprogrammed iPS cells from fibroblasts. 
 
Reprogramming methods for producing human iPS cells, using mRNA to introduce the 
reprogramming factors in a transient manner, are currently inefficient and slow. We sought to 
establish a gold standard for reprogramming by using the commercially sourced Stemgent mRNA 
reprogramming kit (00-0071) to reprogramme human BJ fibroblasts, a cell line that has been 
reported by Stemgent to generate iPS cells efficiently using their system. We confirmed that the 
Stemgent system is effective as claimed, and established a benchmark from which to improve 
the technique. We tested technical and methodological improvements, such as mRNA dose-
ramping, as well as alternative reagents such as the 6-factor reprogramming premix (ABP-SC-
6FMRNA), Allele Biotech’s in vitro transcription templates (ABP-SC-SEIPSET) and modified 
nucleotides, to increase our control over variables that affect the efficiency and speed of the 
reprogramming process.  
 
AIM 2 
 
To test whether the mRNA integration free approach can be used to reprogramme an 
established neuroblastoma cancer cell line to a pluripotent stem cell state despite its 
disrupted, cancer-associated genome, in order to establish a model in which to study the 
mechanisms by which that cancer genome leads to the formation of malignant 
neuroblastomas from neural crest precursors.  
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A neuroblastoma cell line, SK-N-SH, had been previously reprogrammed in our group to an iPS 
cell state using a lentivirus vector system.  However, these cells continued to retain the 
integrated reprogramming genes with significant expression that could compromise their use to 
investigate neural crest differentiation and the ways in which this may be perturbed by the 
genetic changes that characterise the neuroblastoma genome. Successful reprogramming of SK-
N-SH cells using the non-integrating mRNA approach would obviate this difficulty. As a 
contingency to the SK-N-SH cell line proving to be refractory to reprogramming using mRNAs, we 
used the Sendai virus system to reprogramme the SK-N-SH cell line. We then characterised and 
sought to differentiate these iPS cell lines to the neural crest, to see if this provides insights into 
the factors underlying the development of neuroblastoma.   
 
AIM 3 
 
To demonstrate that mRNA can be used to provide a transient signal that can direct cell fate 
by transdifferentiating somatic cells via the repeated addition of lineage-specific mRNA. 
 
Modulating gene activity by transient expression of specific transcription factors is an attractive 
approach both for analysing mechanisms of cell fate determination during differentiation as well 
as providing practical tools for generating specific cell types.  The technique of transfecting 
mRNAs encoding specific transcription factors that we are using to reprogramme somatic cells to 
iPS cells could equally be used to modulate other phenotypic conversions.  The observation that 
overexpression of MYOD1 in fibroblasts will convert them into myoblasts is well documented 
and provides a convenient test system for demonstrating that mRNAs can be used to effect 
transdifferentiation. In this case myoblast conversion typically requires the overexpression of a 
single factor, MYOD1 and the conversion of somatic cells to myoblasts occurs at a high 
frequency compared to transdifferentiation studies on other cell types such as the neural crest. 
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Although MYOD1-mediatedtransdifferentiation of mouse fibroblasts using non-integrating 
techniques has been reported, this methodology has not yet been shown in the context of 
human somatic cell conversion. 
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Chapter 2. 
Materials and Methods. 
 
2.1. Gelatinisation of Cell Culture Vessels 
 
T25 tissue-culture treated vessels (ThermoFisher, 156367) were coated with a solution containing 
500mg of gelatine type-A (Sigma, G2500) which had been diluted in 500ml of sterile water (0.1% 
vol/vol) for 30 minutes. When the culture vessels were required for cell culture, the gelatine was 
removed and replaced with the appropriate cell culture medium. 
 
2.2. Mouse Embryonic Fibroblast preparation 
 
2.2.1. Generating p0 Mouse Embryonic Fibroblasts 
 
Mouse embryonic fibroblast were obtained from MF1 outbred mice, killed using approved 
Schedule 1 procedures. The processes used abide by the criteria and guidelines set out in 
The Humane Killing of Animals under Schedule 1 to the Animals (Scientific Procedures) Act 
1986 [156]. Pregnant females (10.5-12.5 days post coitum) were killed by cervical dislocation 
and the foetuses by decapitation. After evisceration in a petri dish, the foetuses were 
minced and then further dissociated using 0.25% trypsin-EDTA (Sigma, T4049) into single 
cells, which were seeded into tissue culture flasks at a ratio of one foetus per T75, in DMEM 
with 10% FCS. The cells were cultured until the resulting fibroblasts formed a confluent 
layer, when they were harvested and frozen at -80°C in a Nalgene Mr. Frosty freezing 
container (ThermoFisher, 5100-0001). The aliquots were transferred to liquid nitrogen for 
long-term storage.  
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2.2.2. Mouse Embryonic Fibroblast Inactivation 
 
Two aliquots of primary MEFs (passage zero) were defrosted into three T75 cell culture 
vessels (ThermoFisher, 156472). These were passaged in DMEM (Sigma, D5546) containing 
10% HyClone™ FBS (GE Healthcare Life Sciences, SH30071.03) and 1% bFGF (R&D Systems, 
AFL233) at a 1:3 ratio into three T175 cell culture vessels (ThermoFisher, 159920). The MEFs 
were continually passaged every two days or when confluency was reached until they 
reached p5. The fibroblasts were mitotically inactivated by a 2 hour incubation with 1mg/ml 
Mitomycin-C (Sigma, M4287) in batches of six T175’s. The Mitomycin-C was then removed 
and the inactivated MEFs were washed two or three times with 1X Dulbeccos PBS (Sigma, 
D8537). They were then trypsinised with 0.25% trypsin-EDTA for 1-2 minutes at 37°C and 
then neutralised with DMEM containing 10% FBS. The inactivated MEFs were pelleted by 
centrifugation at 1200rpm for 5 minutes and then re-suspended in FBS containing 10% 
DMSO (Sigma, D2650). The inactivated MEFs were aliquoted into cryovials containing 2x106 
cells / 0.5ml FBS 10% DMSO and then frozen at -80°C.  
 
2.2.3. Mouse Embryonic Fibroblasts Seeding 
 
T25 tissue-culture treated vessels were gelatinised for 30 minutes and then the gelatine 
replaced with 3ml /25cm2 DMEM 10% FBS. An aliquot of inactivated MEFs was thawed in a 
37°C water-bath, re-suspended in 5ml DMEM 10% FBS and pelleted by centrifugation at 
1100rpm for 3 minutes. The pellet was re-suspended in DMEM 10% FBS and seeded into 
culture vessels at a density of 3x105 / 25cm2. The MEF-containing culture vessels were then 
incubated at 10% CO2, 37°C to be used within 10 days. 
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2.3. Cell Culture Growth Mediums 
 
 2.3.1. Human Embryonic Stem Cell Medium 
 
The following reagents were sterile-filtered into a 500ml bottle using a 0.22µm Stericup filter 
(Millipore, SCGPU05RE); 400ml DMEM/F12 (Sigma, DF-041), 100ml GIBCO Knock-out Serum 
Replacement (KOSR) (ThermoFisher, 10828028), 5ml 100X GIBCO non-essential amino acids 
(ThermoFisher, 11140050), 5ml 200mM GIBCO L-Glutamine (ThermoFisher, 25030081), 1ml 
GIBCO 2-mercaptoethanol (ThermoFisher, 21985023) and 0.5ml 100ng/ml bFGF. 
 
2.3.2. Pluriton Reprogramming Medium 
 
Pluriton Supplement 2500X (Stemgent, 01-0016) was aliquoted into single-use 4µl aliquots 
and stored at -80°C. Pluriton medium (Stemgent, 01-0015) was aliquoted into 40ml aliquots 
and frozen at -80°C. Upon use, an aliquot of thawed 2500X Pluriton supplement was added 
to 10ml of thawed Pluriton medium and kept in the fridge at 2-8°C for up to 1 month. 
 
2.3.3. Neuroblastoma and Fibroblast medium 
 
The same medium was used to culture both cell types consisting of DMEM 10% FBS. 
 
2.3.4. Myoblast Growth Medium 
 
Myoblast growth medium comprises DMEM F12 basal media supplemented with 20% FBS, 
8ng/ml bFGF and 10ug/ml human insulin solution (Sigma, I9278). 
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2.3.5. Transdifferentiation Medium 
 
Transdifferentiation medium comprises DMEM F12 containing 10µg/ml human insulin 
solution. 
 
2.4. Passaging Pluripotent Stem Cells  
 
2.4.1. Passaging on MEFs 
 
Pluripotent stem cells were grown in MEF-coated cell culture vessels, typically T25’s or in a 
6-Well Plates (6WPs)(Greiner Bio-one, 657160) with hESC medium at 37°C in 5% CO2. 
Healthy cultures were passaged every 3-4 days at a split ratio of 1:3. Cell cultures plated on a 
sub-optimal MEF layer were split less heavily and closer to once per week. Passaging 
consisted of mechanical scraping with a plastic Pasteur pipette (Alpha Laboratories, 
LW4728), i.e. using the pipette to score the flask in areas adjudged, by eye, to contain cells 
that did not appear to be differentiated. Prior to mechanical scraping the culture medium 
was aspirated until 1ml of medium remained in the flask. After scraping, fresh medium was 
added to the cell suspension and then plated onto fresh MEF-coated culture flasks 
containing 6ml or 2ml hESC medium, for a T25 or 6WPs respectively. Typically, 2ml hESC 
medium was added to the cell suspension following scraping to make the total volume up to 
3ml that was then split 1:3. 
 
2.4.2. Passaging on Matrigel 
 
Vials of frozen (-20°C) Matrigel (BD, 354234) were defrosted at 2-8°C in the fridge in a box 
filled with ice. Once in liquid form the Matrigel was diluted 1:40 in DMEM/F12 and then 
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aliquoted into culture vessels to be stored at 2-8°C until used. As the water content in 
Matrigel slowly evaporates at 2-8°C, the volume added was sufficient to coat the culture 
vessels for up to 1 week, for example, 1.5ml in a well of a 6WP. When required for 
passaging, refrigerated culture vessels were placed at room temperature for 1 hour after 
which the Matrigel was aspirated and replaced with 2ml Pluriton medium. Pluripotent stem 
cells were passaged as described above (Methods 2.4.1). However, the cells were re-
suspended in Pluriton medium and split into Matrigel-coated flasks also in Pluriton medium 
at the volumes described previously (Methods 2.4.1). 
 
2.5 Culture of human dermal fibroblasts 
 
Fibroblasts were grown on gelatine-coated T25 culture flasks (methods 2.1) in 7ml/25cm2 DMEM 
10% FBS at 37°C in 10% CO2. To passage, the culture medium was aspirated from the culture vessel 
and replaced with 1ml/25cm2 0.25% trypsin-EDTA. The cells were then incubated for 1-2 minutes at 
37°C. The 0.25% trypsin-EDTA was then neutralised using DMEM 10% FBS and centrifuged at 
1000rpm for 3 minutes. Then, the medium was aspirated to the pellet and the cells were re-
suspended in typically 3ml DMEM 10% FBS and split into three gelatine-coated T25 culture flasks at a 
ratio of 1:3.   
 
2.6. SK-N-SH and SKiPS Cell Culture 
 
SK-N-SH cells were grown in T25’s or 6WPs in DMEM 10% FBS at 37°C in 5% CO2. Cultures were 
passaged once a week at a ratio of 1:6 following a 1-2 minute treatment with 0.25% trypsin-EDTA at 
37°C. SK-N-SH cells were obtained from the ATCC (reference number: HTB-11) [157]. SK-N-SH cells 
that have been reprogrammed using the lentivirus by C. Unger are called SKiPS cells. The SKiPS cells 
are cultured using the method described in methods 2.4. 
 
48 
2.7. NT2 D1 Cell Culture 
 
NT2 D1 cells [158] were grown in cell culture vessels in DMEM 10% FBS at 37°C in 10% CO2. Cultures 
were passaged once a week at a ratio of 1:3 following a 1-2 minute treatment with 0.25% trypsin-
EDTA at 37°C. 
 
2.8 Freezing of Cell Cultures 
 
Cell cultures were harvested from their culture vessels by the passaging method appropriate to their 
cell type and then pelleted by centrifugation at 1000rpm for 3 minutes. The media was then 
aspirated and the pellet re-suspended in 1ml FBS 10% DMSO per 1x106 cells. The cells were then 
aliquoted into 1.5ml cryovials and placed in a Mr. Frosty freezing container (ThermoFisher, 5100-
0001) at -80°C for 24 hours. The vials were then transferred to liquid nitrogen for long-term storage. 
 
2.9. Thawing of Pluripotent Stem Cell Cultures 
 
Cryovials containing frozen cells were thawed in a water bath set to 37°C and then re-suspended in 
5ml fresh hESC medium. The cells were pelleted by centrifugation at 1000rpm for 3 minutes. 
Meanwhile, the medium was changed on one well of a MEF coated 6WP with 2ml fresh hESC 
medium which was then placed at 37°C to pre-warm. Once the cells had pelleted, the supernatant 
was aspirated and the centrifugation tube was gently flicked to dissociate the pellet before being re-
suspended in the 2ml hESC medium from the pre-warmed well. The cell suspension was pipetted 
back in to the MEF-coated 6WP and then the culture vessel was placed in an incubator at 37°C in 5% 
CO2 and their growth was monitored.  
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2.10. Dissociating cell cultures into single cells 
 
Cell culture medium was aspirated from the culture vessel and replaced with 1ml/25cm2 0.25% 
trypsin-EDTA or 1X TrypLE Select (ThermoFisher, 12563029). The cells were then incubated for 1-2 or 
5 minutes respectively at 37°C. If the cells could not be seen to visibly detach from the surface, the 
side of the vessel was given a sharp tap. The trypsin-EDTA was then neutralised using a serum-based 
medium and centrifuged in a Megafuge 1.0R (Heraeus) in a rectangular swinging bucket rotor 
(Heraeus, 75002252) (radius 16.9cm) at 1000rpm (189 x g) for 3 minutes. The supernatant was 
aspirated to the pellet and the cells were then re-suspended in the appropriate medium.   
 
2.11. Cell Counting 
 
Cell cultures were dissociated into single cells prior to counting. Fifteen microlitres of single-cell re-
suspension was then added to 15µl 0.4%Trypan Blue (Sigma, 15250061). Ten microlitres of this 
mixture was then added to a haemocytometer (Hawksley, AC1000) and the four corner quadrants 
were counted (Figure. 2.1). The cell concentration can then be calculated as follows; 
 
Concentration (cells/ml) = Average count of 4 quadrants (outlined in red) x 20,000 
 
Total cell number = concentration (cells/ml) x volume of cell suspension (ml). 
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Figure 2.1: The above schematic is representative of a haemocytometer when viewed 
down the microscope. Cells stained with Trypan Blue are non-viable and should not be 
counted, nor should cellular debris or dead cells. The viable cells are shown as black 
circles with a white fill. The quadrants where cells should be counted are highlighted by 
red squares. 
Figure 2.1. Schematic of a haemocytometer 
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2.12. RNA Extraction 
 
2.12.1. Harvesting Cells 
 
2.12.1.1. Extracting RNA from cells in monolayer culture 
 
Cell medium was aspirated from the cultures and replaced with 1ml Invitrogen™ 
Trizol (ThermoFisher, 15596026) per 1x106 cells. The cells almost instantly became 
unattached from the culture vessel and were transferred to a 1.5ml micro-centrifuge 
tube (STARLAB, E1415-1510). If the sample was not used directly afterwards it was 
placed at -80°C for long-term storage. 
 
2.12.1.2. Extracting RNA from embryoid bodies 
   
Embryoid bodies were transferred to a 55cm2 Corning™ petri dish (Sigma, 
CLS430293) using a 200µl multi-channel pipette. The cell suspension was then 
transferred to a 15ml falcon tube (STARLAB, E1415-0200) and pelleted by 
centrifugation in a Heraeus Megafuge 1.0R at 1000rpm (189 x g) for 3 minutes. The 
supernatant was aspirated and then the pellet dissociated by flicking the tube. 1ml 
Trizol per 1x106 cells was added and the cell suspension was transferred to a 1.5ml 
micro-centrifuge tube. If the sample was not used directly afterwards it was placed 
at -80°C for long-term storage. 
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 2.12.2. Isolating Total RNA 
  
Frozen Trizol samples were thawed on ice and then 200µl chloroform (Sigma, 288306) was 
added to the Trizol sample and inverted vigorously until the solution turned pale pink. The 
samples were left at room temperature for 10 minutes before being placed in a 30-place 
aerosol-tight fixed-angle rotor (radius 9.5cm) and centrifuged at 10,000rpm (10,621 x g) in 
an Eppendorf 5417R refrigerated micro centrifuge, for 10 minutes to achieve phase 
separation. The upper aqueous layer was transferred to a sterile 1.5ml micro-centrifuge tube 
containing an equal volume of 100% ethanol. The sample was thoroughly mixed using a 
vortex and total RNA was isolated using the RNA Clean-Up and Concentration Kit (Norgen 
Biotek, 23600) as per the manufacturer’s protocol. 
 
2.13. Reverse Transcription of RNA into cDNA 
 
Reverse transcription reactions were performed using the Applied Biosystems™ High-Capacity cDNA 
Reverse Transcription Kit (ThermoFisher, 4368814). Reactions were performed in a 0.5ml micro-
centrifuge tube (STARLAB, E1405-0610) by adding 2µl of 10X RT buffer, 0.8µl 25X dNTP mix 
(100mM), 2µl 10X Random Primers, 1µl RNase inhibitor and 3.2µl ddH2O per sample to be reverse 
transcribed. An RNA sample was diluted with ddH2O to 100ng/μl and then 10μl was added to the 
reverse transcription reaction. The entire 0.5ml micro-centrifuge tube was thoroughly mixed using a 
vortex and briefly micro-centrifuged to pool the reagents to the bottom of the tube. Finally, 1µl of 
Applied Biosystems™ MultiScribe Reverse Transcriptase (ThermoFisher, 4368814) was added to the 
reaction. The sample was briefly spun using a micro-centrifuge and placed in an Applied 
Biosystems™ 2720 thermal cycler (ThermoFisher, 4359453) to be run using the cycle shown in 
Figure. 2.2, before being stored at -20°C. 
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Figure 2.2. The run cycle for reverse 
transcription reactions 
Figure 2.2: The run cycle for reverse transcription reactions includes a 10 minute hold at 25°C 
to anneal primers followed by a 2 hour hold for reverse transcription to take place. The 
reaction is terminated by increasing the temperature to 85°C and holding for 5 minutes. The 
reaction is then cooled to 4°C ready for storage. 
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2.14. QPCR on cDNA samples 
 
 2.14.1. Roche system 
 
Frozen cDNA samples were thawed on ice and their concentration was quantified using a 
Nanophotometer P330 (Geneflow, discontinued). The cDNA samples were then diluted to 
5ng/µl with ddH2O. This was added to a mixture on ice containing 2.7µl ddH2O, 5µl Applied 
Biosystems™ 2X Taqman Fast Universal PCR Master Mix (ThermoFisher, 4352042), 0.2µl 
Primer mix (containing 5µM sense and antisense oligonucleotides) and 0.1µl Probe (Roche, 
04683633001). Eight microliters of the mixture was added to each well of a MicroAmp 
Optical 96- or 384-well reaction plate (ThermoFisher, 4316813) followed by 2µl of diluted 
cDNA. The plate was sealed with a MicroAmp Optical Adhesive Film (ThermoFisher, 
4311971), and then centrifuged briefly for 5 seconds at 1200rpm. The plate was then 
analysed on a QuantStudio 12k Flex Real-Time PCR System (ThermoFisher, 4471088) using a 
standard run cycle setup (Figure. 2.3i). The primer sequences and probes used are detailed 
in Table 2.1.  
 
 2.14.2. TaqMan Gene Expression system 
 
CDNA is diluted to 5ng/µl with ddH2O and kept on ice. A mixture containing 2.5µl ddH2O, 5µl 
2X TaqMan Fast Universal PCR Master Mix and 0.5µl TaqMan primer (ThermoFisher, 
Accession numbers provided in Table 2.1) was made per well. Eight microliters of the 
mixture was added to each well of an optical 96- or 384-well reaction plate followed by 10ng 
of pre-diluted cDNA. The plate was sealed, spun and analysed as described in the Roche 
system albeit with an altered run cycle (Figure. 2.3ii). The primer sequences and probes used 
are detailed in Table 2.1. 
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Figure 2.3. The two qPCR run cycles when using the Roche 
Universal Probe Library and the Taqman gene expression systems 
Figure 2.3: The qPCR run cycle setups are shown above. (i) The Roche system includes a hold 
for 2 minutes at 50°C followed by an increase in temperature to 95°C for 10 minutes to fully 
denature the cDNA. A further hold at 95°C and then a 1 minute hold at 60°C is performed to 
allow for annealing and extension of the primers. (ii) The TaqMan system follows the same 
principals albeit with optimised reagents to allow for the run-time to be completed in a fraction 
of the time. 
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2.14.3. Calculating RQ values using the delta CT method. 
 
After running an optical 96- or 384-well reaction plate on the QuantStudio 12k Flex Real-
Time PCR System, each well containing a sample will output a Cycle Threshold (CT) value into 
an excel spreadsheet. The CT values represent the number of PCR cycles it takes for the 
amplification reaction to accumulate a fluorescent signal above a threshold determined 
from the background noise. Typically, a CT value below 30 indicates a large amount of target 
nucleic acid in the sample while a CT value between 30 and 40 indicates a minimal-to-absent 
level of target nucleic acid in the sample. CT values can be converted to relative 
quantification (RQ) values that represent changes in gene expression in a cDNA sample 
relative to a reference cDNA sample, for example, an untreated control. The RQ value 
calculation process, described below, has been illustrated in Figure. 2.4.  
 
As cDNA samples are often run on a plate in technical triplicate, the mean average of three 
grouped CT values is calculated before being normalised to a housekeeping gene to obtain a 
delta CT value that shows the difference in expression between the target gene and the 
housekeeping gene. Two housekeeping genes, GAPDH and b-ACTIN were used with the 
Roche Universal probe library and Taqman gene expression system respectively based on 
their consistent expression across multiple cell types and experiments (data not shown). The 
delta CT values were then averaged to give the mean delta CT value. To compare between 
samples, one sample was selected as the reference sample for all other samples to be 
compared to, such as an undifferentiated control. The delta-Ct for each gene from the 
reference sample is subtracted from the corresponding gene in the remaining samples to 
give for each gene in a sample a so-called delta delta Ct value. The RQ values are finally 
calculated by using the 2^-delta delta CT formula that reveals the fold change in expression 
between two samples normalised to a housekeeping gene. 
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Figure 2.4. Calculating RQ: A worked example 
Figure 2.4: An example of calculating RQ values from the output of a qPCR run is shown. A 
target sample run in technical triplicate is analysed for the abundance of OCT4 nucleic acid. The 
target sample is normalised to GAPDH. Each cDNA sample within the triplicate is used 
repeatedly for each target analysed e.g. the cDNA sample in well position A1 has been used 
again in well position B1 albeit using different primers and probes (GAPDH and OCT4 
respectively). A step-by-step, colour-coded process shows how to calculate RQ values from CT 
values. RQ values are calculated using the 2^-ddCT formula. 
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Gene Accession number Gene Accession number 
β-ACTIN HS01060665_G1 BRN3A HS00366711_M1 
PAX3 HS00240950_M1 PHOX2B HS00243679_M1 
SOX10 HS00366918_M1 FOXD3 HS00255287_S1 
AP2α HS01029413_M1 ALK HS01058318_M1 
 
 
 
Gene Forward Primer, 5'→3" Reverse Primer, 3"→5' 
Probe 
# 
GAPDH agccacatcgctcagacac gcccaatacgaccaaatcc #60 
POU5F1 ccacatcggcctgtgtatatc agcaaaacccggaggagt #35 
SOX2 atgggttcggtggtcaagt ggaggaagaggtaaccacagg #19 
KLF4 gccgctccattaccaaga cgatcgtcttcccctcttt #82 
CMYC cggttttcggggctttat ggctcttccaccctagcc #13  
LIN28 gccaaggaatgcaagctg gaggctaccatatggctgatg #29 
NANOG agatgcctcacacggagact tttgcgacactcttctctgc #31 
FOXA2 cgccctactcgtacatctcg agcgtcagcatcttgttgg #9 
GATA6 aatacttcccccacaacacaa ctctcccgcaccagtcat #90 
ISL1 gcagcccaatgacaaaactaa ccgtcgtgtctctctggact #83 
CD34 gcgctttgcttgctgagt gggtagcagtaccgttgttgt #8 
PECAM tggaaattggaagagcacaa ttcaagtttcagaatatcccaatg #37 
GATA2 ccgggagtgtgtcaactgt caggcattgcacaggtagtg #76 
PAX6 agggcaacctacgcaaga cgttggaactgatggagttg #12 
COL1A1 gggattccctggacctaaag ggaacacctcgctctcca #67 
MITF-m ggtgaaaataatcaactgcatagttc agcatcaccaatgtttccaag #61 
DCT cgactctgattagtcggaactca ggtggttgtagtcatccaagc #33 
c-RET catcaggggtagcgaggtt gggaaaggatgtgaaaacagc #17 
SNAI2 tggttgcttcaaggacacat gcaaatgctctgttgcagtg #7 
PAX3i ttggcaatggcctctcac aggggagagcgcgtaatc #45 
SOX10 cccaggtgaagacagagacc atggctggtcggtgtagtgt #57 
AP2α acatgctcctggctacaaaac gtcaagcagctctggatgc #1 
BRN3A ctccctgagcacaagtaccc ggcgaagaggttgctctg #78 
FOXD3 gaagccgccttactcgtaca cgctcagggtcagcttctt #9 
MYOD cactacagcggcgactcc taggcgccttcgtagcag #70 
MYOG ttaaatggcacccagcagtt gggatgtctcatacagctcca #66 
MYF5 ctatagcctgccgggaca tggaccagacaggactgttacat #10 
MYH7 acaccctgactaaggccaaa gtccatgcgcaccttctt #1 
BCL2L1 cccagggacagcatatcag agcggttgaagcgttcct #66 
Table 2.1: mRNA levels were detected during qPCR using the site specific primer/probe pairs 
that were designed to span across intronic regions as to not represent genomic DNA. Details of 
Roche primers and probes (top table, blue boxes) and Taqman Amplicons (bottom table, peach 
boxes) are given, including; gene name, primer sequences, orientation, primer-matched probe 
numbers and accession numbers. 
Table 2.1. Primer / probe sequences used in 
qPCR to detect target nucleic acids 
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2.15. Immunoassays 
 
 2.15.1. Flow Cytometry 
 
Cell cultures were dissociated into single cells using 0.25% trypsin-EDTA for 1-2 minutes at 
37°C and neutralised using ice cold wash buffer (containing 90% PBS and 10% FBS). The cells 
were washed from the culture vessel and pelleted at 1200rpm for 3 minutes. The pellet was 
re-suspended in wash buffer and split equally between a set of BD Falcon round-bottom 
FACS tubes (BD Falcon, 352063) ensuring a minimum of 1x105 cells per tube. Primary 
antibody was added (Table 2.2) while flicking to mix and the samples were refrigerated at 2-
8°C in darkness for 30 minutes. As a negative control, we used an antibody, P3X, produced 
by the myeloma P3X63.Ag8 [159], the ultimate parent of all the hybridomas used to produce 
antibodies used in this study (Table 2.2). The TRA-1-85 primary antibody that has reactivity 
to a pan-human antigen [160], was used as a positive control for the antibody staining 
procedure. Three millilitres of wash buffer was added to wash the cells before being spun at 
1200rpm for 3 minutes. The supernatant was aspirated down to the 200µl mark on the FACS 
tube before flicking to break up the pellet. Secondary antibody was then added (Table 2.2) 
while flicking to mix and the samples were refrigerated for a second time at 2-8°C in 
darkness for 30 minutes. The cells were washed twice with wash buffer and spun at 
1200rpm for 3 minutes. The supernatant was aspirated to the 200µl mark and the cells were 
re-suspended in 300µl wash buffer. The cells were analysed on a CyAn ADP Analyser 
(Beckman Coulter, discontinued). 
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2.15.1.1 Gating strategy 
 
Cells stained with P3X were run through the CyAn ADP Analyser and a forward 
scatter and side scatter gate was set to exclude cell debris, dead cells and clumps of 
cells based on cell size and granularity. Typically, clumps of cells have high forward 
scatter and debris has low forward scatter and high side scatter. Next, a gate was set 
to filter out doublet cells to ensure only single cell events were being analysed at 
any one time. Finally, a gate was set, based on the fluorescence profile of those cells 
stained with the negative control antibody, P3X, such that only 1%-5% of cells 
stained with the negative control would be scored positive. to determine the 
threshold between negatively and positively labelled cells. 
 
2.15.2. In-situ Live Cell Staining on the IN cell analyser 
 
Cell culture medium was aspirated and replaced with DMEM without phenol red 
(ThermoFisher, 21063). Primary antibody was added directly to the cells and incubated at 
37°C for 30 minutes. The cells were washed twice with DMEM without phenol red and 
analysed on the IN Cell Analyser 2200 scanning microscope  (GE Healthcare Life Sciences, 
29027886).  High content Imaging and analysis services were provided by specialist 
operators from the Centre for Stem Cell Biology, University of Sheffield, and annotated 
image files provided.   
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2.15.3. Immunofluorescence method 
 
Cell cultures were fixed by aspirating the culture medium and replacing with 1ml/25cm2 4% 
PFA for 15 minutes at room temperature. The PFA was then removed and the cells were 
blocked with 1ml/25cm2 PBS containing 10% FBS for 30 minutes at 2-8°C. Then: 
 
For staining with cell surface markers only 
PBS containing primary antibody was added to the cells and incubated at 2-8°C in the dark 
for 1 hour. This was then aspirated, washed three times and then stained with secondary 
antibody diluted in PBS at 2-8°C in the dark for 1 hour. The cells were counterstained with 
Hoescht 33342 (ThermoFisher, 62249) during the incubation period with the secondary 
antibody and then washed a further three times and covered with 3ml PBS.  The fixed cells 
were then visualised using an IN Cell Analyser 2200. 
 
For staining with intracellular markers and cell surface markers 
The blocking buffer was removed and replaced with permeabilisation buffer, comprised of 
1ml/25cm2 PBS 5% FBS containing 0.1% Triton X-100 (Sigma, X100), for 1 hour at 2-8°C. The 
permeabilisation buffer was then removed before the cells were stained with antibodies and 
washed as described above. All intracellular antibody staining, primary and secondary, took 
place before cell surface marker antibody staining. Counterstaining with Hoescht 33342 was 
performed at the same time as the final secondary antibody staining. 
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Primary 
Antibody Secondary Antibody Procedure Source, [Origin] 
P3X 
Alexa Fluor 647 conjugated Goat 
Anti-Mouse 
Flow Cytometry In house, [159] 
SSEA-1 
Alexa Fluor 647 conjugated Goat 
Anti-Mouse 
Flow Cytometry In house, [18] 
SSEA-3 
Alexa Fluor 647 conjugated Goat 
Anti-Mouse 
Flow Cytometry In house, [15] 
SSEA-4 
Alexa Fluor 647 conjugated Goat 
Anti-Mouse 
Flow Cytometry In house, [16] 
TRA-1-60 
Alexa Fluor 647 conjugated Goat 
Anti-Mouse 
Flow Cytometry In house, [161] 
TRA-1-81 
Alexa Fluor 647 conjugated Goat 
Anti-Mouse 
Flow Cytometry In house, [161] 
TRA-1-85 
Alexa Fluor 647 conjugated Goat 
Anti-Mouse 
Flow Cytometry In house, [160] 
OCT4 
Alexa Fluor 488 conjugated Goat 
Anti-Rabbit 
Immunofluorescence C-10, SantaCruz (sc-5279) 
TRA-1-60 
Alexa Fluor 488 conjugated Goat 
Anti-Mouse 
Immunofluorescence In house, [161] 
NCAM 
Alexa Fluor 488 conjugated Goat 
Anti-Mouse 
Immunofluorescence In house, [18] 
DESMIN 
Alexa Fluor 488 conjugated 
Donkey Anti-Rabbit 
Immunofluorescence 
Cell Signalling Technology 
(5332) 
 Hoescht 33342 Immunofluorescence 
ThermoFisher Scientific     
(62249) 
Table 2.2. List of primary and secondary antibodies used                 
for flow cytometry and immunofluorescence 
Table 2.2: Table showing a list of the primary and secondary antibodies and their sources used 
for both flow cytometry and fluorescent activated cell sorting (FACS) (blue) and 
immunofluorescence experiments (peach) using the IN Cell Analyser 2200 (GE Healthcare Life 
Sciences). In house antibodies were obtained from stocks prepared by the Centre for Stem Cell 
Biology from stocks of relevant hybridomas that are referenced above. 
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2.16. Karyotyping  
 
Cell cultures were provided, as live cell cultures in T25 culture flasks, to the Sheffield Diagnostic 
Genetics Service at the Sheffield Children’s NHS Foundation Trust for karyotyping, to be performed 
by a UK Health Professionals Clinical Cytogeneticist. 
 
2.17. Isolating Plasmid DNA 
 
2.17.1. Transforming Bacteria 
 
LB Agar Tablets (Sigma, L7275) were diluted in ddH2O and autoclaved. The liquid agar was 
cooled and GIBCO Ampicillin (ThermoFisher, 11593027) was added at 50µg/ml and then 
poured into a 10cm petri dish. The agar was left to solidify before being refrigerated upside 
down at 2-8°C until needed. Meanwhile, 1µg of plasmid and a 50µl aliquot of One Shot 
TOP10 chemically competent cells (ThermoFisher, C404010) was mixed and then cooled on 
ice for 25 minutes. The cells were heat shocked at 42°C for 30 seconds and then immediately 
placed back on ice for 2 minutes. The mixture was pipetted onto a set agar plate and 
smeared over the surface using a right-angled 230mm disposable Glass Pasteur pipette 
(VWR, 14672-380). The agar plate was incubated upside down at 37°C overnight.  
 
 2.17.2. Colony Picking 
 
Colonies were picked using a non-filtered 200µl pipette tip (STARLAB, S1121) by hand from 
the overnight agar plate. The pipette tip was placed into a 15ml bacterial tube containing 
5ml of liquid LB broth (Sigma, L3022). This was incubated overnight at 37°C while shaking. LB 
broth was reconstituted from 10g LB broth powder using 500ml ddH2O. 
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 2.17.3. Plasmid Extraction 
 
Eighty percent of the overnight bacterial culture was transferred to a 1.5ml micro-centrifuge 
tube and pelleted at 8000rpm for 2 minutes. Twenty percent of the bacterial culture was 
mixed with 80% glycerol and stored at -80°C for long-term use.  Plasmid DNA was then 
isolated using the GeneJET Plasmid Miniprep Kit (ThermoFisher, K0502). 
 
2.17.4. Generating MYOD1 mRNA 
 
The MYOD1 cDNA clone was contained within a pCMV6-XL5 plasmid (Origene, RG209108). 
To generate MYOD1 mRNA the plasmid was initially transformed in to One Shot TOP10 
chemically competent E.coli and selected on LB agar plates containing 50µg/ml ampicillin. 
Ampicillin resistant colonies were picked into LB broth and cultivated overnight in a shaking 
incubator at 200rpm in 37°C followed by plasmid purification using the GeneJET Plasmid 
Miniprep Kit. One microgram of purified plasmid was linearised using ten units of XbaI 
restriction enzyme (New England Biolabs, R0145S) in a 50µl reaction. Linearisation was 
confirmed prior to in-vitro transcription by running five microlitres of the restriction digest 
reaction on one percent agarose gels. In an adjacent well, non-linearised DNA was run to 
confirm the restriction digest had successfully linearised the plasmid. Successfully linearised 
plasmid was then in-vitro transcribed using the MEGAscript T7 kit (ThermoFisher, AM1333). 
The transcription reaction was performed as described in methods 2.20, purified and 
concentrated using the RNA Clean-Up and Concentration Kit (Norgen Biotek, 23600). To 
verify that MYOD1 mRNA had been successfully transcribed, one microgram of mRNA was 
run on a one percent denaturing RNA gel (Methods 2.19.1). A single positive band at 2056 
bases long confirms the mRNA has been successfully transcribed. 
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2.17.5 Generating mRNA from linearised DNA templates 
 
Linearised DNA templates encoding OCT4, SOX2, KLF4, cMYC, LIN28, NANOG and mWASABI 
were supplied by Allele Biotech as part of their iPS Induction IVT Template Set (ABP-SC-
SEIPSSET). Each template structure (shown below) contained a 5’ and 3’ UTR that flanked 
the gene of interest (GOI) (sequences unknown) and a 120-nucleotide polyA tail. 
Transcription was driven by a T7 promoter and the method used for in-vitro transcription is 
described in methods 2.20. 
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2.17.6 OCT4-MYOD1 (M3O) mRNA 
 
M3O mRNA was supplied as part of the 6-factor mRNA reprogramming premix kit (Allele 
Biotech, ABP-SC-6FMRNA). The gene map below (Figure. 2.5) has been drawn according to 
Hirai et al [68] and Berkes et al [162] on the understanding that M3O is a fusion between the 
transcriptional activation domain (TAD) of MYOD1, located at its N-Terminus, that has been 
fused to the N-Terminus of OCT4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Domain structure of MYOD1, a transcription factor of the basic helix-
loop-helix (bHLH) family, from which the transcriptional activation domain (TAD) is 
removed and fused to the N-terminus of human OCT4 protein to create a fusion 
protein called M3O. 
Figure 2.5. Generating M3O, a chimeric protein generated by 
fusing the transcriptional activation domain of MYOD1 with 
human OCT4 protein 
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2.17.7 Generating mRNA from the RN3P plasmid 
 
RN3P is an in-house plasmid (Figure. 2.6) that has been modified from pBluescript SK(-) to 
contain additional linearization sites, PstI and SfiI, and a multiple cloning site that is flanked 
by 5’ and 3’ globin untranslated regions [163]. The plasmid contains eGFP that is driven by a 
T3 promoter. Linearisation of the RN3P plasmid is performed by combining 1µg of RN3P 
plasmid to 10 units of SfiI restriction enzyme (New England Biolabs, R0123S), 5µl 10X 
NEBuffer (New England Biolabs, B7202S) and 100µg/ml BSA (New England Biolabs, B9000S) 
in a 1.5ml micro-centrifuge tube. The mixture is made up to 50µl with ddH2O and then 
heated to 37°C for 1 hour. IVT reactions were performed from the linearised RN3P plasmid 
using the T3 MEGAscript Kit (ThermoFisher, AM1338) following the same procedure as 
described in methods 2.20.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Plasmid map for RN3P 
Figure 2.6: eGFP mRNA was transcribed from the RN3P plasmid. The coding region 
for eGFP was inserted into the RN3P plasmid at a multiple cloning site that is 
flanked by 5′ and 3′ untranslated regions of Xenopus β-globin. The globin region 
resides downstream of a T3 promoter that drives the transcription of eGFP and a 
recombinant polyA tail. Linearisation of the RN3P plasmid was performed using the 
SfiI restriction enzyme. 
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2.18. Restriction Digest 
 
A mixture was made containing 1µg of plasmid DNA, 5µl 10x NEBuffer, 0.25µl BSA, 1 unit of 
restriction enzyme (New England Biolabs) and ddH2O to 50µl. A larger volume of restriction enzyme 
was used when its activity was less than 100% in the appropriate buffer. The mixture was placed in a 
DNA Thermal Cycler 480 (Perkin Elmer,  313002) for 1 hour, typically at 37°C. The plasmid was then 
ready to be verified by gel electrophoresis. 
 
2.19. Gel Electrophoresis:  
 
2.19.1 DNA gels 
 
An EDTA solution (0.5M) was made by diluting 18.61g of EDTA powder (Fisher Scientific, 
S311) in 80mls ddH2O. The pH of the solution was adjusted to 8.0 with 5M NaOH. Then a 10X 
TBE solution was made by adding 40mls of 0.5M EDTA solution to 108g Trizma Base (Sigma, 
T1503) and 55g Boric Acid (Sigma, 185094) before making up to 1 litre with ddH2O. This was 
diluted to a 1X concentration with ddH2O to create a working TBE solution. For a 1% agarose 
gel 1g of Agarose (Fisher Scientific, BP160) was dissolved in 100ml 1X TBE solution. Ethidium 
Bromide (Fisher Scientific, BP1302-10) was added to a final concentration of 100ng/ml and 
then poured into a multiSub Mini Horizontal Gel Tray (Cleaver Scientific, MSCHOICETRIO) 
containing a gel comb. After the gel had set the comb was removed and it was transferred to 
a multiSub Mini Horizontal gel tank containing a sufficient amount of 1X TBE to cover the 
upper surface of the gel. A mixture of 25% linearised plasmid DNA, 25% 6X DNA loading dye 
(Thermo Fisher, R0611), 25% 6X Bromophenol Blue (Sigma, 114391) and 25% ddH2O was 
then added to the agarose gel wells alongside 5µl GeneRuler 1kb DNA ladder (Thermo 
Fisher, SM0312). The gel tank was connected to a PowerPac 300 power supply (Bio-Rad, 
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164-5050) and run for 40 minutes at 120V. The bands were visualised using an InGenius Bio 
Imaging trans-illuminator (SYNGENE) and image acquisition was carried out using Genesnap 
(SYNGENE) software. 
 
2.19.2. Gel Electrophoresis: running RNA gels 
 
RNA was run on a 1% agarose/formaldehyde gel containing 0.5μg/ml ethidium bromide. The 
Agarose gel was made by combining 20ml 5X MOPS buffer (Sigma, M1254) with 72ml ddH2O 
and 1g of Agarose. To make a two-litre stock of 5X MOPS buffer, 83.72g of MOPS and 8.23g 
of sodium acetate was added to 1.6 litres of ddH2O. The mixture was stirred until it had 
completely dissolved. To this, 20ml 0.5M EDTA was added and the pH adjusted to 7.0 using 
10M NaOH. The volume was made up to two litres with ddH2O and then autoclaved. The 
agarose gel mixture was boiled in a microwave until molten and then cooled to 55°C. To this, 
17.6ml 37% formaldehyde (Sigma, F15587) and 0.5μg/ml ethidium bromide was added 
before the gel was poured into a gel tray (as described in 2.19.1). Once the gel had set it was 
submersed in 1X MOPS buffer in a multiSub Mini Horizontal gel tank containing a sufficient 
amount of 1X MOPS buffer to cover the upper surface of the gel. To prepare RNA samples 
for loading, 5µl RNA was mixed with 10µl RNA buffer. RNA buffer was made by mixing 2ml 
5X MOPS buffer with 3.5ml 37% formaldehyde and 10ml Formamide (Sigma, F9037). To this, 
5μl RNA loading Dye 2X (New England Biolabs, B0363S) was added before loading into wells 
of the 1% agarose/formaldehyde gel alongside 5µl ssRNA ladder (New England Biolabs, 
N0362S). The gel tank was connected to a PowerPac 300 power supply and run at 7V/cm 
until the loading dye could be seen to have migrated 2/3 the length of the gel. The bands 
were visualised using an InGenius Bio Imaging trans-illuminator and image acquisition was 
carried out using Genesnap software. 
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2.20. In-vitro Transcription of mRNA with modified nucleotides 
 
The enzyme mix and reaction buffer from the T7 MEGAscript Kit (Thermo Fisher, AM1333) was used 
to in-vitro transcribe mRNAs from linearised DNA templates. A mixture was made at room 
temperature consisting of 2µl 75mM ATP and 2µl 75mM GTP solution (Thermo Fisher, AM1333), 2µl 
100mM 5-Methylcytidine-5’-Triphosphate (Stratech, Table 2.3), 2µl 100mM Pseudouridine-5’-
Triphosphate (Stratech, Table 2.3), 2µl 60mM Anti-Reverse Cap Analog (Stratech, Table 2.3), 2µl 10X 
reaction buffer, 1µg linearised template DNA and 2µl enzyme mix. The mixture was made up to 20µl 
with ddH2O and pipetted to mix before being micro-centrifuged. The mixture was then incubated in 
a DNA Thermal Cycler 480 at 37°C for one hour. The mRNA was then purified using the RNA Clean-
Up and Concentration Kit and stored at -80°C in working aliquots.  
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Reprogramming Reagent Catalogue # 
  Stemgent Reprogramming 00-0071 
  2 vials - Stemgent Oct4 mRNA, Human, 20µg 05-0014 
  1 vial - Stemgent Klf4 mRNA, Human, 20µg 05-0015 
  1 vial - Stemgent Sox2, Human, 20µg 05-0016 
  1 vial - Stemgent Lin28 mRNA, Human, 20µg 05-0017 
  1 vial - Stemgent c-Myc mRNA, Human, 20µg 05-0018 
  1 vial - Stemgent nGFP mRNA, 20µg 05-0019 
  Allele Biotech iPS Induction IVT template set ABP-SC-SEIPSET 
  Oct3/4 IVT Template 5 μg  ABP-SC-SEOCT34 
  SOX2 IVT Template 5 μg  ABP-SC-SESOX2 
  Klf4 IVT Template 5 μg  ABP-SC-SEKLF4 
  c-Myc IVT Template 5 μg  ABP-SC-SECMYC  
  Lin28 IVT Template 5 μg ABP-SC-SELIN28  
  Nanog IVT Template 5 μg  ABP-SC-SENANOG  
  mWasabi IVT Template 5 μg ABP-FP-SEMWASABI 
  Anti Reverse Cap Analog, 5mg (Stratech) NU-855-5-JEN 
  5-Methylcytidine-5'-Triphosphate, 5 μmol (Stratech) 5-0613-295-IBA 
  Pseudouridine-5'-Triphosphate, L Pack, 5 x 10μl (Stratech) NU-1139L-JEN 
  MEGAscript® T7 Transcription Kit (Thermo Fisher) AM1333 
  75mM ATP solution (Thermo Fisher), Megascript T7 AM1333 
  75mM GTP solution (Thermo Fisher), Megascript T7 AM1333 
  T7 Enzyme Mix (Thermo Fisher), Megascript T7 AM1333 
  10X reaction buffer (Thermo Fisher), Megascript T7 AM1333 
  Allele Biotech 6-factor mRNA Reprogramming ABP-SC-6FMRNA 
  6F mRNA Reprogramming Premix ABP-SC-6FMRNA 
  Additional Reagents   
  B18R Recombinant Protein, Carrier-Free (eBioscience) 34-8185 
  Stemfect RNA Transfection Kit 00-0069 
  MEGAscript® T3 Transcription Kit (Thermo Fisher) AM1338 
  B18R Recombinant Protein, Carrier-Free, 50µg 03-0017 
  0.2 ml of Pluriton™ Supplement 2500X 01-0016 
  500 ml of Pluriton™ Medium 01-0015 
 
 
 
Table 2.3. Commercially sourced    
reprogramming reagents 
Table 2.3: The reagents used for reprogramming have been listed above. The reagents have 
been placed in categories: Stemgent reprogramming, Allele Biotech 6-factor mRNA 
Reprogramming or Allele Biotech iPS Induction IVT template set depending on where they were 
primarily used. 
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2.20.1 In-vitro Transcription of mRNA without modified nucleotides 
 
In-vitro transcribing mRNA without modified nucleotides follows the same procedure as in-
vitro transcribing mRNA with modified nucleotides albeit the modified nucleotides 
Pseudouridine-5’-Triphosphate (Stratech, NU-1139L-JEN) and 5-Methylcytidine-5’-
Triphosphate (Stratech, 5-0613-295-IBA) are substituted with UTP and CTP respectively. 
Unmodified mRNAs are still capped and polyadenylated. 
 
2.21. mRNA Transfection 
 
Cells were plated in a well of a 6WP on day -1 at a density that would achieve 50-90% confluency 
after 24 hours. On day 0, Pluriton media was added to a sterile well of a 6WP and equilibrated to 5% 
CO2 at 37°C in either low O2 (5% O2) or normoxia (normal atmospheric oxygen levels – 21% O2) for 
>30 minutes. Meanwhile mRNA was diluted to 100ng/µl with ddH2O. An mRNA cocktail was then 
made consisting of 10% mRNA and 90% Stemfect Transfection Buffer (Stemgent, 00-0069). Stemfect 
RNA transfection reagent (Stemgent, 00-0069) was then added at 4µl / µg of mRNA. The mRNA 
cocktail was mixed and incubated at room temperature for >15 minutes. It was then added to the 
equilibrated media and the plate was rocked back and forth by hand to mix. The cell media was 
aspirated and replenished with the equilibrated media containing the mRNA cocktail. The cells were 
then put back in a 5% CO2 incubator at 37°C in normoxia or at low O2 (5% O2) for 24 hours.  
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2.22. Cell Imaging 
 
 2.22.1. Fluorescent Microscopy 
 
Cells treated with mRNA encoding a fluorescent protein such as nGFP (Stemgent, 05-0019) 
or mWASABI (Allele Biotech, ABP-FP-SEMWASABI) would fluoresce upon successful 
transfection. The monomeric green fluorescent protein, mWASABI, is derived from 
Clavularia coral and is 1.6-fold brighter than eGFP [164]. The fluorescent proteins were 
visualised in real-time using an EVOS FL Cell Imaging System (ThermoFisher, AMEFC4300). 
 
2.22.2. Whole-well Imaging 
 
When imaging an entire well of a 6WP was necessary, whole-well imaging was undertaken 
using a BioStation CT (Nikon). This was achieved by setting up a tiling experiment set to 
capture a grid of 18x18 images at 4X magnification in both phase contrast and the 472-
520nm fluorescent channel. Images were then stitched together by importing the tiling 
micro.CSV file into the CL Quant (Nikon) software to produce a whole-well image. 
 
2.23. Directed Differentiation via Embryoid Body Formation 
 
 2.23.1. Pre-attachment Vessel Preparation 
 
A T25 of MEFs was made at least 3 days prior to the harvesting of cell cultures that were to 
be differentiated as EBs. Cell cultures that were differentiated as EBs included pluripotent 
stem cells or iPS cells derived from SK-N-SH or fibroblasts. The day before cells were to be 
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harvested, the conditioned MEF media was transferred to a sterile T25 and incubated at 
37°C in 10% CO2 until required. 
  
2.23.2. Plate Setup 
 
For directed differentiation, four round-bottom CELLSTAR 96-Well Plates (Sigma, M9436) 
were used for each cell line, constituting the four differentiation conditions; neutral, 
endoderm, mesoderm and ectoderm containing APEL medium (STEMCELL Technologies, 
05270) and combinations of growth factors and inhibitors (Table 2.4). Five millilitres of APEL 
media was added to 4X 15ml falcon tubes containing different types and amounts of growth 
factors and inhibitors (Table 2.4). Gentamicin was added at 1:500 and the supplemented 
media was transferred to a StarTub Reagent Reservoir (STARLAB, S4026-5806) where it was 
pipetted into the inner 60 wells of the appropriate 96-well plate. One hundred microliters of 
PBS was added to the outer 36 wells to prevent evaporation. The plates were then 
transferred to a 37°C incubator in 5% CO2 until required.  
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[165, 166] 
Table 2.4. Growth factor and inhibitor 
combinations used for directed EB differentiation 
Table 2.4: Pluripotent stem cells, iPS cells derived from SK-N-SH or fibroblasts that were 
differentiated as embryoid bodies were subjected to four conditions. The neutral condition 
contained only APEL media to induce spontaneous differentiation to the three germ layers. The 
three other conditions comprised a mixture of APEL media and combinations of growth factors 
and inhibitors to direct differentiation to the three primary germ layers. Directed 
differentiation towards Ectoderm was driven by 100ng/ml bFGF, 1uM/ml DMH1 that inhibits 
BMP to promote neurogenesis in hESCs and 10uM/ml SB431542 that inhibits differentiation 
toward mesendodermal lineages by disrupting TGFβ/activin/nodal signalling [164]. Mesoderm 
differentiation was induced by 20ng/ml Activin A that activates the TGFβ/activin/nodal 
signalling pathway and 20ng/ml BMP4 that upregulates SLUG to drive the transition of cells 
from epithelial to mesenchymal derivatives [165]. Endoderm differentiation was induced by 
100ng/ml Activin A and 1ng/ml BMP4. While endoderm and mesoderm differentiation both 
require Activin A and BMP4, the differing concentrations specify the lineage that differentiation 
is driven towards.  
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 2.23.3. Harvesting cells and pre-attachment 
 
The process for embryoid formation (Figure. 2.7) is as follows. T25 cell culture vessels 
containing pluripotent stem cells or iPS cells derived from SK-N-SH or fibroblasts were 
dissociated into a single cell suspension using 0.5mls TrypLE at 37°C for 2 minutes. After 2 
minutes the culture vessels were given a sharp tap to dislodge the cells. The TrypLE was 
neutralised with 3ml hESC media. The media from the pre-attachment vessel (methods 
2.23.1) was then aspirated and the single-cell suspension was added to this vessel and then 
incubated at 37°C for 30 minutes. The media was then aspirated and replaced with a further 
3ml hESC media containing Y-27632 dihydrochloride solution (Sigma, Y0503) at a final 
concentration of 10µM. The Rho-associated kinase (ROCK) inhibitor, Y-27632 aids in cell 
survival of dissociated pluripotent stem cells at low densities [167]. The vessel was incubated 
for 30 minutes at 37°C in 5% CO2 and then scraped using a sterile cell scraper (VWR, 89260-
222) into a 15ml falcon tube. The cells were counted and then pelleted at 1000rpm for 3 
minutes. Cells were re-suspended at a final concentration of 3000 cells / 50µl and then 
pipetted into the pre-prepared plates (methods 2.23.2). The plates were then spun at 
1000rpm for 3 minutes to collect the cells in the centre of the wells before being transferred 
into a 5% CO2 incubator at 37°C for 10 days. 
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Figure 2.7: Pluripotent stem cells form embryoid bodies (EBs) when differentiated in a low-
attachment culture vessel. Differentiation toward endoderm, mesoderm and ectoderm can be 
directed by creating EBs in medium containing combinations of growth factors and inhibitors 
(shown in the table provided and Table 2.4). Once EBs are formed they are analysed by qPCR 
for the presence of markers that distinguish the three germ layers. 
Figure 2.7. Embryoid Body formation process 
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Chapter 3. 
Developing a reproducible, fast and efficient reprogramming  
method using non-integrating mRNAs. 
 
3.1. Introduction 
 
Reprogramming has been achieved using a variety of different methods that introduce 
reprogramming factors into somatic cells such as; retrovirus [36], lentivirus [45], Sendai virus 
[70], piggyBac transposition [71] and episomal vectors [72]. The reprogramming factors are 
often constitutively expressed when delivered using these methods and therefore do not need 
to be repeatedly added to the somatic cells during reprogramming. However, despite the 
technical simplicity of reprograming using these methods there are potential drawbacks, for 
example DNA and viruses can integrate freely and at random sites within the genome. This can 
induce carcinogenic behaviour, lead to insertional mutagenesis and cause undesirable off-target 
effects [73]. For instance it has been shown that mice will develop tumours following the 
reactivation of retroviral vectors when the site of integration is downstream of nearby promoter 
regions. There is also the issue that integrating methods create transgenes and that there is a 
lack of control over the number of stable integrations that take place, affecting the ability to 
control gene expression. To circumvent these problems it is necessary to develop 
reprogramming methodologies that do not interfere with the target cell’s underlying genetic 
code.  
 
Warren et al showed that exogenous mRNA encoding OCT4, SOX2, KLF4, cMYC and LIN28 [76, 
168]  could be utilised to efficiently generate human iPS cells in a safe manner. MRNAs offer an 
integration-free alternative to viruses for reprogramming and directing cell fate. There is also no 
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requirement to produce viral vectors as mRNAs are created through in vitro transcription 
reactions from linearised DNA templates or from PCR products containing a double stranded 
promoter region, making them much safer to work with. The main limitation to utilising mRNAs 
was mitigating against degradation and overcoming the innate interferon immune response 
induced by single stranded RNAs [84].  
 
Warren et al [76] identified that the limitations to mRNA-mediated reprogramming can be 
circumvented by performing transcriptional and chemical modifications to mRNAs. 
Transcriptional modifications included substituting the nucleotides CTP and UTP during in vitro 
transcription reactions with 5-methylcytidine-5'-triphosphate and pseudouridine-5'-triphosphate 
respectively that decrease the susceptibility of mRNA to degradation by nucleases and 
deadenylation pathways. Warren polyadenylated and capped mRNAs to further reduce their 
susceptibility to degradation in addition to flanking the mRNA coding sequence with 
untranslated regions (UTRs). Untranslated regions are designed to facilitate mRNA localisation, 
stability, export, and translational efficiency [169]. However, the sequence of the untranslated 
regions used in this study is unknown and therefore mRNAs transcribed from IVT templates 
containing different UTRs may have different functional properties. It is therefore important to 
determine the properties of mRNAs prior to reprogramming to ensure they are capable of being 
taken up by somatic cells with high efficiency to improve the probability that reprogramming will 
occur. 
 
Despite the advances in mRNA modifications and the suppression of interferon, mRNA-mediated 
reprogramming is not without its disadvantages. Firstly mRNA reprogramming takes two weeks 
and requires the daily addition of mRNA which is both costly and time-consuming and secondly 
current methods involve splitting the cells mid-way throughout reprogramming. This is done to 
promote fibroblast proliferation and ease overcrowding in the culture vessel [56] however in 
 
80 
doing so, any reprogramming efficiency statistics are nullified by the possibility that all of the 
emerging iPS cell colonies have been derived from a single colony that has proliferated from a 
single iPS cell. In addition, a single clonal cell line does not truly reflect the heterogeneity of the 
bulk reprogramming culture with respect to gene expression, differentiation capacity or 
cytogenetics. It is therefore important to develop reprogramming methods that avoid splitting 
the cells so that better insights into iPS cell heterogeneity can be gained through comparing iPS 
cell lines of independent clonal origin. 
 
A study by Hanna et al [56] suggested that the kinetics of reprogramming can be accelerated by 
increasing the number of cell divisions that occur during reprogramming. By inhibiting p53/p21 
expression they induced a 2-fold increase in the average cell population doubling rate that 
correlated to a ~2-fold increase in the kinetics of reprogramming. They attribute this to the 
acquisition of epigenetic marks during cell division that improve chromatin accessibility so that 
transcription factors that promote pluripotency are more actively transcribed. The study also 
describes how measures were taken to avoid reprogramming cultures from becoming over-
confluent. Over-confluency induces cells to upregulate p57 expression that inhibits cell 
proliferation which consequently reduces the efficiency of reprogramming [170]. 
 
The suggestion that the success of reprogramming is dependent upon the number of cell 
divisions [56] but that over-confluency inhibits this process [170], alludes to the notion that 
reprogramming is most efficiently executed when a balance between cytotoxicity and cellular 
proliferation is strictly controlled, enabling cells to continually divide without becoming over 
confluent. Avoiding over-confluency will also negate the requirement to passage the cells during 
reprogramming. If existing methods were optimised so that there were no requirement to split 
the cells during reprogramming then this will be advantageous in two ways. Firstly splitting the 
cells adds confusion to the process as it is unknown whether splitting improves reprogramming 
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itself or improves the survival and proliferation of emergent iPS cells. For instance, splitting the 
cells could facilitate the acquisition of epigenetic marks that enhance reprogramming or it could 
simply increase the amount of space available for iPS cells to emerge and proliferate. Secondly, 
not splitting the cells during reprogramming allows for the isolation of truly independent iPS cell 
clones, allowing for reprogramming efficiencies to be accurately calculated. Splitting cells during 
reprogramming makes it impossible to determine whether the presence of multiple iPS cell 
colony outgrowths have arisen from a single colony or from individual reprogramming events.     
 
In this chapter, we tried to establish the best possible way for our laboratory to reprogramme 
cells with mRNA in a quick and efficient manner. Even though protocols exist, they still result in a 
lot of variability and scientists often fail to achieve reprogramming [54] so we intended to 
develop our own protocol. We determined the kinetics and efficiency of reprogramming using 
mRNAs contained within commercial kits from Stemgent and Allele Biotech in addition to being 
derived from in-house DNA templates. Our findings and the characterisation of the iPS cells 
generated are presented in this results chapter. 
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3.2. Results 
   
 3.2.1. Characterisation of BJ fibroblasts 
 
In order to establish a gold standard for reprogramming we sought to use a cell 
line that can be reproducibly reprogrammed into iPS cells using mRNAs. In respect 
of this, we used the BJ fibroblast cell line (Stemgent, 08-0027) that has been 
functionally verified by Stemgent to be amenable to reprogramming. 
Characterisation was performed on BJ fibroblasts to identify endogenous mRNA 
levels and cell surface markers that are characteristically different between 
fibroblasts and pluripotent stem cells. The comparison will enable us to monitor 
the shift toward pluripotency during reprogramming experiments, described 
throughout Chapter 3.  
 
BJ fibroblasts are a widely utilised human new born foreskin fibroblast cell line that 
has a longer replicative lifespan than other established human fibroblast cell lines 
due to slower telomere shortening [104]. In addition, the BJ fibroblast cell line was 
used for reprogramming as several studies have reproducibly demonstrated that it 
can be reprogrammed using mRNAs [39, 76, 168]. Upon receipt of the BJ fibroblast 
cell line, cell banks were created to maintain a low passage working stock for future 
reprogramming experiments. BJ fibroblasts were analysed for chromosomal 
abnormalities by karyotype analysis but were found to be karyotypically normal 
exhibiting a 46XY male karyotype (Figure. 3.1A). BJ fibroblasts were analysed by flow 
cytometry to confirm a panel of cell-surface markers that are differentially 
expressed between fibroblasts and iPS cells (Figure. 3.1B). It was found that: SSEA-3, 
SSEA-4, TRA-1-60 and TRA-1-81, that are known to be expressed in hESCs and iPS 
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cells in an undifferentiated stem cell state, are not expressed in BJ fibroblasts. SSEA-
1 that is expressed when hESCs and iPS cells differentiate is also not expressed in BJ 
fibroblasts (Figure. 3.1B). One hundred percent of fibroblasts expressed TRA-1-85, a 
pan-human antigen, that shows the antibody staining procedure was successful. 
   
BJ fibroblasts were further characterised by qPCR to detect endogenous mRNA 
levels for OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG (Figure. 3.2). There were no 
detected endogenous mRNA levels for OCT4, SOX2, LIN28 or NANOG in fibroblasts 
relative to the undifferentiated control hESC line, Shef6, when analysed by qPCR. BJ 
fibroblasts do however contain a 324-fold higher level of endogenous KLF4 relative 
to levels detected in Shef6. It was also shown that endogenous cMYC mRNA levels 
were 1.8-fold higher in fibroblasts than the control hESC line. 
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6+3+10
46,XY
SSEA1 1% +ve SSEA3 7% +ve
SSEA4 18% +ve Tra-1-60 1% +ve
Tra-1-81 1% +ve Tra-1-85 100% +ve
associated with pluripotent stem cells. Metaphase spread of the BJFibroblast cell line
displaying a normal karyotype (A).
histograms represent the cell population. R3 indicates the positive expressing cells as
determined by a P3X negative control. The spread of the histogram denotes variations
debris and to discriminate against doublet cells.
A
B
Figure 3.1. Karyotyping and flow cytometric 
analysis of the BJ fibroblast cell line 
Figure 3.1: (A) Metaphase spread (methods 2.16) of the BJ Fibroblast cell line shows that BJ 
fibroblasts are karyotypically normal. (B) Flow cytometric analysis of BJ fibroblasts show that 
they do not express cell surface markers associated with pluripotency in human embryonic 
stem cells. The blue histograms represent the cell population and the spread of the 
histogra  denotes variations in fluorescent intensity. Gating was performed as described in 
methods 2.15.1.1. TRA-1-85 is a pan-human marker and 100% expression confirms th t the 
cells are human. 
Passage 19 
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Figure 3.2. Analysis of the BJ fibroblast cell line by qPCR 
Figure 3.2: The mRNA levels of OCT4, SOX2, KLF4, CMYC, LIN28 and NANOG were compared 
between the BJ fibroblast cell line at passage +9 and an undifferentiated control hESC line, 
Shef6, at passage +92. BJ fibroblasts do not express OCT4, SOX2, LIN28 and NANOG but 
cMYC and KLF4 mRNA levels were found to be ~2-fold and 324-fold higher respectively, 
relative to Shef6. CT values were normalised to GAPDH. N=1 (error bars derived from 
technical triplicates). 
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3.2.2. Comparing fluorescence levels and intensities induced by mRNAs derived 
from the RN3P plasmid and Allele Biotech IVT templates 
 
Does mRNA encoding the mWASABI fluorescent protein, derived from the Allele 
Biotech iPS induction template (ABP-FP-SEMWASABI), transfect BJ fibroblasts 
more efficiently than mRNA encoding eGFP derived from the RN3P template 
(methods 2.17.7)? If the Allele Biotech templates generate mRNA that is less 
susceptible to degradation compared to mRNAs transcribed from RN3P, mRNAs 
transcribed from Allele Biotech templates may be more appropriate for use in 
reprogramming experiments that rely on the overexpression of exogenous mRNAs 
to be sustained.  
 
MRNAs encoding fluorescent proteins mWASABI and eGFP, were transcribed from 
the Allele Biotech IVT template (ABP-FP-SEMWASABI) and the RN3P DNA template 
(methods 2.17.7) respectively and introduced into BJ fibroblasts to determine the 
efficiency that each mRNA was taken up by the cells, based on fluorescence levels 
and fluorescence intensity. The successful uptake of mRNA by the fibroblasts will 
cause the fibroblasts to fluoresce. BJ fibroblasts were seeded at a density of 2x105 in 
Pluriton medium and then 400ng of modified (methods 2.20) or unmodified 
(methods 2.20.1) mWASABI or eGFP mRNA was introduced into the cells for 24 
hours. After 24 hours, the cells were visualised under an EVOS FL Cell Imaging 
System (Figure. 3.3). The only well that did not contain visibly fluorescing cells was 
that introduced to unmodified RN3P eGFP mRNA.  
 
After imaging, the percentage of fluorescing cells and the median fluorescent 
intensities were quantitatively analysed by flow cytometry. It was found that >95% 
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of fibroblasts were fluorescing following the addition of modified and unmodified 
mWASABI and modified eGFP (Figure. 3.3) mRNA, indicating the fibroblasts had 
taken up both mRNAs successfully. Adding unmodified eGFP mRNA into fibroblasts 
resulted in less than 10% of cells fluorescing. Fewer than 5% of BJ fibroblasts were 
fluorescing in the untreated and mock transfected controls and were 350-fold and 
200-fold dimmer respectively than the well containing modified mWASABI mRNA. 
However, the addition of modified mWASABI mRNA into BJ fibroblasts induced 
fluorescent intensity levels 19-fold brighter compared to when modified eGFP was 
added to BJ fibroblasts. The fluorescent intensities of the other wells that had been 
introduced to mRNA appeared to diminish in the following order; unmodified 
mWASABI, modified eGFP and lastly unmodified eGFP. Controls included an un-
treated well of BJ fibroblasts and a mock transfected well. The mock transfected well 
contained Stemfect transfection reagent and buffer to test whether the reagents 
affected the fluorescence levels or intensities in any way relative to the untreated 
control. 
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Figure 3.3. Comparing fluorescence levels and intensities induced by 
mRNAs derived from the RN3P plasmid and Allele Biotech IVT templates 
Figure 3.3:  A dose of 400ng modified (methods 2.20) and unmodified (methods 2.20.1) eGFP and 
mWASABI mRNA was introduced in to BJ fibroblasts for 24 hours. One hundred percent of cells 
fluoresced when introduced to unmodified and modified mWASABI and modified eGFP, however the 
fluorescent intensity of modified mWASABI was ~19-fold higher than modified eGFP. Untreated and 
mock transfected controls contained <5% fluorescing cells. N=1. Scale bars = 400µm. 
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3.2.3 Commercial template-derived mRNAs induce higher levels of mRNA in 
fibroblasts compared to mRNAs derived from in-house DNA templates after a 
single transfection 
 
mWASABI mRNA was determined to be 19-fold brighter than eGFP mRNA when 
introduced in to BJ fibroblasts. One reason this may occur is that the former was 
better at getting into the cells and thus there were more vectors per cell resulting 
in a higher fluorescent intensity. Are mRNAs encoding the reprogramming factors 
that are derived from Allele Biotech IVT templates (ABP-SC-SEIPSET) also better at 
getting into BJ fibroblasts compared to mRNAs encoding the reprogramming 
factors derived from RN3P templates (methods 2.17.7)?  
 
To test this I introduced a cocktail of exogenous mRNAs encoding OCT4, SOX2, KLF4, 
cMYC, LIN28 and NANOG derived from Allele Biotech IVT templates (ABP-SC-
SEIPSET) or from RN3P templates (methods 2.17.7) into BJ fibroblasts and assessed 
mRNA levels by qPCR after 24 hours. This was to determine how efficiently the 
reprogramming factor mRNA can get in to the cells. The comparison was extended 
to include Allele Biotech’s 6-factor mRNA reprogramming premix (ABP-SC-6FMRNA) 
that contains pre-made mRNAs encoding the six factors; M3O, SOX2, KLF4, cMYC, 
LIN28 and NANOG. M3O is a fusion between the OCT4 gene and the transcriptional 
activation domain of MYOD1 [68], a potent inducer of gene expression [171].  
 
The mRNA cocktails contained a three-fold relative increase of OCT4 or M3O to 
SOX2, KLF4, cMYC, LIN28 and NANOG. Human foreskin fibroblasts were seeded at a 
density of 3x105 on Matrigel in Pluriton medium. After 24 hours, 400ng of each 
mRNA cocktail derived from the three aforementioned sources (ABP-SC-SEIPSET, 
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ABP-SC-6FMRNA and RN3P) were added to the cells for a further 24 hours. The cells 
were then harvested and analysed by qPCR to quantify the mRNA levels in the 
fibroblasts relative to an undifferentiated hESC control cell line (Figure. 3.4). Un-
treated fibroblasts were used as a negative control. The 6-factor reprogramming 
premix (ABP-SC-6FMRNA) increased mRNA levels in fibroblasts to a greater extent 
than mRNAs that had been in vitro transcribed from the Allele Biotech IVT templates 
(ABP-SC-SEIPSET) or from RN3P, relative to an undifferentiated Shef6 hESC line 
(Figure. 3.4). The levels of mRNA in BJ fibroblasts following the introduction of the 6-
factor reprogramming premix were between 4-fold and 21-fold higher than those 
induced by Allele Biotech IVT template-derived mRNAs and were between 1.3-fold 
and 442-fold higher than mRNA levels induced by RN3P template-derived mRNAs. 
The addition of cMYC mRNA derived from the Allele Biotech IVT template (ABP-SC-
SEIPSET) did not increase cMYC mRNA levels in BJ fibroblasts after 24 hours. No 
effect was observed on LIN28 and OCT4 mRNA levels after 24 hours following the 
addition of mRNAs derived from RN3P templates.  
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Figure 3.4. Comparing mRNA levels in BJ fibroblasts following the                           
introduction of exogenous mRNAs from different sources 
Figure 3.4: Three mRNA cocktails containing OCT4 / M3O, SOX2, KLF4 CMYC, LIN28 and NANOG derived 
from the 6-factor mRNA reprogramming premix (ABP-SC-6FMRNA), RN3P templates (methods 2.17.7) and 
Allele Biotech IVT templates (ABP-SC-SEIPSET) were added to separate wells containing BJ fibroblasts at a 
dose of 400ng and analysed by qPCR to determine the level of each mRNA in the cells. The levels of mRNA 
in BJ fibroblasts following the introduction of 6f mRNA reprogramming premix were between 4-fold and 
21-fold higher than mRNA levels induced by Allele Biotech IVT template-derived mRNAs and were 
between 1.3-fold and 442-fold higher than mRNA levels induced by RN3P template-derived mRNAs. CT 
values were normalised to GAPDH. N=1 (error bars derived from technical triplicates). 
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3.2.4 Inactivated mouse embryonic fibroblasts act as a buffer during mRNA 
transfection by taking up mRNAs 
 
Inactivated MEFs are commonly used to support reprogramming by acting as a 
feeder layer that releases nutrients into the culture medium. If mRNAs can enter 
into mitotically inactivated MEFs, it is perceivable that repeated addition of mRNA 
during reprogramming will trigger an intracellular immune response that will 
cause the inactivated MEFs to die and thus inhibit reprogramming. Are mRNAs 
added during reprogramming taken up by inactivated MEFs?  
 
To determine whether mRNAs are taken up into inactivated MEFs, 1x105 MEFs were 
plated in a 6-well plate in DMEM 10% FBS for 24 hours. Four hundred nanograms of 
mWASABI mRNA was added to the cells for a further 24 hours. The cells were then 
imaged on an EVOS fluorescent microscope and analysed by flow cytometry to 
quantify the number of fluorescing cells. It was found that 83% of the inactivated 
MEFs fluoresced green after 24 hours following the single addition of 400ng 
mWASABI mRNA (Figure. 3.5).   
 
 
 
 
 
 
 
 
 
 
93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Inactivated MEFs are capable of taking up  
and translating mRNA introduced exogenously 
Figure 3.5: Adding mWASABI mRNA in to inactivated MEFs causes them to fluoresce. A cell density of 
1x105inactivated MEFs were plated in a 6-well culture plate on gelatinised plastic in DMEM 10%  
FCS for 24 hours. A dose of 400ng of mWASABI mRNA was then introduced into the MEFs for a further 
24 hours. (i) Images of fluorescent cells (white arrows) were taken on an EVOS FL Cell Imaging System 
(Life Technologies) (GFP settings: 80% light intensity, 250ms exposure). (ii) Fluorescence levels were 
assessed by flow cytometry and it was found that 83% of the MEFs expressed mWASABI (mWASABI is 
detectable via the GFP channel at a wavelength of 488nm). The untreated control contained 0% 
fluorescing cells after 24 hours. White arrows indicate fluorescing MEFs. Scale bars = 400µm. 
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  3.2.5. Initial reprogramming attempt takes 32 days and requires passaging 
 
In order to improve upon the kinetics and efficiency of reprogramming, a ‘gold 
standard’ process must first be established. Modifications to this process can then 
be made to try and improve the speed and efficiency that iPS cells can be 
generated. In this section (3.2.5) we establish the gold standard process by 
generating a set of integration-free iPS cells, derived from BJ fibroblasts using the 
fully tested and validated mRNA reprogramming kit from Stemgent (00-0071).  
 
The mRNAs included within the Stemgent kit (00-0071) encode five reprogramming 
factors; OCT4, SOX2, KLF4, cMYC and LIN28 that are separately aliquoted to allow for 
adjustments to be made to individual mRNA concentrations and combined mRNA 
cocktail stoichiometry if required. An mRNA cocktail containing the five 
reprogramming factors was created as per the manufacturer’s instructions and 
frozen at -80°C in single use aliquots so that when the mRNA was required during 
reprogramming, the number of freeze-thaw cycles the mRNA was subjected to 
would be limited. Each mRNA cocktail contained a three-fold relative increase of 
OCT4 on the basis that this improves the efficiency of reprogramming [53]. The 
mRNA reprogramming kit (00-0071) also contained B18R that was frozen in 2µg 
aliquots to be used at a final concentration of 200ng/ml.  
 
On day minus-one of reprogramming, BJ fibroblasts were seeded at a density of 
1x105 in a 6-well culture plate containing 2x105 inactivated MEFs. From day zero 
onwards on a once-daily basis, one microgram of the mRNA cocktail was added to 
the BJ fibroblasts in 2ml Pluriton medium to achieve a final concentration of 
500ng/ml. The fibroblasts were cultured in a 37°C incubator at 5% O2. One hundred 
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nanograms of nuclear-GFP (nGFP) was added daily with the OCT4, SOX2, KLF4, cMYC 
and LIN28 mRNA cocktail to monitor the successful uptake of mRNA in to the cells.  
 
On day three, the fibroblasts had reached near confluency and on day 22, mounds of 
cells had appeared in the culture (Figure. 3.6B, white arrows) indicating the cell 
culture had become over-confluent or potentially iPS cells had emerged. On day 32, 
the BJ fibroblasts began to senesce so the culture was trypsinised and split amongst 
three wells containing MEF feeder layers that had been seeded at a density of 2x105 
in Pluriton medium. Cell counting of the fibroblast cells following the splitting step 
was not performed as to not lose potential iPS cells in the cell counting process. On 
day 36, iPS cell colony outgrowths could be seen in the culture (Figure. 3.6B, orange 
boxes). The iPS cell colonies were isolated from the culture and grown as individual 
cell lines, characterised and then frozen in liquid nitrogen. The cell lines were named 
‘2SG PiPS X’ after the reprogramming experiment from which they were obtained 
(i.e. 2), the mRNA manufacturer (SG), type of cell line (iPS) and clone number (001 < 
n < 018).  
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Figure 3.6. IPS cell generation using the Stemgent Reprogramming Kit 
Figure 3.6: (A) Generation of iPS cells using the Stemgent reprogramming kit (00-0071) was achieved in 
37 days. (i) Inactivated MEFs were seeded at 2x105 into a 6-well culture plate in 10% DMEM FCS for 48 
hours. (ii) BJ fibroblasts were then seeded at a density of 1x105 onto the MEF feeder layer in 10% 
DMEM FCS for 24 hours. (iii) After 24 hours, the media was replaced with 2mls MEF conditioned hESC 
media. (iv) Reprogramming factor mRNA from the Stemgent reprogramming kit was added daily until 
day 32. (v) As the cells had formed a monolayer, they were trypsinised using 0.25% trypsin-EDTA 
(Sigma) and seeded onto an inactivated MEF feeder layer. (B) Phase contrast images depicting 
mounding cells (white arrows) and the emergence of iPS cell colonies (orange rectangles). Scale Bars = 
1000μm 
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3.2.6 Characterisation of iPS cell lines 
 
IPS cells were generated using the Stemgent mRNA reprogramming kit (00-0071) 
however it is necessary to assess the characteristics of these iPS cells to validate 
that they are representative of pluripotent stem cells. To do this, the phenotype 
and functional characteristics of the iPS cells was determined by analysing mRNA 
levels (qPCR analysis), expression of cell surface markers (flow cytometry), 
presence of chromosomal abnormalities (karyotype analysis) and assessing their 
capacity to differentiate (embryoid body formation), compared to a positive 
control pluripotent stem cell line. 
 
Following the successful reprogramming of the BJ fibroblast cell line, two of the iPS 
cell lines were characterised; 2SG PiPS 006 and 010, to test whether they had truly 
manifested pluripotency. These clonal lines were selected for characterisation, as 
they were the quickest to be expanded after isolation from single colonies. The 2SG 
PiPS 006 and 010 cell lines were analysed by qPCR and flow cytometry at passage 
six, 30 days after the final addition of mRNA took place during reprogramming. QPCR 
analysis detected that the 2SG PiPS 006 cell line contained a ~7-fold increase in 
NANOG mRNA levels relative to the control hESC line (Shef6). The mRNA levels for 
OCT4, SOX2, KLF4, cMYC and LIN28 in the 2SG PiPS 006 cell line were detected at 
similar levels relative to Shef6 (Figure. 3.9). In the 2SG PiPS 010 cell line, SOX2 mRNA 
levels were found to be similar to the hESC control cell line however the remaining 
factors were detected at elevated levels: OCT4 (2-fold), KLF4 (8-fold), cMYC (2.5-
fold), LIN28 (4-fold) and NANOG (7-fold), relative to the Shef6 control hESC line.   
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Karyotyping was performed on both iPS cell lines at passage 22. Both cell lines were 
karyotypically normal (Figure. 3.7). The cell lines were then analysed by flow 
cytometry and were found to express cell-surface markers typically expressed in 
pluripotent stem cells including SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 at similar 
levels (Figure. 3.8) to the control hESC line.  
 
To test whether the 2SG PiPS 010 cell line was pluripotent, the cells were induced to 
differentiate spontaneously as embryoid bodies for ten days alongside a control 
hESC line (Figure. 3.10) in neutral conditions (Table 2.4). After 10 days, RNA was 
extracted from the embryoid bodies, reverse transcribed to cDNA and then analysed 
by qPCR to detect the expression of markers characteristic of the three germ layers 
endoderm, mesoderm and ectoderm. The markers used to identify differentiation 
toward the three germ layers were GATA6, FOXA2 and ISL1, indicative of 
differentiation towards endoderm, CD34 and COL1A1 to mesoderm and PAX6 and 
GATA2 to ectoderm. The expression of OCT4, NANOG and SOX2 was also assessed to 
determine the differentiation status of the cells. Inducing the 2SG PiPS 010 cell line 
to differentiate as embryoid bodies resulted in the down-regulated expression of 
OCT4, NANOG and SOX2 suggesting that the cells were analysed in a differentiated 
state. In this differentiated state, the 2SG PiPS cell line expressed markers of all 
three germ layers (Figure. 3.10) thus confirming the iPS cell line’s pluripotency 
status. 
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Figure 3.7: Two iPS cell lines of independent clonal origin were isolated from a single 
reprogramming culture following repeated addition of Stemgent mRNA. The two cell 
lines, 2SG PiPS 006 and 010 were cultured to passage +22 and following karyotype 
analysis (methods 2.16) were determined to be karyotypically normal (46XY). 
PiPS 006
   +22
PiPS 010
   +22
46,XY
Metaphase spread of (i) PiPS 010 and (ii) PiPS 006 cell lines.
Figure 12. Karyotype analysis of the 2SG PiPScell lines
46,XY
i
ii
Figure 3.7. Karyotype analysis of two clonal iPS cell lines                    
derived using the Stemgent mRNA reprogramming kit:                              
2SG PIPS 010 and 2SG PIPS 006 
Passage 22 
Passage 22 
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Figure 3.8. The 2SG PiPS 006 and 010 cell lines exhibit similar cell           
surface marker expression profiles to that of a control hESC line 
Figure 3.8: Flow cytometric analysis of (i) H9 hESC line passage +89, (ii) 2SG PiPS 006 passage +6 
and (iii) 2SG PiPS 010 passage +6 cell lines have similar expression for markers; SSEA-1, SSEA-3, 
SSEA-4, TRA-1-60, TRA-1-81 and TRA-1-85. Fluorescent cells were determined by gating against a 
P3X control (dashed line). Gating strategy is described in methods 2.15.1.1. The spread of the 
histogram denotes variations in fluorescent intensity.  
 
H9 hESC line 
Passage 89 
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Figure 3.9. Analysis of the 2SG PiPS 006 and 010 cell lines by qPCR 
Figure 3.9: qPCR analysis of the 2SG PiPS 006 and 010 cell lines at passage +6 reveal mRNA 
levels comparable to an undifferentiated control hESC line, Shef6, with respect to genes; 
OCT4, SOX2, KLF4, CMYC, LIN28 and NANOG. 2SG PiPS 010 has elevated levels of the  
aforementioned genes compared to both the control hESC line and 2SG PiPS 006. CT values 
were normalised to GAPDH. N=1 (error bars derived from technical triplicates). 
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Figure 3.10. Spontaneous differentiation of the 2SG PiPS cell line        
induces gene expression for markers of all three germ layers 
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Figure 3.10. Spontaneous differentiation of the 2SG PiPS cell line         
induces gene expression for markers of all three germ layers 
Figure 3.10: The 2SG PiPS 010 cell line was spontaneously differentiated as embryoid bodies for 10 
days in the neutral condition (Table 2.4). Following qPCR analysis, the RQ values showed increased 
gene expression levels for endodermal (GATA6, FOXA2), mesodermal (CD34) and ectodermal (PAX6) 
markers relative to an undifferentiated control. Under the same conditions, Shef6 cells increased 
gene expression for ISL1 (endodermal), CD34, COL1A1 (mesodermal) and PAX6 (ectodermal) 
markers. CT values were normalised to GAPDH. N=1 (error bars derived from technical triplicates). 
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3.2.7. The kinetics of reprogramming can be accelerated by using mRNAs that have been in 
vitro transcribed with modified nucleotides 
 
Successfully reprogramming BJ fibroblasts using the Stemgent mRNA reprogramming kit 
(00-0071) set a benchmark for the efficiency and kinetics of reprogramming that we can 
aim to improve through modifications to the process. Here we test whether the 
incorporation of modified nucleotides in to mRNAs transcribed from the Allele Biotech IVT 
induction templates (ABP-SC-SEIPSET) can improve upon the speed and efficiency of the 
reprogramming process.  
 
The Allele Biotech IVT templates (ABP-SC-SEIPSET) are either linearised DNA templates or 
PCR products containing a double stranded promoter region. As the in vitro transcription 
(IVT) reactions are performed in house, this afforded us control over the incorporation of 
modified nucleotides, capping and polyadenylation of mRNAs during the IVT reactions. We 
determined whether these modifications, specifically the incorporation of 5-Methylcytidine-
5'-Triphosphate (Stratech, 5-0613-295-IBA) and Pseudouridine-5'-Triphosphate (Stratech, 
NU-1139L-JEN) modified nucleotides into mRNAs during IVT reactions enhances the 
reprogramming process.  
 
The IVT templates supplied within the kit (ABP-SC-SEIPSET) contained coding regions for 
OCT4, SOX2, KLF4, cMYC and LIN28 as well as a monomeric green fluorescent protein 
mWASABI and NANOG that has previously been shown to increase the efficiency of 
reprogramming [39, 45]. The templates for all seven factors were in vitro transcribed using 
the T7 MEGAscript Kit (Thermo Fisher, AM1333) as described in methods 2.20 and then 
diluted to a concentration of 100ng/µl. All of the factors with the exception of mWASABI 
mRNA were then combined to form an mRNA cocktail at a molar ratio of 3:1:1:1:1:1, 
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containing a three-fold relative increase of OCT4 to the other reprogramming factors and 
then stored at -80°C. The mWASABI mRNA was stored separately from the mRNA cocktail so 
that it could be introduced independently and intermittently throughout reprogramming to 
report whether the mRNAs being added to the reprogramming cultures were being taken up 
by the cells. Single-use aliquots of both the mRNA cocktail and mWASABI mRNA were frozen 
at -80°C until required.  
 
Once the mRNA cocktails had been prepared, reprogramming was executed as follows. BJ 
fibroblasts were plated onto hESC-qualified Matrigel-coated 6-well plates at a density of 
1x105 in Pluriton medium. A Matrigel extra-cellular matrix was used to limit the unwanted 
transfection of mRNAs into inactivated MEFs (as shown in Figure. 3.5). Eight hundred 
nanograms of the mRNA cocktail was then added daily for eight days into the BJ fibroblasts 
and by day three there was evidence of morphological changes in the reprogramming 
culture in that the fibroblasts had compacted and appeared to lack fibroblastic processes 
(Figure. 3.11B, white arrows). On day nine the addition of mRNA was ceased and 2x105 
inactivated MEFs were added to the reprogramming well to support the emergence of iPS 
cells. The culture was maintained in Pluriton medium until day 21 and a further 2x105 MEFs 
were added on day 13. On day 21, it was observed that no iPS cells had emerged so the 
culture was trypsinised with 0.25% trypsin-EDTA and replated onto a MEF coated 6-well 
culture plate. After 24 hours, iPS cell colonies could be seen in the culture vessel. 
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Figure 3.11: (A) Reprogramming using the Allele Biotech iPS induction template set (ABP-SC-SEIPSET) 
generated iPS cells in 22 days. (i) BJ fibroblasts were seeded at a density of 1x105 onto hESC-qualified 
Matrigel-coated 6-well culture plates. (ii) mRNAs derived from Allele Biotech templates (OCT4, SOX2, KLF4, 
CMYC, LIN28 and NANOG) were added daily at a dose of 800ng until day 9. (iii) Between days 9 and 20 no 
further mRNA was added but the reprogramming culture was fed daily with Pluriton medium 
supplemented with 1X Pluriton Supplement and 200ng/ml B18R for a further 12 days. (iv) Inactivated MEFs 
were added at day 9 (v) and day 13 to support emergent iPS cells (vi) The entire culture was trypsinised on 
day 21 and replated onto a MEF feeder layer. iPS cell colonies (orange rectangles) could be seen to emerge 
after 24 hours. (B) Phase contrast images depicting morphological changes (white arrows) throughout the 
reprogramming process. Scale bars = 1000μm. 
Figure 15. Timeline of reprogramming and cell morphology
changes throughout reprogramming (3AB)
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transfectionswere performed until day 9 and then (iii) continually fed with Pluriton
supplemented with 1XPluriton Supplement and 200ng/ml B18Rfor a further 12 days.
Inactivated MEFswere added at (iv) day 9 and (v) day 13. (vi)The entire culture was
changes throughout the reprogramming process and the emergence of iPScolonies.
5
Figure 3.11. Reprogramming BJ fibroblasts with mRNAs                                   
from t e All le Biotech iPS induction template set 
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3.2.8. Emergence of iPS cell colonies without passaging 
 
It has been shown that a fusion protein between OCT4 and MYOD1 (called M3O) more 
effectively recruits chromatin modifying proteins, than OCT4 alone, to pluripotent loci 
during reprogramming [68]. We determined whether the reprogramming process could be 
accelerated by using the 6-factor reprogramming premix (ABP-SC-6FMRNA) that contains 
the synthetically engineered OCT4-MYOD (M3O) fusion gene in replacement for 
conventional OCT4.  
 
Reprogramming was initiated by seeding BJ fibroblasts onto hESC-qualified Matrigel in 
Pluriton at a cell density of 5x104 for 24 hours. One millilitre of Pluriton medium was added 
to a sterile 6-well plate and equilibrated for 15 minutes at 37°C in 5% O2. After equilibration, 
B18R was added at 200ng/ml and the 6-factor premix (ABP-SC-6FMRNA) was added at 
400ng/ml rocking back and forth to mix. The supplemented media was placed onto the 
target cells on day zero and the process repeated daily until day 11 (Figure. 3.12A). Adding 
mRNA to the media before it is placed on the cells as opposed to adding the mRNA directly 
to target cells in a drop-wise fashion prevents pockets of high concentrations of mRNA from 
accumulating that, if insufficiently mixed into the media, can be toxic to the cells. As cells 
respond unfavourably to high concentrations of mRNA and are sensitized to environmental 
cues during reprogramming it is desirable to supplement and mix the media prior to adding 
it to the target cells, adding the media to the side of the well during each media change. 
Cytotoxicity was counteracted on day five by increasing the B18R concentration to 400ng/ml 
and on day six and nine through the addition of 1.5x105 and 3x105 inactivated MEFs 
respectively. On days 7 through 9, the mRNA concentration was decreased by half to 
200ng/ml to mitigate against any mRNA-induced toxicity. The target cells were gradually 
rescued from cell death via the aforementioned anti-apoptotic measures. Signs of cellular 
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proliferation ensued and thus the mRNA concentration was increased to 300ng/ml on day 
10. Signs of emerging colonies resulted in no further mRNA being added to the cells and the 
media was switched to un-supplemented Pluriton, containing no B18R or exogenous mRNA, 
for three days to both encourage iPS cell growth and support non-reprogrammed 
fibroblasts. Large, undifferentiated iPS cell colonies were picked on day 14 (Figure. 3.12B) 
into MEF-coated 12-well plates. Prior to passaging, a phase contrast and GFP image of the 
reprogrammed well was captured to show the location and number of colony outgrowths 
(Figure. 3.12C). In addition, the GFP image shows the prevalence of cytotoxicity that 
occurred when using the reprogramming method outlined in Figure 3.12A. Most of the cell 
death was situated towards the middle of the well possibly due to the use of non-meniscus 
free culture ware.  
 
Twelve colonies emerged in total, all of which were expanded in culture and frozen down. 
One of these clonal lines named 5AB PiPS, was further characterised to assess the level of 
newly manifested pluripotency. This cell line was shown to be karyotypically normal (46 XY) 
(Figure. 3.13) and expressed cell-surface markers; SSEA-1, SSEA-3 and TRA-1-60 at 
comparable levels to an undifferentiated control hESC line, H7 S14 (Figure. 3.14). QPCR 
analysis for genes; OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG confirmed the mRNA levels 
in 5AB PiPS after four and fifteen passages were similar to those found in Shef6 hESCs 
(Figure. 3.15). While all the mRNA levels were elevated in the 5AB PiPS cell line after four 
passages in comparison to undifferentiated Shef6 cells, by passage fifteen the mRNA levels 
had normalised to levels more closely resembling the hESC control. The differentiation 
capacity of the 5AB PiPS cell line was then determined by inducing the cells to differentiate 
as embryoid bodies for ten days in the neutral condition (Table 2.4). Embryoid bodies 
formed from differentiated 5AB PiPS cells expressed markers of all three germ layers when 
analysed by qPCR (Figure. 3.16) thus confirming the 5AB PiPS cell line was pluripotent. 
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Figure 16. Reprogramming Timeline, colony morphology and the
distribution of emerging iPScolonies (5AB)
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mRNA was transfected everyday until day 11.Toxicity during reprogramming was mitigated by
(iii) increasing the B18Rconcentration to 400ng/ml from 200ng/ml (iv) adding 1.5x10 feeders
on day 6 and (vi) 3x10   on day 9 and (v) decreasing the mRNA concentration to 200ng/ml between
days 7 and 10. (vii)The mRNA concentration was increased to 300ng/ml and (viii) colonieswere
images of colony outgrowths. (C) Stitched GFP image portraying the extent of toxicity and the
locations of emergent colonies on day 14.
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Figure 3.12. Generating iPS cells using the Allele                                        
Biotech 6-factor reprogramming premix 
Figure 3.12: (A) Reprogramming timeline using the Allele Biotech 6-factor premix mRNA (ABP-SC-6FMRNA). (i) BJ 
fibroblasts were seeded at a density of 5x105 onto hESC-qualified Matrigel-coated 6-well culture plates on day -
1. (ii) After 24 hours, 400ng/ml 6-factor premix mRNA was added daily for 11 days. (iii) On day 5, a small number 
of cells were observed to have died so the B18R concentration was increased to 400ng/ml from 200ng/ml. (iv) 
To further support the cells in the face of apoptosis, inactivated MEFs were added on day 6 at a density of 
1.5x105 and (vi) on day 9 at a density of 3x105. (v) The mRNA concentration was also decreased to 200ng/ml 
between days 7 and 10. (vii) The mRNA concentration was increased to 300ng/ml on the observation that cells 
had begun to proliferate. (viii) IPS cells appeared on day 11 so no more mRNA was added and the medium was 
replenished daily with fresh Pluriton medium. (ix) iPS cell colonies were picked on day 14. (B) Phase contrast 
images of an iPS cell colony on day 14 and six days later following passaging (orange rectangles). (C) Stitched 
GFP image portraying the extent of toxicity (grey area) and the locations of emergent colonies on day 14 (black 
arrows). 
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Figure 3.13. Karyotype analysis of the 5AB PiPS cell line 
Figure 3.13: Karyotype analysis was performed on the 5AB PiPS cell line that was 
reprogrammed from BJ fibroblasts using the Allele Biotech 6-factor premix mRNA 
(ABP-SC-6FMRNA). The cell line was karyotypically analysed (methods 2.16) for 
chromosomal abnormalities at passage +15 and was determined to be karyotypically 
normal (46XY). 
5ABPiPS
    +15
Figure 17. Karyotype analysis of the 5ABPiPScell lines
Metaphase spread of the 5ABPiPScell line exhibiting a 46, XY normal karyotype.
46,XY
Passage 15 
 
111 
  
Figure 3.14. Flow cytometric analysis of the 5AB PiPS cell line            
compared to a control hESC line and the parental BJ fibroblasts 
Figure 3.14: Flow cytometric analysis of the 5AB PiPS cell line at passage +6 compared 
to an undifferentiated hESC control line, H7 S14 at passage +28. Both cell lines 
express markers of undifferentiated pluripotent stem cells SSEA-3 and TRA-1-60. 
SSEA-1 is not expressed in either cell line indicating the cells were analysed in an 
undifferentiated state. P3X was used to gate the cells prior to analysis as described in 
methods 2.15.1.1. TRA-1-85 was used as a positive control for the antibody staining 
procedure.  
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Figure 3.15. Analysis of the 5AB PiPS cell line by qPCR 
Figure 3.15: The 5AB PiPS cell line at passages +4 and +15 was analysed by qPCR to compare 
mRNA levels for OCT4, SOX2, KLF4, CMYC, LIN28 and NANOG relative to Shef6, an 
undifferentiated control hESC line. At passage +4, endogenous mRNA levels were elevated 
relative to the control hESC line. By passage +15 the previously elevated levels of mRNA had 
decreased to a level more similar to that of Shef6 with the exception of KLF4 and NANOG 
which are expressed 6-fold and 11-fold higher respectively. The standard error of 
measurement on the 5AB PiPS +4 analyses is consistent with a slightly elevated CT value for 
one of the three technical triplicate repeats for the loading control, GAPDH. N=1 (error bars 
derived from technical triplicates). 
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Figure 3.16. Spontaneous differentiation of the 5AB PiPS cell line                 
induces gene expression for markers of all three germ layers 
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Figure 3.16. Spontaneous differentiation of the 5AB PiPS cell line         
induces gene expression for markers of all three germ layers 
Figure 3.16: The 5AB PiPS 010 cell line was spontaneously differentiated as embryoid bodies for 10 days in 
the neutral condition (Table 2.4). Following qPCR analysis, the RQ values showed increased gene 
expression levels for endodermal (GATA6, ISL1), mesodermal (CD34, COL1A1) and ectodermal (PAX6) 
markers relative to an undifferentiated control. Under the same conditions, Shef6 cells increased gene 
expression for ISL1 (endodermal), CD34 (mesodermal) and PAX6 (ectodermal) markers. CT values were 
normalised to GAPDH. N=1 (error bars derived from technical triplicates). 
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3.2.9. mRNA dose ramping and a flexible approach to reprogramming allows for 
rapid iPS colony generation with reduced cytotoxicity 
  
The Allele Biotech 6-factor reprogramming premix (ABP-SC-6FMRNA) accelerated 
the kinetics of reprogramming, presumably owing to the inclusion of M3O mRNA 
that resulted in the generation of iPS cells, without passaging within 11 days. 
However, cytotoxicity was prevalent (Figure. 3.12C) and is a limiting factor to the 
success of reprogramming. Could the daily dose of mRNAs during reprogramming 
be optimised so that the cells would not succumb to apoptosis, were not 
prevented from proliferating and was sufficient to generate fully reprogrammed 
iPS cells? 
 
In order to assess whether increased iPS cell colony outgrowth would be achievable 
if the target cells were not lost to cytotoxic or pro-apoptotic events during 
reprogramming, mRNA dose-ramping was implemented. The rationale was that 
dose ramping provides better control over the mRNA dose per cell ratio as mRNAs 
are added in line with proliferation as opposed to being added irrespective of cell 
behaviour as most protocols suggest (Figure. 3.17E). BJ fibroblasts were plated onto 
hESC-qualified Matrigel at a density of 1x105 in Pluriton medium for 24 hours. On 
days zero and one, 200ng of 6-factor premix mRNA (ABP-SC-6FMRNA) was pipetted 
into 0.5mls of low oxygen-equilibrated (5% O2) Pluriton medium containing B18R at 
400ng/ml. The supplemented medium was then placed onto the target cells and a 
further 500µl of Pluriton medium was added four hours later to prevent 
evaporation. Upon the observation that the cells were continuing to proliferate 
despite the repeated addition of 6-factor premix mRNA (ABP-SC-6FMRNA (Figure. 
3.18B), the mRNA dose was increased to 300ng on days two through eight. On day 
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four a small percentage of the cell population had died, which is to be expected due 
to the stresses of reprogramming, so to counteract further cell death, 2x105 MEFs 
were added to the reprogramming culture and the mRNA dose was not increased. 
On day seven, clusters of cells that morphologically resembled iPS cell colonies were 
observed (Figure. 3.18B) and these cells stained positive for TRA-1-60 when analysed 
via high content screening in-situ (Figure. 3.18C). The reprogramming kinetics of our 
optimised protocol that incorporates mRNA dose-ramping has been compared to 
the kinetics of basic commercial protocols supplied with other kits (Figure. 3.17A-D). 
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Figure 3.17. Optimisation of the basic reprogramming protocol 
Figure 3.17: (A) The Stemgent protocol (00-0071) comprises 18 days whereby mRNA is repeatedly 
added to the cells. A splitting step between days 5-8 is recommended to avoid over-confluence. (B) 
The Allele Biotech iPS induction kit (ABP-SC-SEIPSET) used by Warren et al [76] adds mRNA over 17 
days and contains a splitting step at day 6. (Ci) The manufacturer’s protocol for the Allele Biotech 6-
factor reprogramming premix (ABP-SC-6FMRNA) comprises 9 days where mRNA is added to the cells 
under a strict dose-ramping regimen. (Cii) The same protocol was modified in a study by Warren [39] 
whereby mRNA (ABP-SC-6FMRNA) was added for 3 days more than the suggested protocol and a 
splitting step was used on day 6. (D) Our optimised protocol, that uses 6-factor premix mRNA (ABP-SC-
6FMRNA), uses a flexible dose ramping approach and generates iPS cells by day 9 without a splitting 
step.  
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Figure 3.17. Optimisation of the basic reprogramming protocol 
Figure 3.17: (E)  The Allele Biotech 6-factor reprogramming premix protocol (top) incorporates a 
strict dose ramping regimen whereby the mRNA dose (red line) is increased daily by 200ng 
between days 0 and 3. Our optimised protocol (bottom) increases the mRNA dose in response to 
an observed increase in cell numbers (increased height of blue area, indicated by arrows) 
compared to the day before and does not increase by a set amount each day. This modified way of 
dose-ramping provides greater control over the balance between cell proliferation and apoptosis, 
thus reducing the probability of over-confluence and cell culture-wide apoptosis that inhibit 
reprogramming.   
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Figure 3.18. Reprogramming kinetics are improved                                        
using an optimised dose-ramping approach  
Figure 3.18: (A) The 10-day reprogramming timeline using Allele Biotech 6-factor reprogramming 
premix (ABP-SC-6FMRNA). (i) BJ fibroblasts were seeded at a density of 1x105 onto hESC-qualified 
Matrigel-coated 6-well culture plates. (ii) A dose of 200ng mRNA (ABP-SC-6FMRNA) was added on 
day 0 and 1 and increased to 300ng on days 2 through 8. MRNA was added to 0.5mls of low 
oxygen-equilibrated (5% O2) Pluriton medium containing B18R at 400ng/ml and a further 500µl of 
Pluriton medium was added four hours later to a total volume of 1ml. (iii) Inactivated MEFs were 
added at a density of 2x105 on day 4 to support fibroblast proliferation. (iv) iPS cell colonies 
emerged on day 7 and were picked onto a MEF feeder layer on day 9. (B) Phase contrast images of 
emerging colonies (orange rectangles). (C) The detection of TRA-1-60 positive iPS cell colonies by 
in-situ live cell staining (methods 2.15.2) on day 9 of reprogramming (white arrows). (D) NT2 cell 
control positively fluorescing TRA-1-60 (left hand side) and NT2 negative control analysed for 
secondary antibody binding only. Scale bars =1000µm 
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3.2.10 Characterisation of iPS cell lines 
 
IPS cells were generated using an optimised mRNA dose-ramping approach in 
conjunction with the Allele Biotech 6-factor reprogramming premix (ABP-SC-
6FMRNA). In this sub-chapter, the phenotype and functional characteristics of 
these iPS cells was assessed by qPCR, flow cytometry and karyotype analysis. The 
iPS cells were also subjected to spontaneous differentiation as embryoid bodies 
for 10 days to assess their capacity to differentiate.  
 
One resultant clonal iPS cell line, named 7AB PiPS, was determined to be 
karyotypically normal (46 XY) (Figure. 3.19A). The cells were analysed by flow 
cytometry (Figure. 3.20) which showed that markers; SSEA-3, SSEA-4, TRA-1-60 and 
TRA-1-81 were expressed in over 96% of cells analysed. SSEA-1 was expressed on 
only 15% of the cells. Expression of the pan-human marker TRA-1-85 in both 7AB 
PiPS and the hESC control confirmed the staining procedure worked and was thus 
performed correctly. Considering the cell markers analysed by flow cytometry were 
expressed at abnormally high levels, for example SSEA-3 was expressed in 98% of 
the cells, it is possible that the cells had acquired a genetic mutation that maintains 
cells in an undifferentiated state. The cells were analysed by qPCR to check for a 
potential mutation in BCL2L1, a common chromosomal abnormality that once 
overexpressed confers a selective advantage over other cells. It was determined that 
BCL2L1 was not overexpressed and did not have an abnormal copy number when 
compared to negative and positive control cell lines, H7 S14 and H7 S6 respectively 
(Figure. 3.19B).  
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The 7AB PiPS cell line was further characterised at passage +5 to determine its gene 
expression profile compared to that of a control hESC line and the parental BJ 
fibroblast cell line (Figure. 3.21). QPCR analysis confirmed the 7AB PiPS cells were 
phenotypically different from the BJ fibroblast cell line from which it was derived, 
endogenously expressing genes; OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG similar 
to the hESC control. The mRNA levels for all of the genes analysed were elevated 
relative to the Shef6 control hESC line. Most notably, NANOG mRNA levels were 15-
fold higher and LIN28 mRNA levels were 5-fold higher relative to the hESC control.  
 
To qualitatively confirm the presence of endogenous OCT4 and TRA-1-60 protein, 
the cells were analysed by high content screening by staining the cells with OCT4 
and TRA-1-60 primary antibodies, goat anti rabbit AF488 (OCT4) and goat anti-
mouse AF488 (TRA-1-60) secondary antibodies and counterstaining with Hoescht 
33342 (Figure. 3.22). High TRA-1-60 and OCT4 endogenous expression was 
confirmed in the cells. Lastly to assess the differentiation capacity of the 7AB PiPS 
cell line, the cells were subjected to ten days embryoid body differentiation in the 
neutral condition (Table 2.4). The embryoid bodies were shown to express markers 
of all three germ layers after qPCR analysis (Figure. 3.23) highlighting the 7AB PiPS 
cell line’s pluripotent capacity. 
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7ABPiPS
    +6
46,XY
Figure 21. Cytogenetic analysis of the 7ABPiPScell lines
7ABPiPS are karyotypically normal and don’t express the BCL2L1 CNV. (A) Metaphase spread
of the 7ABPiPScell line exhibiting no karyotypical abnormalities and (B) qRT-PCR analysis
detected no amplification of CNV 20q11.21 determined by BCL2L1 in the 7ABPiPScell line.
H7 S14 was used as a negative control and H7 S6 was used a positive control for the 20q11.21
amplification.
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Figure 3.19. Cytogenetic analysis of the 7AB PiPS cell line 
Figure 3.19: (A) Karyotype analysis (methods 2.16) on the 7AB PiPS cell line at passage +6 revealed 
that it is karyotypically normal (B) 7AB PiPS+6 were subjected to a genomic qPCR assay to 
determine the copy number for BCL2L1, a gene commonly expressed in karyotypically abnormal 
hESCs. The copy number analysis detected no amplification of BCL2L1 in the 7AB PiPS cell line. H7 
S14 was used as a negative control and H7 S6 was used a positive control for the BCL2L1 
amplification. CT values were normalised against the housekeeping gene RELL1, a gene that 
displays a low incidence of genomic instability in hESCs. EPHA5 confirms the suitability of the first 
control.  N=1 (error bars derived from technical triplicates). 
A 
B 
Passage 6 
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Figure 3.20. Flow cytometric analysis of the 7AB PiPS cell                              
line compared to an undifferentiated hESC line 
Figure 3.20: Flow cytometric analysis of the 7AB PiPS cell line compared to an undifferentiated 
hESC control, Shef6. Both cell lines positively express markers: SSEA-3, SSEA-4, TRA-1-60 and TRA-
1-81 that are associated with an undifferentiated stem cell state. Fifteen percent of 7AB PiPS cells 
expressed SSEA-1, a marker of differentiated hESCs / iPS cells, indicating the cells were 
predominantly undifferentiated when analysed. SSEA-3 was expressed in 56% of Shef6 cells 
compared to 98% of 7AB PiPS cells suggesting that Shef6 had begun to differentiate sooner than 
7AB PiPS cells given they were both cultured in the same conditions (MEF feeder layer in hESC 
medium) for 5 days prior to the analysis. TRA-1-85 was used a positive control for the antibody 
staining. Gating (dashed line) was performed as described in methods 2.15.1.1 using P3X. 
Passage 57 Passage 20 
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Figure 3.21. Analysis of the 7AB PiPS cell line by qPCR 
Figure 3.21: qPCR analysis of the 7AB PiPS cell line at passage +5 shows mRNA levels comparable 
to the hESC control cell line, Shef6, and dissimilar to the parental BJ fibroblast line at passage +9. 
The mRNA levels for; OCT4, SOX2, cMYC and LIN28 are expressed 1.7-fold, 2.7-fold, 1.7-fold and 
2.5-fold higher respectively in 7AB PiPS cells compared to Shef6 while KLF4 and NANOG mRNA 
levels are 5-fold and 15-fold higher respectively. Analysing 7AB PiPS cells in a pristine, 
undifferentiated stem cell state or Shef6 cells that had begun to differentiate may be the reason 
for elevated levels of NANOG in 7AB PiPS cells relative to Shef6. BJ fibroblasts endogenously 
express cMYC and KLF4 as shown in Figure 3.2. CT values were normalised to GAPDH. N=1 (error 
bars derived from technical triplicates). 
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Figure 3.22. The 7AB PiPS cell line endogenously                                  
expresses OCT4 and TRA-1-60 
Figure 3.22: 7AB PiPS express intracellular OCT4 and TRA-1-60 cell surface marker as assessed by 
immunomicroscopy. 7AB PiPS were grown on MEFs in hESC medium for 4 days then fixed with 4% 
PFA. Cell surface marker staining was performed prior to permeabilisation with 0.1% Triton X 
followed by intracellular staining. Primary antibodies used were OCT4 (rabbit) at 1:100 and TRA-1-
60 (mouse) at 1:10. Secondary antibodies used were goat anti rabbit AF488 (OCT4) at 1:100 and 
goat anti-mouse AF488 (TRA-1-60) at 1:100. Controls were dual stained with the secondary 
antibodies only and all wells were stained with Hoescht 33342 at 1:1000. Scale bars = 1000µm. 
 
126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23. Spontaneous differentiation of the 7AB PiPS cell line induces 
gene expression for markers of all three germ layers 
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Figure 3.23: Two biological replicates of the 7AB PiPS cell line were spontaneously differentiated as embryoid 
bodies for 10 days in the neutral condition (Table 2.4). Following qPCR analysis, the RQ values for both 
replicates showed increased gene expression levels for endodermal (GATA6, ISL1, FOXA2), mesodermal (CD34, 
COL1A1) and ectodermal (PAX6,GATA2) markers relative to an undifferentiated control. Under the same 
conditions, Shef6 cells increased gene expression for ISL1 (endodermal), CD34 (mesodermal) and PAX6 
(ectodermal) markers. CT values were normalised to GAPDH. N=1 (error bars derived from technical 
triplicates). 
Figure 3.23. Spontaneous differentiation of the 7AB PiPS cell line induces 
gene expression for markers of all three germ layers 
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3.3. Discussion 
 
MRNAs derived from different sources were found to exhibit different efficiencies in terms of 
their ability to get into the fibroblast cells and the number of vectors that enter each cell. In 
fibroblasts, the addition of mWASABI mRNA containing modified nucleotides derived from an 
Allele Biotech IVT template (ABP-SC-SEIPSET) and eGFP mRNA derived from the RN3P plasmid 
(methods 2.17.7) resulted in >95% of the cells exhibiting fluorescence. However, the addition of 
mRNAs into fibroblasts that were derived from the RN3P plasmid and did not contain modified 
nucleotides resulted in less than ten percent of the cells fluorescing. Possible reasons for this 
include mRNA degradation or a failure for mRNAs to successfully enter the cells following 
lipofection. Considering that the mRNAs used were flanked by identical untranslated regions 
(UTRs), capping structure and polyA tail, suggests the mRNA open reading frame where the 
modified nucleotides are incorporated is the specific region whereby differences regarding the 
susceptibility to degradation may occur, possibly via miRNAs and endonucleases. It is unlikely 
that the reason why mRNAs that were not transcribed with modified nucleotides had low 
fluorescence levels was attributable to an inability to enter the cells. This is reinforced by the 
finding that mRNAs derived from Allele Biotech templates (ABP-SC-SEIPSET) that were 
transcribed without modified nucleotides could achieve near 100% transfection efficiency.  
 
Fibroblasts that were subjected to the addition of mWASABI mRNA transcribed with modified 
nucleotides were determined to be 19-fold brighter than when eGFP mRNA containing modified 
nucleotides was added. While this could be due to an increased mRNA per cell ratio or by virtue 
of its derivation from Clavularia coral, it is more likely that mWASABI mRNA is more resilient to 
degradation or is more easily translated. Firstly mWASABI protein has been reported to fluoresce 
only 1.6-fold brighter than eGFP [164] which does not then account for the 19-fold difference in 
median fluorescent intensity. Secondly, the same transfection reagent and amounts were used 
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for all transfections concerning both eGFP and mWASABI mRNAs therefore making the 
transfection reagent a non-limiting factor as to why cells transfected with mWASABI were 
brighter than those transfected with eGFP. It is therefore more likely that mWASABI fluoresces 
at a higher intensity than eGFP because the Allele Biotech IVT template (ABP-SC-SEIPSET) from 
which it was transcribed is more efficiently designed to improve the half-life of the mRNA 
transcript, prevent degradation by nucleases and / or increase how efficiently the mRNA is 
translated. To further this point it was found that mRNAs encoding OCT4, SOX2, KLF4, cMYC, 
LIN28 and NANOG derived from Allele Biotech IVT templates (ABP-SC-SEIPSET) increased mRNA 
levels on average to 206-fold higher than what is endogenously expressed in undifferentiated 
hESCs. In comparison, mRNAs encoding OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG derived 
from the RN3P template induced a 99-fold increase in mRNA levels relative to the same control 
hESC line. This supports the hypothesis that mRNAs derived from Allele Biotech IVT templates 
(ABP-SC-SEIPSET) facilitate mRNA localisation, stability, export or translational efficiency more 
efficiently that mRNAs transcribed from linearised RN3P plasmids. 
 
Prior to reprogramming using mRNAs derived from Allele Biotech IVT templates (ABP-SC-
SEIPSET) (results 3.2.3), I showed that mitotically inactive MEFs are capable of taking up 
exogenous mRNA. Considering reprogramming protocols require the use of an inactivated / 
irradiated fibroblast feeder layer, I investigated whether mRNAs would be taken up by the 
feeder layer. This could be problematic for the following reason. If mRNAs can enter into 
mitotically inactivated MEFs, it is likely that the repeated addition of single-stranded mRNAs 
would trigger an intracellular immune response that would cause the inactivated MEFs to die. As 
a result, the feeder layer would be eradicated, inhibiting the emergence of iPS cell colonies. I 
tested whether this was the case by adding a single dose of mWASABI mRNA into inactivated 
MEFs and analysed the fluorescence levels by flow cytometry after 24 hours. I found that the 
MEFs were positively expressing mWASABI protein in that they were fluorescing after 24 hours 
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indicating they do take up exogenous mRNA. Considering MEFs are transfected at the same time 
as the intended fibroblast cells it is important to add MEFs to cell cultures where a MEF layer is 
used and when repeated transfection of mRNAs is necessary, so that the supportive feeder layer 
can be replenished. 
 
I have successfully shown reprogramming of the BJ fibroblast cell line firstly with the Stemgent 
reprogramming kit (00-0071), secondly using mRNAs in-vitro transcribed from the Allele Biotech 
IVT templates (ABP-SC-SEIPSET) and then on two occasions with the 6-factor premix mRNA (ABP-
SC-6FMRNA). IPS cells were generated after 32, 21, 14 and 9 days respectively indicating a 
consistent improvement in the kinetics of reprogramming. I found that reprogramming using the 
6-factor premix mRNA (ABP-SC-6FMRNA) gave rise to iPS cells in a shorter timeframe than mRNA 
from other sources. This could be attributable to a reduced susceptibility to degradation or a 
higher translational efficiency. It could also be that the 6-factor premix (ABP-SC-6FMRNA) 
contains codon-optimised mRNAs. Codon optimisation is a technique used to modify mRNAs to 
enhance mRNA stability that results in an increase in protein expression compared to their non-
codon-optimised counterparts. Achieving a sufficient level of exogenous transcription factor 
expression is a necessity in driving target cells to reprogramme and may explain why mRNAs that 
produce insufficient expression levels have difficulty in activating an endogenous pluripotency 
network that leads to the emergence of iPS colonies. The 6-factor premix (ABP-SC-6FMRNA) also 
contains M3O mRNA as opposed to OCT4, which has been shown to facilitate reprogramming 
[39] via chromatin remodelling and protein recruitment to pluripotency genes [68] and may 
explain variability in reprogramming success between cocktails that utilise OCT4-MYOD1 mRNA 
and those that contain endogenous OCT4 transcripts. Speculatively the 6-factor premix mRNA 
(ABP-SC-6FMRNA) may also contain antagomirs that irreversibly bind to miRNAs, known to 
inhibit the reprogramming process such as miR-29 and mir-21 [172], to prevent mRNA 
degradation via the RNA-induced silencing complex. 
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The final two reprogrammings using the 6-factor premix mRNA (ABP-SC-6FMRNA) did not 
require passaging to yield iPS cells thus represents an improvement upon existing 
reprogramming efficiencies. The first of these reprogrammings took eleven days before iPS cell 
colonies could be identified while the latter reprogramming took only seven days. The difference 
can be attributed to a key optimisation that I implemented during the reprogramming process. 
This was a flexible dose-ramping approach for the addition of mRNAs during reprogramming. 
What this means is that mRNAs were not added at a certain amount on a certain day as most 
protocols suggest but instead, the mRNA dose would be determined by an approximation of the 
number of cells in the culture compared to the previous day. As the cells proliferated, the mRNA 
dose would increase. If the confluency markedly increased then too little mRNA was added the 
previous day, conversely if there was less cells than the day before then too much mRNA was 
added. This optimisation allowed for better control over the mRNA dose per cell ratio by using 
cellular cues as opposed to strict protocols to more optimally determine the mRNA dose on a 
given day. Typical mRNA-reprogramming methods result in a large amount of cell death 
following repeated addition of mRNA however, mRNA dose-ramping ameliorates this effect. 
MRNA dose ramping can therefore help increase the number of viably reprogrammable target 
cells to enhance the efficiency of reprogramming.  
 
These findings show that by utilising highly modified mRNAs in a dose-dependent manner while 
tightly regulating cellular proliferation and rapidly responding to cellular cues in the face of pro-
apoptotic and cytotoxic events is key to a more efficient, accelerated reprogramming. We have 
employed two simple method adaptations to limit reprogramming toxicity and generate iPS cells 
with accelerated kinetics from fibroblasts. Firstly, we used an optimised dose ramping approach 
that starts with a lower mRNA dose in the ﬁrst couple of days and increases to a larger dose only 
if the cells continue to proliferate. Secondly, we add extra human ﬁbroblasts during 
reprogramming if cell death was higher than cell proliferation. Future mRNA-based 
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reprogramming methodologies would benefit from implementing a similar approach when 
trying to produce informative iPS cells in a reduced timeframe. 
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Chapter 4. 
Determining the applicability of mRNA reprogramming  
in a neuroblastoma cell line. 
 
4.1. Introduction 
 
We have previously demonstrated that SK-N-SH-derived iPS cell lines can be obtained (named 
SKiPS) by overexpressing the reprogramming factors: OCT4, SOX2, KLF4, cMYC, using lentivirus 
vectors. However, the resultant neuroblastoma-iPS cell lines contained irremovable transgenes. 
Informative analyses on disease-derived iPS cells ideally do require that the cells are devoid of 
transgenes so that the characterisation and functional analyses on the cells can more accurately 
model aspects of disease development. So I decided to test whether integration free 
neuroblastoma-derived iPS cells could be created following the repeated addition of mRNAs. 
Fibroblasts were most efficiently reprogrammed with mRNAs when using the 6-factor 
reprogramming premix (ABP-SC-6FMRNA) so this provides a good basis to test whether this 
mRNA cocktail could reprogramme the SK-N-SH neuroblastoma cell line to generate integration-
free neuroblastoma-iPS cells. The decision to select this neuroblastoma cell line was based on its 
amenability to the reprogramming process. The resultant iPS cells could then be functionally 
analysed, for example, by differentiating the cells as embryoid bodies in defined conditions 
(Figure. 2.7 and Table 2.4) to test whether the disease genome has affected the resultant iPS 
cells ability to differentiate, a finding that would mirror a small aspect of early neuroblastoma 
development.  
 
Early neuroblastoma development has been modelled in vivo in mouse [134]. This study 
demonstrated that neuroblastoma can be initiated by overexpressing Myc-n in migrating neural 
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crest under the control of a tyrosine hydroxylase promoter. There are, however, at the time of 
writing, no in vitro models for neuroblastoma development that are iPS cell-based. To establish 
such models, in addition to mRNA reprogramming, the SK-N-SH cell line was sent to a 
collaborative group at the Karolinska Institutet in Sweden to be reprogrammed using the Sendai 
virus. There were two reasons for this. Firstly, the Sendai virus provides an additional method for 
reprogramming and secondly it allows for comparisons to be made between methods that 
introduce transgenes as mRNA or as viral RNA.  
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4.2. Results 
 
4.2.1. Reprogramming SK-N-SH cells using mRNAs induces TRA-1-60 expression in 
over a third of the cell population that form iPS-cell like colonies after cell sorting.   
 
It is unknown what the consequences are for forcing a human cancer genome to 
operate in the context of a distinct lineage. We can begin to address this by 
applying the optimised reprogramming method that successfully reprogrammed BJ 
fibroblasts, to a neuroblastoma cell line. The resultant neuroblastoma-derived iPS 
cells will create a platform from which we can improve our understanding of the 
molecular mechanisms underlying neuroblastoma development. 
 
In order to obtain a set of integration-free neuroblastoma-derived iPS cells, an 
mRNA cocktail containing OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG derived from 
Allele Biotech IVT templates (ABP-SC-SEIPSET) was added into the SK-N-SH cell line 
at a stoichiometry containing a relative three-fold increase of OCT4 to the other 
factors. SK-N-SH cells were plated at a density of 3x105 on to an inactivated MEF 
layer for 24 hours. A higher plating density was used in comparison to that of BJ 
fibroblasts after finding that SK-N-SH cells fail to proliferate on Matrigel in Pluriton 
medium when seeded at low densities (Figure. 4.1). The target cells were 
transfected daily until day eight with the mRNA cocktail (ABP-SC-SEIPSET) at a dose 
of 800ng in 2 ml of Pluriton medium to a final concentration of 400ng/ml (Figure. 
4.2A). In addition, mWASABI mRNA was introduced periodically throughout 
reprogramming to report whether the reprogramming factor mRNA cocktail being 
added to the reprogramming cultures was being taken up by the cells. B18R was 
added to the media every day at a concentration of 400ng/ml. The target cells grew 
to 100% confluency by day five and by day eight the cells had begun to mound on 
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top of one another (Figure. 4.2B). The cells were passaged as single cells using 0.25X 
trypsin-EDTA at a split ratio of 1:3 on day eight onto fresh MEF-coated culture 
dishes. This was done to firstly promote iPS cell survival in the event that any of the 
SK-N-SH cells had been reprogrammed and secondly to create space for further cell 
divisions to take place. After passaging, the addition of mRNA was ceased and the 
growth medium was switched to hESC media to promote cell survival and encourage 
iPS cell growth. On day 16, it became difficult to visually detect the presence of iPS 
cells as the reprogramming culture had become over-confluent and formed a 
monolayer. To isolate any putative iPS cells from the culture, the cell population was 
sorted for TRA-1-60. Upon sorting it was observed that 36% of the population was 
TRA-1-60+ve (Figure. 4.3iii). TRA-1-60 positive (6.5x104 cells) and negative fractions 
were seeded onto MEFs in hESC media to compare phenotypic differences between 
the two fractions. 
 
The replated TRA-1-60-ve cells were indistinguishable from SK-N-SH cultures made up 
of small, spiny neuronal cells. However, the TRA-1-60+ve cells were morphologically 
dissimilar to SK-N-SH cells and more closely resembled iPS cells. The iPS-like cells 
were characterised by the way they formed tightly packed epithelial-like colonies, 
with domed centres and jagged borders (Figure. 4.2B, white arrows). Upon 
subsequent passaging, the TRA-1-60+ve cells lost their iPS cell-like colony morphology 
and returned to a TRA-1-60-ve SK-N-SH phenotype indicating that the reprogrammed 
cells had not formed a stable cell line. One reason for this could be that the cells 
were in a partially reprogrammed state. To determine whether this could be the 
case, the original sort data was re-analysed to assess the fluorescence levels of 
mWASABI present in the TRA-1-60+ve sorted cells. As found in my fibroblast 
reprogrammings and in line with other reports, cells that express TRA-1-60 tend not 
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to co-express mWASABI protein or other fluorescent proteins translated from 
vectors that have been added during reprogramming to monitor transfection 
efficiency. To re-evaluate the original sort data, the original histograms and gates 
used to control for cell size, granularity and doublet discrimination were maintained 
and this population was plotted against the GFP channel that detect mWASABI 
expression. It was found that 36% of the gated population positively expressed 
mWASABI (Figure. 4.4i). This was then gated against TRA-1-60 to quantify the 
number of cells that co-expressed TRA-1-60 and mWASABI (Figure. 4.4ii). The 
resultant TRA-1-60 histogram showed that the re-seeded population after sorting 
contained two sub-populations, one that was 50% TRA-1-60+ve / mWASABI+ve and the 
other that was 50% TRA-1-60+ve / mWASABI-ve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
138 
 
 
 
 
  
Figure 4.1. Seeding SK-N-SH cells at low densities on                             
Matrigel in Pluriton affects its ability to proliferate 
Figure 4.1: SK-N-SH cells do not proliferate on Matrigel in Pluriton medium at sub-optimal densities. 
SK-N-SH cells were plated down at a density of (i) 5x104, (ii) 1.5x105 or (iii) 2.5x105 in Pluriton medium 
on Matrigel. The cells were placed in a Biostation CT (Nikon) at 37°C in 5% CO2 and phase contrast 
images at co-ordinates (x000000, y000000) were taken every 6 hours for 6 days. The cells succumbed 
to apoptosis within 4 days at a density of 5x104. Near-confluency was reached at days 4 and 3 at 
densities of 1.5x105 and 2.5x105 respectively. SK-N-SH cells plated at a density of 5x104 failed to 
proliferate. 
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Figure 4.2. Reprogramming SK-N-SH cells using mRNAs                               
from the Allele Biotech iPS induction template set 
Figure 4.2: (A) SK-N-SH reprogramming timeline using mRNAs derived from the Allele Biotech 
iPS induction templates (ABP-SC-SEIPSET). (i) Inactivated MEFs were seeded at a density of 
1x105 onto a gelatinised 6-well culture plate for 24 hours (ii) SK-N-SH cells were plated onto 
this at a density of 3.5x105 in hESC media. (iii) mRNAs from the Allele Biotech iPS induction kit 
(ABP-SC-SEIPSET) encoding OCT4, SOX2, KLF4, CMYC, LIN28, NANOG and mWASABI were 
added daily at a dose of 800ng until day 8. (iv) On day 8, the culture became over confluent 
and was split at a ratio of 1:3 with 0.25% trypsin-EDTA (Sigma) onto a MEF coated 6-well plate 
in hESC media. (v) On day 9 until day 16, the passaged reprogramming culture was fed with 
hESC media without the addition of further mRNAs. (vi) On day 16, the cells were sorted for 
TRA-1-60, and replated onto a MEF feeder layer in hESC medium. (B) Phase contrast images 
showing iPS cell-like colonies (white arrows). Scale bars = 1000μm 
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Figure 4.3. Sorting reprogrammed SK-N-SH                                               
cultures for cells that express TRA-1-60 
Figure 4.3: Histograms and gate parameters used to sort out a TRA-1-60+ population during SK-N-
SH reprogramming. (Left Hand Side, i) A population of viable cells (62%) based on cell size (forward 
scatter) and granularity (side scatter) were identified in the control well that had been stained 
with P3X as described in methods 2.15.1.1. (Left Hand Side ii) This population was plotted on a 
pulse width Vs. forward scatter histogram and gated to remove doublet cells that represented 
15% of the gated population. (Left Hand Side iii) This population was finally gated to determine a 
threshold for positively and negatively labelled cells. (Right Hand Side, i-iii) Once the gates were 
set on the control well, the SK-N-SH reprogramming well was analysed to determine the number 
of cells that expressed TRA-1-60. It was found that 36% of the cells were TRA-1-60+ve. 
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Figure 4.4: Histograms and plots showing sub-populations of mWASABI+ve and mWASABI-ve cells 
within the TRA-1-60+ve population. (i) One percent of cells in the control well expressed TRA-1-60 
compared to 36% in the reprogramming well. (ii) The TRA-1-60+ve population in the 
reprogramming well was then plotted against cells that expressed mWASABI. mWASABI had been 
added throughout reprogramming to monitor the efficiency of mRNAs getting into the cells. Cells 
that were mWASABI+ve were detected through the GFP channel, that detects mWASABI 
expression. The percentage of cells in the TRA-1-60+ve population in the reprogramming well that 
also expressed mWASABI was 53%. The control well contained no mWASABI+ve/TRA-1-60+ve cells. 
Figure 4.4. Emergent cell populations that express TRA-1-60 following             
SK-N-SH reprogramming contain sub-populations of GFP+ve and GFP-ve cells 
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4.2.2. Retinoic Acid treated SK-N-SH cells exhibit perturbed growth that may 
elongate the transfection phase of reprogramming 
 
When reprogramming SK-N-SH cells, the cell culture became confluent within 
three days when seeded at a density determined to prevent cells from succumbing 
to apoptosis (Figure. 4.1). Over confluency could inhibit reprogramming by 
decreasing the mRNA dose per cell ratio to a level that is insufficient to generate 
fully reprogrammed iPS cells. In order to generate fully reprogrammed iPS cells we 
need to decrease the rate that SK-N-SH cells proliferate. Retinoic acid has been 
shown to induce growth arrest in neuroblastoma cells [173] including the SK-N-SH 
cell line in vitro [174]. We determined the levels of growth arrest that occur in SK-
N-SH cells following treatment with varying concentrations of RA. 
 
MRNA-mediated reprogramming of SK-N-SH cells induced 36% of the population to 
express TRA-1-60 but none of these cells formed a stable iPS cell line. It was found 
that it is necessary to plate SK-N-SH cells prior to reprogramming at higher cell 
densities than fibroblasts to prevent cell death (Figure. 4.1) but this resulted in the 
cells reaching confluency within three days. In order to determine if the proliferative 
capacity of SK-N-SH cells could be decreased to maintain a more optimal mRNA dose 
per cell ratio over an extended period of time, the cells were treated with retinoic 
acid (RA) (Figure. 4.5A). RA was dissolved in DMSO to a working concentration of    
10-2M and then further diluted in tenfold decreasing concentrations to 10-6 M. These 
RA working stocks were then added to SK-N-SH cultures at 1:1000 to yield final 
concentrations between 10-5 and 10-9M. The cells were maintained in RA-containing 
Pluriton medium on Matrigel for seven days, replenishing the media and 
supplementing fresh RA on days zero and four. The number of viable cells were 
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counted on day seven and quantified as a percentage of the cell growth achieved in 
a control well that was treated with 0.1% DMSO (Table 4.1). Growth arrest was 
inhibited in a concentration dependent manner. In the experiment, 80% growth 
inhibition of SK-N-SH cells was detected when using a RA concentration of 10-5M.  
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Figure 4.5: Retinoic Acid induces growth arrest and neuronal differentiation in SK-N-SH. (A) Retinoic 
Acid was dissolved in DMSO to a concentration of 10-2 and then diluted in tenfold decreasing  
concentrations to 10-6. This was then added daily for 7 days at 1:1000 (0.1% vol/vol) to SK-N-SH cells 
plated at a density of 3.85x104 in 2mls of Pluriton media to yield the final range of concentrations 
10-5 to 10-9. The level of growth arrest is determined by comparing the mean cell counts from 3 
biological replicates (shown on the next page), from treated cultures to that of an untreated 
control. (B) Phase contrast images showing SK-N-SH with neurite-like extensions after treatment 
with RA. N=3 
   
Figure 4.5. Dose response relationship between Retinoic Acid                     
induction and growth inhibition of SK-N-SH after 7 days 
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Parameter Count 1 Count 2 Count 3 Count 4
Average 
Count
Cells/ml
Total 
cells
Cell growth (% of 
control culture)
Control (DMSO 0.1% vol/vol) 39 54 20 27 35 350000 700000 100.0%
RA 10-5 6 5 9 3 6 57500 115000 16.4%
RA 10-6 12 4 12 4 8 80000 160000 22.9%
RA 10-7 23 7 14 14 15 145000 290000 41.4%
RA 10-8 14 17 20 19 18 175000 350000 50.0%
RA 10-9 22 18 20 25 21 212500 425000 60.7%
Parameter Count 5 Count 6 Count 7 Count 8
Average 
Count
Cells/ml
Total 
cells
Cell growth (% of 
control culture)
Control (DMSO 0.1% vol/vol) 33 42 29 37 35 352500 705000 100%
RA 10-5 5 7 6 6 6 60000 120000 17%
RA 10-6 7 8 9 6 8 75000 150000 21%
RA 10-7 19 15 14 13 14 140000 280000 40%
RA 10-8 18 19 23 14 19 185000 370000 52%
RA 10-9 24 19 21 20 21 210000 420000 60%
Parameter Count 9 Count 10 Count 11 Count 12
Average 
Count
Cells/ml
Total 
cells
Cell growth (% of 
control culture)
Control (DMSO 0.1% vol/vol) 25 35 31 41 33 330000 660000 100%
RA 10-5 4 7 5 6 6 55000 110000 17%
RA 10-6 10 8 7 10 9 87500 175000 27%
RA 10-7 17 9 16 18 15 150000 300000 45%
RA 10-8 18 21 18 19 19 190000 380000 58%
RA 10-9 19 24 20 22 21 212500 425000 64%
Parameter
Average 
Count
Cells/ml
Total 
cells
Cell 
growth 
(% of 
control 
culture)
Control (DMSO 0.1% vol/vol) 34 344167 688333 100.0%
RA 10-5 6 57500 115000 16.7%
RA 10-6 8 80833 161667 23.5%
RA 10-7 15 145000 290000 42.1%
RA 10-8 18 183333 366667 53.3%
RA 10-9 21 211667 423333 61.5%
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Table 4.1. Dose response relationship between Retinoic Acid                     
induction and growth inhibition of SK-N-SH after 7 days 
Table 4.1: SK-N-SH cells treated with retinoic acid for 7 days were counted (as described in methods 2.11) 
and compared to a control sample that had been treated with DMSO 0.1% vol/vol. It was found that the 
population of SK-N-SH cells that had been treated with the highest dose of RA (10-2) contained the fewest 
amount of cells after 7 days. RA treatment inhibits cell proliferation in a dose dependent manner. N=3.  
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4.2.3. Reprogramming SK-N-SH cells following treatment with Retinoic Acid  
 
We found that growth inhibition of SK-N-SH cells can be induced by 80% following 
treatment with 10-5M RA. If we treated SK-N-SH cells with RA prior to 
reprogramming, could this reduce the rate that SK-N-SH cells proliferate and thus 
increase the number of times that mRNA could be added to the cells before the 
culture became confluent, so that fully reprogrammed iPS cells can be generated? 
 
To test this hypothesis, SK-N-SH cells were plated at a density of 1.5x105 onto 
Matrigel in Pluriton (Figure. 4.6Bi). The cells were treated for four days prior to 
reprogramming-day zero with 10-5M RA. In this reprogramming attempt, we decided 
to use the 6-factor reprogramming premix (ABP-SC-6FMRNA), instead of mRNAs 
derived from Allele Biotech IVT templates (ABP-SC-SEIPSET). This was based on the 
finding that the 6-factor premix (ABP-SC-6FMRNA) generated iPS cells from BJ 
fibroblasts more efficiently in that a splitting step was not required and iPS cells 
were generated with accelerated kinetics (Figure. 3.17 and 3.18). The addition of 
800ng 6-factor premix mRNA (ABP-SC-6FMRNA) at a final concentration of 400ng/ml 
was performed between days zero to six and eleven to fourteen with a decreased 
concentration of 200ng/ml used between days seven to ten in response to 
cytotoxicity. Cytotoxicity was further alleviated through the addition of 1.5x105 
MEFs on day seven and by increasing the B18R concentration to 400ng/ml from 
200ng/ml on days six and nine. In addition, 100ng mWASABI mRNA was periodically 
added to the reprogramming culture to verify that the exogenous mRNA was being 
successfully taken up by the cells. By day 15, the target well could be separated into 
regions that expressed distinctly different levels of confluency (Figure. 4.6Bii). For 
example some areas were densely compacted in multiple layers, others were absent 
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of cells and some regions represented clusters of cells in a single layer. 
Morphological transformations could be observed on the periphery of clusters of 
cells that were centrally located. These cells appeared to look more epithelial than 
neuronal (Figure. 4.6Biii) and may be indicative of an initial phase in reprogramming 
but their incidence was rare. The culture was sorted for TRA-1-60+ve / mWASABI-ve 
cells to isolate any fully reprogrammed iPS cells however no cells were found within 
these parameters. The cells were then re-plated onto MEFs in hESC medium and 
cultured for ten days to encourage iPS cell outgrowths. No iPS cell colonies were 
seen to emerge, so the 6-factor premix mRNA (ABP-SC-6FMRNA) was repeatedly 
added to the cells at a dose of 800ng (400ng/ml) for a further 18 days. On day 43, 
the reprogramming was terminated since there was a lack of emergent colonies and 
cell death was ubiquitously prevalent (Figure. 4.6Ci and ii). 
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Figure 4.6. Reprogramming SK-N-SH cells using the 
Allele Biotech 6-factor reprogramming premix 
Figure 4.6: (C) On day 43 of the SK-N-SH reprogramming using the Allele 
Biotech 6-factor premix mRNA (ABP-SC-6FMRNA), (i) a stitched whole-
well image captured on a Biostation CT (Nikon) shows large areas of cell 
death (green circles) and overgrowth (orange circles). (ii) An enlarged 
section of the stitched image showing areas of cytotoxicity (black 
arrowheads) and areas of differentiation (arrows).  
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4.2.4. SK-N-SH cells are less tolerant to the conditions of mRNA reprogramming 
compared to BJ fibroblasts 
 
Treating SK-N-SH cells with retinoic acid prior to reprogramming induced growth 
arrest sufficient to increase the number of days that mRNA could be added prior to 
the cells reaching confluency. However, the cells succumbed to apoptosis that may 
have been caused by an overdose of the 6-factor premix mRNA (ABP-SC-6FMRNA).     
When reprogramming BJ fibroblasts, mRNA dose ramping improved the 
survivability of cells by providing greater control over the mRNA dose per cell 
ratio. We tested whether the optimised mRNA dose-ramping protocol (Figure. 
3.17D) improved the survivability of SK-N-SH cells during reprogramming, 
sufficient to generate fully reprogrammed iPS cells. 
 
On day minus one of the reprogramming protocol, SK-N-SH cells were plated on to 
hESC-qualified Matrigel at a density of 1.5x105 in Pluriton medium. On day zero, the 
6-factor premix mRNA (ABP-SC-6FMRNA) was then added to the cells at a dose of 
200ng to a final concentration of 400ng/ml in 0.5ml Pluriton medium. MRNA dose 
ramping was implemented thereafter whereby the 6-factor premix mRNA (ABP-SC-
6FMRNA) was added to the cells at a dose that was determined by comparing an 
estimate of the number of cells in the culture from one day to the next. To prevent 
evaporation of the medium, a further 0.5ml of Pluriton medium was added four 
hours after the addition of mRNA. The Pluriton medium used throughout the 
reprogramming was supplemented with 300ng/ml B18R. Twenty four hours after 
the first addition of the 6-factor reprogramming premix mRNA (ABP-SC-6FMRNA) 
the cells had proliferated yet showed early signs of toxicity (Figure. 4.7B) therefore 
the mRNA dose on day one was kept to 200ng. This was in contrast to when 200ng 
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of mWASABI mRNA was added to the reprogramming control in parallel that showed 
no signs of toxicity (Figure. 4.7C). On day 2 of reprogramming, the cell density was 
judged to be less than that observed 24 hours prior therefore the mRNA dose was 
not increased and instead, 5x104 inactivated MEFs were added as a supportive 
measure. MRNA transfections were ceased on day four on the finding that ~95% of 
the cells had died. The cells were maintained in Pluriton medium until day eight and 
further supplemented with 1x105 MEFs however the extent of toxicity obligated the 
termination of reprogramming. 
 
We found that SK-N-SH cells succumbed to apoptosis during reprogramming 
following the addition of the 6-factor premix mRNA (ABP-SC-6FMRNA) but not when 
mWASABI mRNA was added at an identical dose to a control well in parallel. We 
determined whether cell death is dependent upon the dose of mRNA added to the 
cells and whether this could be exacerbated by increasing the dose of mRNA. To test 
this, we treated SK-N-SH cells with an increasing dose of mWASABI mRNA between 
1μg and 5μg for 24 hours. SK-N-SH cells were seeded at a density of 1.5x105 in 
Pluriton medium and a dose between 1μg and 5μg of mWASABI mRNA was added to 
the cells for 24 hours. After 24 hours, fluorescing cells were imaged using an EVOS FL 
Cell Imaging System and then analysed by flow cytometry on a CyAn ADP Analyser. 
Fluorescence levels were detected on the GFP channel at a wavelength of 488nm 
and gating using the P3X antibody was performed as described in methods 2.15.1.1. 
The cells were simultaneously stained with propidium iodide to detect the number 
of dead cells relative to an untreated SK-N-SH control. It was found that a dose of 
1μg mWASABI mRNA induced cell death in 15% of the cells, suggesting that the 
widespread cell death induced during reprogramming of SK-N-SH cells (Figure. 4.7B) 
is not due to the mRNA dose but more likely due to a specific mRNA. 
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B
throughout reprogramming
(A) SK-N-SHreprogramming timeline using the Allele Biotech 6f premix mRNA. (i) 1.5x10
SK-N-SHcellswere seeded onto Matrigel-coated 6-well culture plates. (ii) Between days 0
and 4, 200ng mRNAwas added to 1ml low-oxygen equilibrated Pluriton medium containing
300ng/ml B18R. 5x10   and 1x10 feederswere added on (iii) day 3 and (v) day 9 respectively.
(iv)The cellswere fed with Pluriton medium and the transfectionswere ceased to limit the
amount of cytotoxicity. (vi)The reprogramming wasterminated due to severe cytotoxicity.
5
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Figure 4.7. Adding a low (200ng) daily dose of 6-factor premix              
mRNA to SK-N-SH cells during reprogramming induces apoptosis  
Figure 4.7: (A) SK-N-SH reprogramming timeline using the All le Biotech 6-factor premix mRNA 
(ABP-SC-6FMRNA). (i) SK-N-SH cells were plated at a density of 1.5x105 onto Matrigel-coated 6-
well culture plates. (ii) Betwe n days 0 and 4, 200ng mRNA was added to 1ml low-oxygen (5% 
O2) equilibrated Pluriton medium containing 300ng/ml B18R. Inactivated MEFs at a density of 
5x105 and 1x105 were added on (iii) day 3 and (v) day 9 respectively. (iv) On day 4, the addition 
of mRNA was stopped on the observation that cells had begun to die however the Pluriton 
medium was continually replenished daily until day 8. (vi) The reprogramming was terminated 
on day 8 due to severe cytotoxicity. (B) Phase contrast images taken on the Biostation CT 
(Nikon) showing the onset of apoptosis between day 0 and 7. 
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Figure 4.7. Adding a low (200ng) daily dose of 6-factor premix              
mRNA to SK-N-SH cells during reprogramming induces apoptosis  
Figure 4.7: (C) mWASABI mRNA was added to a control well containing 1.5x105 SK-N-SH cells during 
reprogramming to monitor the uptake of mRNAs. After 7 days, SK-N-SH cells can be seen fluorescing 
(white arrows) and no cell death was observed. (D) SK-N-SH cells were treated with 1-5μg of mWASABI 
mRNA for 24 hours to test whether the cells would succumb to apoptosis. After 24 hours, the cells were 
analysed by flow cytometry to detect the number of cells that were positively fluorescing mWASABI and 
were simultaneously stained with Propidium Iodide (ThermoFisher, P3566) to detect the number of dead 
cells relative to an untreated control. A dose of 1μg mWASABI mRNA induced cell death in 15% of the cells 
that gradually rose to 30% at a dose of 5μg. Scale bars = 200μm 
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A second reprogramming was initiated under the same conditions as the previous 
reprogramming attempt (Figure. 4.7) albeit SK-N-SH cells were plated at an 
increased density of 2.5x105 (Figure. 4.8). It appeared that SK-N-SH cell death was 
less prevalent when reprogramming of SK-N-SH cells was conducted using the higher 
plating density of 2.5x105 cells. An mRNA dose of 200ng 6-factor premix mRNA (ABP-
SC-6FMRNA) was added on days zero and one. This was increased to 300ng on day 
two upon the observation that the cells were continuing to proliferate despite the 
repeated addition of mRNA. This dosage (300ng) was added daily and stopped on 
day 12, as there was no observed incidence of morphological transformations that 
suggest reprogramming was taking place(Figure. 4.8Bi), such as the compaction of 
cells, that had been previously found during SK-N-SH cell reprogramming (Figure. 
4.2B). Cytotoxicity was observed on the periphery of cell clusters (Figure. 4.8B, white 
arrows) and was mitigated against by the addition of 2x105 MEFs on day 2 and 4. On 
day eleven, the reprogramming culture was analysed by in-situ live-cell staining 
(methods 2.15.2) for TRA-1-60 however it was found that no cells were positive for 
TRA-1-60 (Figure. 4.8Bii) suggesting that the cells were not transitioning toward 
pluripotency. 
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Figure 4.8. Plating SK-N-SH cells at high densities (2.5x105)                        
prior to reprogramming, promotes cell survival   
Figure 4.8: (A) SK-N-SH reprogramming using 6f premix mRNA. (i) 2.5x105 SK-N-SH cells were plated 
onto Matrigel-coated 6-well culture plates and (ii) transfected in Pluriton containing 300ng/ml B18R 
with 200ng mRNA on days 0 and 1 and 300ng on days 2 to 11. MEFs were added at 2x105 on (iii) day 2 
and (iv) day 4. (v) Live-cell in-situ TRA-1-60 staining was performed revealing no positive colonies for 
TRA-1-60. (vi) Reprogramming was terminated on day 12. (B) Brightfield images depicting (i) areas of 
variable cell densities. (ii) Live-cell staining for TRA-1-60 reveals no emerging colonies, (iii) NT2 cell 
control positively fluorescing TRA-1-60 (left hand side) and NT2 negative control analysed for 
secondary antibody binding only. Scale Bars = 1000µm. 
 
156 
4.2.5. SK-N-SH cells downregulate endogenous cMYC following the addition of 
mRNA 
 
One of the limiting factors to reprogramming SK-N-SH cells is that they respond 
poorly to the addition of mRNAs (Figures. 4.7, 4.8 and 4.9) and the culture 
conditions (Figure. 4.1) proven to successfully reprogramme BJ fibroblasts. 
However, SK-N-SH cells do not succumb to apoptosis when mWASABI mRNA is 
added to the cells (Figure. 4.7C & D). Therefore, we tested whether the toxicity 
that is induced in SK-N-SH cells during reprogramming is due to a specific mRNA. 
 
During SK-N-SH cell reprogramming, mWASABI mRNA derived from the Allele 
Biotech iPS induction template (ABP-FP-SEMWASABI) is added to an SK-N-SH control 
well in parallel at the same dose that the mRNA cocktail, containing OCT4/M3O, 
SOX2, KLF4, cMYC, LIN28 and NANOG mRNA, is added to the main reprogramming 
well. In all of the SK-N-SH reprogrammings performed, none of the control wells 
treated with mWASABI mRNA succumbed to apoptosis. This suggests that it was not 
the mRNA dose that resulted in cell death of SK-N-SH cells during reprogramming 
but more likely a specific mRNA-induced toxicity. In order to determine whether this 
was the case, each individual mRNA factor that amasses to make up the 
reprogramming cocktail (OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG) was added 
separately into SK-N-SH cells. The dose of each factor added to the cells was 100ng 
with the exception of OCT4 that was added at a dose of 300ng that corresponds to 
the mRNA dosage used during reprogramming. SK-N-SH cells were seeded onto 
Matrigel coated plates in Pluriton at a density of 1x105 in 5% O2 at 37°C. Individual 
mRNAs encoding one of the six factors (OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG) 
from the iPS induction kit were added daily to the SK-N-SH cells for seven days to a 
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final concentration of 100ng/ml or 300ng/ml for OCT4. It was found that minimal 
cell death had resulted from the addition of each factor independently into SK-N-SH 
cells over a seven day period. 
 
Upon finding that the addition of each independent factor did not induce cell death 
in SK-N-SH cells after 24 hours, further addition of mRNA was performed daily over a 
seven day period to determine whether each individual factor had an effect on the 
expression of any of the other factors. This was investigated to see whether the 
addition of one exogenous factor can affect the mRNA levels of another factor 
postulating that the SK-N-SH cell death may be attributable to a cumulative effect 
between multiple factors. To assess this, the SK-N-SH cells that had been treated 
with mRNA for 24 hours were treated under the same conditions for a further 6 days 
and then analysed by qPCR (Figure. 4.9) to detect OCT4, SOX2, KLF4, cMYC, LIN28 
and NANOG mRNA levels. QPCR analysis showed that the addition of OCT4, SOX2, 
KLF4, LIN28 and NANOG mRNA in to SK-N-SH cells, increased mRNA levels for none 
of the factors other than their own with the exception of cMYC. Interestingly, cMYC 
mRNA levels decreased 3-fold comparable to endogenous levels of cMYC in SK-N-SH 
cells following the independent addition of each of the six factors. 
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Figure 4.9. QPCR analysis following the addition of individual mRNAs         
in to SK-N-SH cells to determine a possible cause for cytotoxicity 
Figure 4.9: mRNAs encoding OCT4, SOX2, KLF4, CMYC, LIN28 and NANOG derived from the Allele Biotech iPS 
induction templates (ABP-SC-SEIPSET) were added individually at a concentration of 100ng/ml (300ng/ml for 
OCT4) into SK-N-SH cells to verify the uptake of mRNA into the cells and to test whether mRNA levels for other 
reprogramming factors are affected. If one mRNA leads to the upregulation of another, this may lead to mRNA-
induced cytotoxicity that inhibits reprogramming. SK-N-SH cells were seeded on Matrigel-coated 6-well culture 
plates at a density of 1x105 in 5% O2 at 37°C. A dose of 100ng mRNA encoding the aforementioned factors was 
added daily into the cells for 6 days into 1ml of Pluriton medium. The cells were analysed by qPCR on day 7. It 
was found that mRNAs added to SK-N-SH cells were successfully taken up with the exception of cMYC. SK-N-SH 
cells endogenously express cMYC however adding mRNA, encoding any of the reprogramming factors, reduced 
the cMYC mRNA levels in SK-N-SH cells ~3-fold. CT values were normalised to GAPDH. N=1 (error bars derived 
from technical triplicates). 
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4.2.6. Characterisation of iPS cells derived from the SK-N-SH cell line using the 
Sendai virus. 
 
Despite failing to create neuroblastoma-derived iPS cells using mRNA we were 
able to obtain, from our collaborators at the Karolinska Institutet, an iPS cell line 
(named SeViPS-NB2) that had been reprogrammed from SK-N-SH cells by 
overexpressing OCT4, SOX2, KLF4 and CMYC using non-integrating Sendai viral 
vectors. We determined the extent to which the SeViPS-NB2 cells resembled 
undifferentiated pluripotent stem cells and assessed, via embryoid body formation 
in defined conditions, whether genotypic differences affected their ability to 
differentiate. 
 
The SeViPS-NB2 cell line was generated using the Cytotune kit (Invitrogen) as per the 
manufacturer’s instructions. The Cytotune kit was used by the Karolinska Institutet 
to also reprogram fibroblasts yielding a reprogramming efficiency of ~0.1%. The 
efficiency of the SK-N-SH reprogramming is not known but it is believed to be less 
than 0.1%. Upon receiving the SeViPS-NB2 cell line we performed an initial 
characterisation to establish the extent to which they resembled undifferentiated 
human pluripotent stem cells. Characterisation of the SeViPS-NB2 cell line included 
analysis through qPCR, flow cytometry and karyotyping. In addition, the 
differentiation capacity of the cells was assessed in vitro by inducing the cells to 
differentiate as embryoid bodies in defined conditions that differentiate cells toward 
the three germ layers: endoderm, mesoderm and ectoderm (Table 2.4).  
 
The SeViPS-NB2 cell line was analysed by qPCR (Figure. 4.10) to determine the 
mRNA levels of OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG in the cells compared to 
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the parental SK-N-SH cell line and to an undifferentiated hESC control line, Shef6. 
We found that the SeViPS-NB2 cell line exhibited mRNA levels of the 
aforementioned genes that more closely resembled undifferentiated hESCs than SK-
N-SH cells.  
 
The SeViPS-NB2 cell line was then analysed by flow cytometry to determine the 
percentage of cells that expressed, SSEA-1, SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 
compared to SK-N-SH and NT2 D1 cell lines (Figure. 4.11). We found that SeViPS-NB2 
and NT2 D1 cells expressed the cell surface markers at similar levels. Comparatively 
SK-N-SH cells had high SSEA-1 expression but did not express the other cell-surface 
markers analysed.  
 
The SeViPS-NB2 cell line was karyotyped to check for chromosomal abnormalities 
and to compare metaphase spreads between the parental SK-N-SH cells and the 
SKiPS cell line (Figure. 4.12) that is an iPS cell line reprogrammed from SK-N-SH cells 
using lentivirus. It was found that SK-N-SH cells exhibited a gain of whole 
chromosome 7, deletion on the short arm of chromosome 14 between q13 and q22 
and translocations from 2p21 to 9q34 and 17q21 to 22q13. In contrast, the SeViPS-
NB2 cell line exhibited a gain of whole chromosome 12 and loss of trisomy 7 while 
the SKiPS cell line maintained trisomy 7 but gained a whole chromosome 1 and lost 
whole chromosomes 3, 13 and 15.  
 
The differentiation capacity of SeViPS-NB2 was assessed by inducing the cells to 
differentiate as embryoid bodies (Figure. 4.13) for ten days in defined conditions as 
described in Table 2.4. The embryoid bodies were harvested and analysed by qPCR 
to determine the gene expression levels for markers of the three germ layers 
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compared to SeViPS-NB2 cells in an undifferentiated state (Figure. 4.14). In addition, 
MIFF1 iPS cells were differentiated in the same conditions to act as a control. The 
endodermal genes analysed were; GATA6, ISL1 and FOXA2, mesodermal; CD34, 
COL1A1 and PECAM and ectodermal; PAX6, GATA2, SOX10, AP2α, BRN3A PHOX2B, 
ALK and FOXD3. The expression of OCT4, NANOG and SOX2 was also analysed. As 
these genes are typically upregulated in undifferentiated hESCs and iPS cells, their 
down-regulation serves as a positive control for differentiation. QPCR analysis 
represented as delta CT values showed expression levels for OCT4 and NANOG had 
decreased indicating that the cells had differentiated while the expression levels for 
all of the differentiation markers tested had increased. Combining the results of the 
SeViPS-NB2 characterisation and then comparing it to the genotype and phenotype 
of SK-N-SH and control hESC/iPS cell lines indicated that the SeViPS-NB2 cell line had 
activated an endogenous pluripotency network that was absent prior to 
reprogramming. 
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Figure 4.10: qPCR analysis of the SeViPS-NB2 cell line at passage +47 shows mRNA levels 
comparable to the hESC control cell line, Shef6, and dissimilar to the parental SK-N-SH cell line at 
passage +70. The mRNA levels for KLF4 and NANOG in SeViPS-NB2 cells relative to Shef6 are ~3.5-
fold and ~2-fold higher respectively. SK-N-SH cells endogenously express cMYC ~5-fold higher than 
expressed in Shef6. CT values were normalised to GAPDH. N=1 (error bars derived from technical 
triplicates). 
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Figure 35A. SeViPS-NB2 cells upregulate expression
of hESC-associated transcription factors
SeViPS-NB2 cellsexpress transcription factors associated with pluripotent stem cells. qRT-PCR
analysis of SeViPS-NB2 cells relative to undifferentiated hESCs show increased mRNA levels of
OCT4, SOX2, KLF4, c-MYC, LIN28 and NANOG, and the absent expression of these transcription
factors with the exception of c-MYC in SK-N-SH.Values are represented asRQvalues which have
been normalised against an undifferentiated Shef6 hESCcontrol line.
Figure 4.10. Analysis of SeViPS-NB2 cells by qPCR 
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Figure 4.11. Flow cytometric analysis of the SeViPS-NB2                                                    
cell line compared to SK-N-SH and NT2-D1 cells 
Figure 4.11: SeViPS-NB2 cells at passage +54 express cell surface markers SSEA-3, SSEA-4, TRA-1-
60 and TRA-1-81 that are expressed in undifferentiated pluripotent stem cells. The NT2 D1 cell line 
at passage +103 was used as a positive control and exhibits a similar cell surface marker 
expression profile to that of the SeViPS-NB2 cell line. The parental cell line, SK-N-SH at passage +73 
from which SeViPS-NB2 was derived does not express markers associated with undifferentiated 
pluripotent stem cells. P3X was used to gate the cells (shown by the dashed line) as described in 
methods 2.15.1.1.  
Passage 73 Passage 54 Passage 103 
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Figure 4.12. Karyotype analysis of SeViPS-NB2 cells                             
compared to SK-N-SH and SKiPS cell lines 
Figure 4.12: Karyotype analysis was performed on the SeViPS-NB2 cell line that was reprogrammed 
from SK-N-SH cells by the Karolinska Institutet using the Cytotune Sendai Virus Kit (Invitrogen). The 
karyotype was compared to the parental SK-N-SH cell line and a cell line reprogrammed from SK-N-SH 
using the lentivirus, SKiPS-1.5-2. The SK-N-SH cell line shows a gain of whole chromosome 7, deletion on 
14p between q13 and q22 and translocations from 2p21 to 9q34 and 17q21 to 22q13. SeViPS-NB2 cells 
show a gain of whole chromosome 12 and loss of trisomy 7. The SKiPS 1.5-2 cell line maintains trisomy 
7, but exhibits gains of whole chromosome 1 and loss of chromosome 15. Each cell line is karyotypically 
abnormal and different from one another.   
SK-N-SH Passage 73 
SeViPS-NB2 Passage 52 
SKiPS-1.5-2 Passage 13 
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Figure 4.13. Embryoid bodies formed from SeViPS-NB2 are   
morphologically dissimilar to those formed from MIFF1 iPS cells 
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Biological Replicate 1 
      (Image 1)              (Image 2) 
Biological Replicate 2 
      (Image 1)              (Image 2) 
Biological Replicate 1 
     (Image 1)              (Image 2) 
Biological Replicate 2 
      (Image 1)              (Image 2) 
Figure 4.13: Directed differentiation of SeViPS-NB2 toward the three germ layers: endoderm, 
mesoderm and ectoderm in defined conditions (Table 2.4), results in the formation of small, 
fragmented embryoid bodies after 10 days. This is dissimilar to the control iPS cell line, MIFF1, 
which forms compact, large embryoid bodies when induced to differentiate following the same 
protocol. Two phase contrast images of each biological replicate was taken. Scale bars = 
1000µm. N=2  
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Figure 4.14. Comparing gene expression levels between                        
SeViPS-NB2 and a control iPS cell line, MIFF1 
Figure 4.14: SeViPS-NB2 cells were differentiated as embryoid bodies for 10 days toward the three germ 
layers (endoderm, mesoderm and ectoderm) in defined conditions (Table 2.4). Differentiated SeViPS-NB2 
cells were analysed by qPCR and expressed elevated levels of endodermal (GATA6, ISL1, FOXA2), 
mesodermal (CD34, PECAM) and ectodermal (PAX6) genes relative to an undifferentiated control. MIFF1 
iPS cells were differentiated under the same conditions and increased gene expression levels for GATA6, 
ISL1, FOXA2 (endodermal), CD34, COL1A1, PECAM (mesodermal) and PAX6, GATA2 (ectodermal). QPCR 
was performed using the Roche system (methods 2.14.1) and CT values were normalised to GAPDH. N=2. 
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Figure 4.14. Comparing gene expression levels between                        
SeViPS-NB2 and a control iPS cell line, MIFF1 
Figure 4.14: The expression levels for OCT4, NANOG and SOX2 did not decrease as much when SeViPS-NB2 or 
MIFF1 cells were differentiated in the defined condition for endoderm (Table 2.4). Differentiation may be 
counteracted by the levels of Activin A (100ng/ml) supplemented in the medium. Activin A could be signalling 
via the TGFβ pathway to drive the transcription of pluripotency genes that are preventing the cells from 
differentiating (Figure. 1.1). It was found that the defined conditions did not always drive differentiation 
toward the desired germ layer however, the SeViPS-NB2 did express markers for all three germ layers. N=2 
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Figure 4.14. Comparing gene expression levels between                        
SeViPS-NB2 and a control iPS cell line, MIFF1 
Figure 4.14: The cDNAs isolated from the differentiated SeViPS-NB2 and MIFF1 cells were also analysed by 
qPCR using the TaqMan system (methods 2.14.2) to determine the expression levels for a further panel of 
ectodermal markers: SOX10, AP2α, BRN3A, PHOX2B, ALK and FOXD3. It was found that all of the 
aforementioned genes were upregulated in SeViPS-NB2 cells when differentiated in the ectodermal 
condition (Table 2.4). CT values were normalised to β-ACTIN. N=2 
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4.3. Discussion 
 
We have successfully demonstrated that the SK-N-SH cell line can be successfully reprogrammed 
to a pluripotent state. This has been achieved using lentiviral vectors to generate the SKiPS cell 
lines (unpublished work by Christian Unger) and as described in this report using the Sendai virus 
vector. The SeViPS-NB2 cell line, which was reprogrammed by overexpressing OCT4, SOX2, KLF4 
and cMYC using Sendai Viral vectors to introduce the reprogramming factors, was shown to 
possess a capacity to differentiate similar to hESCs in that it was capable of forming embryoid 
bodies that expressed markers for each of the three germ layers. One noticeable difference, 
however, was the morphology of the embryoid bodies. It was observed that the SeViPS-NB2 
embryoid bodies were small and fragmented in both repeats, which is dissimilar to the Shef6-
derived embryoid bodies that were induced to differentiate under the same conditions. The 
difference in embryoid body morphology may be as a result of perturbed differentiation, for 
example, via persistent replication of the Sendai virus inducing OCT4 and NANOG to be 
constitutively expressed, although this was not tested. Even though OCT4 and NANOG were 
downregulated during the differentiation process, it was not to the same extent to which OCT4 
and NANOG was downregulated in the control MIFF1 iPS cell line. If the Sendai virus was 
persistently replicating OCT4 and NANOG, two genes that promote and maintain a pluripotent 
state, this may have affected the embryoid body’s ability to differentiate.  
 
It is also possible that following reprogramming the SeViPS-NB2 cells have retained what is 
called an ‘epigenetic memory’ whereby the reprogrammed cells have inherited characteristics of 
the epigenome of the parental cells, which can influence the properties of iPS cells [175], for 
example, their differentiation capacity. We did not perform RNA-sequencing analysis to compare 
the transcriptome profile of SeViPS-NB2 and SK-N-SH cells but this may help to identify RNAs 
that are exhibited at similar levels. Candidate RNAs can then be tested to determine the extent 
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to which they affect the differentiation capacity of the SeViPS-NB2 cells. It is also possible that 
genomic differences between the SeViPS-NB2 cells, which contain the neuroblastoma genome 
and the MIFF1 cells, which contain a normal diploid karyotype are affecting the differentiation 
capacity of the SeViPS-NB2 cells. It would be pertinent to identify the role that MYCN [129], 
PHOX2B [130] and ALK [131] have on the SeViPS-NB2 cells given they regulate neural crest 
development in normal cells. 
 
The SeViPS-NB2 cell line was further characterised by analysing its karyotype. The results of this 
karyotype compared to one previously performed by our collaborators at the Karolinska 
Institute showed the cells had altered their karyotype, showing a gain of whole chromosome 12 
and loss of trisomy 7, during continued maintenance in culture (Figure. 4.12). Long-term 
culturing of iPS cells reprogrammed using Sendai viral methods is necessary to dilute out the 
presence of viral vectors introduced into the cell cytoplasm. Unfortunately, the time taken to 
achieve this in the SeViPS-NB2 cell line overlapped with the onset of chromosomal alterations, 
specifically in chromosomes 7 and 12. Whole gains of chromosome 12 in human embryonic stem 
cells are typically associated with adaptation to an in vitro culture environment while the loss of 
whole chromosome 7 (trisomy to diploid) in the SeViPS-NB2 cell line indicates the loss of a 
pertinent mutation that is prevalent in the majority of neuroblastomas [176, 177]. It is possible 
that the SeViPS-NB2 cells have acquired chromosomal aberrations as a mechanism associated 
with culture adaptation to provide a selective advantage over non-adapted cells, which is a 
common consequence of maintaining hESCs and iPS cells in culture for prolonged periods of 
time [178]. Genomic alterations can influence a cell’s capacity to differentiate [111] and 
therefore may affect the ability to recreate the developmental conditions required to model 
aspects of neuroblastoma development. It may be possible to clone out non-adapted cells from 
a chromosomally mosaic culture, but it was my intent to generate a set of neuroblastoma-
derived iPS cells that maintained genomic integrity by using non-integrating mRNAs. 
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Repeated addition of an mRNA cocktail containing: OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG 
mRNAs transcribed from Allele Biotech IVT templates (ABP-SC-SEIPSET) into the SK-N-SH cell line 
induced 36% of the population to express cell-surface marker TRA-1-60 (Figure. 4.3 and 4.4). 
Given that TRA-1-60 is expressed on bona fide iPS cells [179] but not on neuroblastoma cells, 
suggests that the SK-N-SH cells had shifted towards a pluripotent state. Following cell sorting 
and re-plating of TRA-1-60+ve cells from reprogrammed SK-N-SH cultures, the cells formed iPS 
cell-like colonies. This highlighted a phenotypic change as SK-N-SH cells do not grow in colonies. 
Nevertheless, the iPS cell-like colonies appeared to contain neural-looking cells that were 
indistinguishable from SK-N-SH cell cultures. After a few passages, the iPS-like cells reverted back 
to the SK-N-SH phenotype, forming a monolayer of neural cells that did not grow as colonies and 
did not express TRA-1-60. It is possible that a subset of TRA-1-60+ve iPS-like cells may have been 
only partially reprogrammed. It is possible to determine via FACS analysis whether a cell is likely 
to be partially or fully reprogrammed by analysing cells that express TRA-1-60 and the reporter 
gene mWASABI [179]. It is known that iPS cells and hESCs are difficult to transfect with a 
reporter gene [180], such as mWASABI and as a result when mWASABI is added to 
reprogramming cultures, the cells that surround emergent iPS colonies, such as neuroblastoma 
cells, fluoresce while the cells within the iPS colony itself do not, even after repeated addition of 
the reporter gene. I determined that a subset of the TRA-1-60+ve cells that we sorted out from 
the reprogramming culture via FACS also expressed mWASABI, which had been added into the 
reprogramming culture repeatedly to monitor mRNA getting in to the cells. This suggests there is 
a possibility that partially reprogrammed, mWASABI+ve cells were sorted out from the 
reprogramming culture along with bonafide, fully reprogrammed TRA-1-60+ve cells, which may 
have resulted in the culture of sorted cells reverting back to a neuroblastoma phenotype. Any 
future strategies to sort iPS cells from neuroblastoma reprogramming cultures would greatly 
benefit from using a combination of cell surface and intracellular markers. Sorting for cells based 
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on a TRA-1-60+ve, SSEA-4+ve , mWASABI-ve and NANOG+ve phenotype may represent a reliable 
combination to isolate fully reprogrammed cells [179]. 
 
Neuroblastoma cells were successfully reprogrammed over a period of time exceeding ten 
weeks using lentiviral and Sendai viral methods. This is problematic for mRNA-mediated 
approaches considering that SK-N-SH cells would reach confluency prior to ten weeks in culture 
and that mRNA penetrance is inhibited when added to cells that are densely compacted. This is 
made worse by the fact that unlike fibroblasts, SK-N-SH cells are non-contact inhibited. This 
means that during SK-N-SH reprogramming, if transfections are required beyond the cells 
reaching confluency, maintaining a sufficient mRNA dose per cell ratio may require large doses 
of mRNA. Large doses of mRNA encoding the reprogramming factors may become toxic to the 
cells and thus inhibit reprogramming. This led to treating the cells with Retinoic Acid (RA) as RA 
has been found to induce growth arrest in SK-N-SH cells due to the down-regulation of cell cycle-
promoting cyclins and cyclin-dependent kinases (CDKs) [181]. After treatment with RA, SK-N-SH 
cells were found to have an inhibited proliferative capacity which increased the number of 
transfections that could be performed prior to the cells reaching confluency. After 15 days of 
repeatedly adding mRNAs to SK-N-SH cells (Figure. 4.6), a small number of larger, flatter cells 
appeared which were morphologically distinguishable from the neuronal cell phenotype that 
populates the majority of the culture. This possibly indicated that these cells had entered an 
early phase of reprogramming based on the finding that fibroblasts also change morphology 
during the initial phase. Unfortunately, after the further addition of mRNAs over a 43-day 
protocol, SK-N-SH cells did not reprogramme to iPS cells. These findings highlight that the 
expression of mRNAs in the current reprogramming cocktail is insufficient to allow for the 
transition to pluripotency and possibly more mRNAs encoding further transcription factors may 
be required to execute reprogramming. It may also be that additional events are required to 
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overcome major epigenetic barriers that inhibit reprogramming of neuroblastoma cells such as 
chromatin inaccessibility. 
 
In an attempt to increase chromatin accessibility, I performed reprogramming using the 6-factor 
premix mRNA cocktail (ABP-SC-6FMRNA) that contained M3O mRNA instead of conventional 
OCT4 transcripts. However, adding the M3O mRNA cocktail to SK-N-SH cell cultures resulted in 
most of the cells succumbing to apoptosis. Under the same conditions in fibroblasts this did not 
happen, highlighting different survival thresholds between SK-N-SH cells and fibroblasts 
following the addition of exogenous mRNAs. However, the addition of mWASABI mRNA to SK-N-
SH cultures did not succumb the cells to apoptosis (Figure. 4.7C and D) highlighting that it is not 
the dose of mRNA but more likely a specific mRNA or combination of mRNAs that induce 
cytotoxicity in SK-N-SH cells. Cytotoxicity induced by the 6-factor mRNA cocktail (ABP-SC-
6FMRNA) in SK-N-SH cells can be partially mitigated by reducing the mRNA dose-per-cell ratio 
during reprogramming. However, lowering the mRNA dose to promote SK-N-SH cell survival did 
not result in the emergence of iPS-like cells that were morphologically dissimilar from SK-N-SH 
cells or that expressed TRA-1-60. My findings indicate that the method optimised for 
reprogramming fibroblasts is not directly translational to neuroblastoma cells considering that 
iPS cells failed to emerge following the same protocol that induced pluripotency in fibroblasts. 
However, the method should act as a reprogramming template when attempting to 
reprogramme the SK-N-SH cell line on the finding that following the method did induce over a 
third of SK-N-SH cells to endogenously express TRA-1-60, indicative of a shift towards 
pluripotency. It is conceivable that further optimisations to the current method possibly 
alterations that better facilitate chromatin remodelling of the disease genome may overcome 
epigenetic barriers to allow for the generation of mRNA-mediated disease-iPS cells.  
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Chapter 5. 
Transdifferentiation of fibroblasts using mRNAs. 
 
5.1.  Introduction 
 
MRNA-mediated reprogramming is an established integration-free method for converting 
somatic cells in to iPS cells but there is little experience of using transfection of mRNAs as a tool 
for transdifferentiating somatic cells into specialised cells. Unlocking this potential would be 
invaluable for generating integration-free differentiated cell types that could be used in the 
future not only for cell replacement therapies but also as a tool for investigating mechanisms 
that underlie the conversion of cell states. Converting somatic cells from one lineage to another 
while bypassing an intermediate pluripotent state is advantageous over reprogramming for a 
couple of reasons. Firstly, the process is much simpler, because it can be executed using as little 
as one defined factor in a simple defined medium. Secondly, transdifferentiation protocols tend 
to require much less time to acquire the desired cell type in comparison to reprogramming 
methods that first require conversion of somatic cells to a pluripotent state before being 
subsequently differentiated.  
 
MYOD1 is a transcription factor that has binding sites in the promoter regions of myoblast-
associated genes, such as MYOGENIN, and once bound induces a cascade of events (Figure. 5.1) 
that is sufficient to convert fibroblasts into myoblasts. Through DNA methylation, the 
transcription of myoblast-associated genes is typically repressed in fibroblasts. However, it has 
been shown that MYOD1 is able to remodel the chromatin structure and directly activate genes, 
such as MYOGENIN and MCK (muscle creatine kinase) [182] that are involved in myogenic 
conversion. MYOD1 achieves this through the recruitment of histone acetyltransferase (HAT) 
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p300, which acetylates H3K27 (H3K27ac) and methyltransferase Set7 that methylates histone 
H3K4 (H3K4me1) at myogenic enhancer regions [183]. In addition, MYOD1 recruits the 
SWItch/Sucros Non-Fermentable (SWI/SNF) complex that uses enzymatic activity to remodel the 
way chromatin is packed. The SWI/SNF complex possesses an ATPase that breaks down ATP to 
destabilise the interaction between histones and DNA in the promoter regions of muscle-specific 
genes, brahma-related gene-1 (BRG1) and human brahma (BRM) [184]. When chromatin 
becomes unstable it opens up previously inaccessible binding sites that allow for transcription 
factors to easily bind to DNA and initiate transcription. 
 
Transdifferentiating fibroblasts to myoblasts has been demonstrated in mouse [150-153] and 
human [76] by overexpressing MYOD1 using different delivery mechanisms: cDNA transfection 
[150], lentivirus [151] retrovirus [152] and mRNA [116]. The conversion frequency for generating 
myoblasts from fibroblasts is high, ranging from 5% [112] to 50% [111] [87] in addition to being a 
technically uncomplicated 6-day process. I therefore set out to transdifferentiate human 
fibroblasts to myoblasts because this transdifferentiation model can be achieved by 
overexpressing a single factor, MYOD1, has a high conversion frequency and is an established 
model in mouse fibroblasts but not human fibroblasts. This model will provide the most suitable 
platform to determine whether mRNA can be used for transdifferentiation but also to provide 
proof of concept that mRNA can be used as a tool to drive the conversion of cell states. 
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Figure 5.1: MYOD1 is recruited to the MYOGENIN promoter by MEIS and PBX that are 
constitutively bound to the MYOGENIN promoter. MYOD1 then recruits histone 
acetyltransferases (HATs) and the SWI/SNF complex to acetylate and repackage chromatin 
respectively. The chromatin undergoes remodelling and closed transcription binding sites are 
opened. 
Figure 5.1. Mechanism of Action for MYOD1 
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5.2. Results 
  
5.2.1. Generation and validation of MYOD1 mRNA 
 
We have shown that the repeated introduction of reprogramming factor mRNAs into BJ 
fibroblasts is capable of converting them into iPS cells (Figures. 3.6, 3.11, 3.12, 3.18). We 
decided to test whether the repeated introduction of an mRNA encoding a gene 
associated with a myoblastic phenotype (MYOD1), could transdifferentiate fibroblasts into 
muscle cells  without the need to enter a pluripotent state. The first step to achieving this 
involves testing the capacity of fibroblasts to uptake MYOD1 mRNA. 
  
We sought to transdifferentiate fibroblasts to myoblasts through the repeated addition of 
MYOD1 mRNA. In order to obtain the necessary mRNA, we obtained the pCMV6-XL5 MYOD1 
DNA plasmid from Origene (Methods 2.17.4) (Figure. 5.2A) that contained a cDNA clone for 
MYOD1. Generating MYOD1 mRNA from this plasmid, including the linearization process and 
the parameters of the restriction digest are described in methods 2.17.4. Prior to 
linearisation, the sequence of pCMV6-XL5 MYOD1 was inputted into a plasmid editor (ApE) 
software and a virtual restriction digest was performed using the XbaI restriction enzyme to 
predict the band sizes that would be expected when performing gel electrophoresis (Figure. 
5.2B). A predicted band size of 6179 base pairs was suggested. The plasmid was then 
linearised as described in methods 2.17.4 and verified, prior to performing in-vitro 
transcription reactions, by running 5µl of the restriction digest reaction on a one percent 
agarose gel (Figure. 5.2C). An undigested DNA control was run in a well adjacent to this to 
verify that the restriction digest had successfully linearised the pCMV6-XL5 MYOD1 plasmid. 
We found that the linearised plasmid, that was 6.2kb in length, migrated as a single band 
while the undigested plasmid failed to migrate as a single band or at the same speed 
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through the gel, possibly because the undigested plasmid was circular in shape or nicked 
that can result in slower migration [185] (Figure. 5.2C). The single band coupled with a faster 
migration through the gel suggests that the plasmid had been successfully linearised. The 
linearised pCMV6-XL5 MYOD1 plasmid was then in-vitro transcribed using the MEGAscript 
T7 kit using modified nucleotides (methods 2.20). To verify that MYOD1 mRNA had been 
successfully transcribed, one microgram of mRNA was run on a one percent denaturing RNA 
gel (Figure. 5.2D) alongside an ssRNA ladder. MYOD1 mRNA was identified by a band at 
~2056 base pairs in length that was consistent with what was expected. 
 
To test the ability for MYOD1 mRNA to enter fibroblasts, a dose of 400ng MYOD1 mRNA was 
added to HFFs that had been plated at a density of 1x105 in plastic wells of a 6-well plate in 
10% DMEM FCS for 24 hours. To serve as controls, HFFs in separate wells were mock 
transfected with Stemfect and Stemfect buffer, left untreated or contained 100ng mWASABI 
mRNA for 24 hours. After 24 hours, RNA was extracted from the cells, reverse transcribed 
into cDNA and then analysed by qPCR to detect the mRNA levels for MYOD1 (Figure. 5.3). It 
was found that MYOD1 mRNA levels in the well in which MYOD1 mRNA was added, 
increased 9.7x104-fold relative to the untreated control. 
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Figure 5.2. Linearizing and in-vitro transcribing                                       
MYOD1 mRNA from the pCMV6-XL5 plasmid 
Figure 5.2: MYOD1 mRNA was in-vitro transcribed from a linearised pCMV6-XL5 MYOD1 plasmid. (A) 
The plasmid map shows a linearisation site, XbaI, downstream of a polyA tail that is incorporated at 
the 3’ end of mRNA following in vitro transcription. IVT reactions are driven by a T7 promoter 
upstream of the MYOD1 coding sequence. (B) The sequence of pCMV6-XL5 MYOD1 was inputted into 
a plasmid editor (ApE) software that performed a virtual restriction digest on the plasmid using the 
XbaI restriction enzyme. A predicted band size of 6179 base pairs was suggested. (C) The plasmid was 
linearised using 5 units of XbaI restriction enzyme as described in methods 2.17.4. Linearisation was 
verified by running the plasmid on a 1% agarose DNA gel and single band size at ~6179 base pairs, as 
predicted, is shown (methods 2.19). (D) An in-vitro transcription reaction was then performed on the 
linearised plasmid. The resultant modified MYOD1 mRNA was verified on a 1% denaturing RNA gel 
(methods 2.19.1). A 1kb DNA ladder and an ssRNA ladder were used for DNA and RNA gels 
respectively. 
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Figure 5.3. MYOD1 mRNA levels increase 9.7x104-fold                                               
following its addition into human fibroblasts 
Figure 5.3: MYOD1 mRNA at a dose of 400ng was introduced into HFF cells at passage +15 for 24 
hours and then analysed by qPCR to verify that it was taken up by the cells. MYOD1 mRNA levels were 
9.7x104-fold higher compared to untreated HFFs verifying that MYOD1 mRNA is highly penetrant in 
HFFs. Controls included untreated HFFs, mock transfected HFFs that had been treated with Stemfect 
and Stemfect buffer (Stemgent, 00-0069) and HFFs where mWASABI mRNA had been added at a dose 
of 400ng for 24 hours. CT values were normalised to GAPDH. N=1 (error bars derived from technical 
triplicates). 
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5.2.2. MYOD1 mRNA induces human fibroblasts to transdifferentiate to myoblasts 
 
It was found that MYOD1 mRNA is highly penetrant in fibroblasts. We tested whether the 
repeated introduction of MYOD1 mRNA into fibroblasts would cause them to 
transdifferentiate into myoblasts.  
 
Firstly, HFFs were dissociated into single cells using 0.25% trypsin-EDTA and seeded down 
onto untreated 6-well plates at a density of 5x103 / cm2 in DMEM containing 10% FBS. 
Controls were also included to ensure that any myoblasts that formed following the 
transdifferentiation process were not as a result of spontaneous differentiation. The controls 
included an untreated well that was maintained in DMEM 10% FBS, a well controlling for 
phenotypic changes that may occur due to media changes i.e. switching from DMEM 10% 
FBS to myoblast growth medium and then to transdifferentiation medium and finally a mock 
transfected well that was treated with Stemfect transfection reagent and buffer.  
 
For transdifferentiation, twenty four hours after the HFFs had been plated the medium was 
changed to myoblast growth medium (methods 2.3.4) containing 200ng/ml B18R. The cells 
were grown in this medium until the cells reached 80% confluency which took typically 72 
hours. During this time period, MYOD1 mRNA at a dose of 200ng was repeatedly added into 
HFFs daily to a final concentration of 200ng/ml. After 72 hours, the media was switched to 
transdifferentiation medium for three days (methods 2.3.5) to encourage any 
transdifferentiated myoblasts to fuse together to from multinucleated myotubes. Cells that 
morphologically resembled myoblasts appeared in the culture one day after the first 
addition of MYOD1 mRNA (Figure. 5.4A, Day 1, indicated by white arrows). These cells were 
characteristically compact, irregularly shaped with a large nucleus to cytoplasm ratio and 
granular edges. This is distinctly different to fibroblasts that have a typically elongated cell 
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body, contain fibroblastic processes and exhibit little granularity. Following the 
transdifferentiation process the cells were fixed and stained, on day 7, with NCAM and 
DESMIN and analysed via high content screening to detect the presence of cells that had 
converted to a myoblast-like phenotype (Figure. 5.4B). It was determined on day seven that 
0.08% of cells had transdifferentiated to myoblast-like cells, based on NCAM expression.  
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Figure 5.4. Transdifferentiation of fibroblasts to myoblast-like                 
cells after repeated addition of MYOD1 mRNA 
B 
A 
Figure 5.4: Fibroblasts that were introduced to a dose of 200ng MYOD1 mRNA for four days were 
induced to transdifferentiate into myoblasts which stain positive for NCAM and DESMIN. One day 
after the first addition of MYOD1 mRNA, the cell population contained myoblast-like cells (white 
arrows). On day three and five, cells containing multiple nuclei emerged (orange arrows). 
Immunofluorescence analysis was performed on day seven using the IN Cell Analyser 2200 (GE 
Healthcare Life Sciences) that found that 0.08% of the population expressed NCAM and DESMIN. The 
KMISS human myoblast cell line was used as a positive control. Cells were counterstained with 
Hoescht at 1:1000. Scale bars = 50µm (day 1-5), 200µm (day 7, 20X), 100µm (day 7, 40X) 400µm (day 
7, 10X) 
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5.2.3. The NCAM cell surface marker and DESMIN intracellular marker are expressed on 
myoblasts and myotubes but not on fibroblasts 
 
Cultures of fibroblasts and myoblasts are distinguishable by morphology however this 
characteristic alone is insufficient to confirm that fibroblasts have transdifferentiated to 
myoblasts. In order to facilitate the unambiguous identification of myoblasts within 
transdifferentiated fibroblast cultures, we determined the expression levels of two 
markers, a cell-surface marker NCAM and an intracellular marker DESMIN. 
 
In order to distinguish between fibroblasts, myoblasts and myotubes, HFFs and a myoblast 
positive control cell line named KM155 were obtained [186]. Myotubes form following the 
fusion between multiple myoblasts and were obtained by seeding KM155 cells at a density 
of 2x105 in a 6-well plate in myoblast growth medium (methods 2.3.4) until the cells reached 
approximately 80% confluency. The media was then switched to transdifferentiation 
medium (methods 2.3.5) for 48-72 hours to give rise to multinucleated myotubes. HFFs, 
KM155 myoblast cells and KM155-derived myotubes were then analysed by flow cytometry, 
qPCR and high content screening for the expression of NCAM and DESMIN, two markers that 
have been reported to distinguish fibroblasts from myoblasts and myotubes.  
 
Analysis by flow cytometry was performed by seeding HFFs and KM155 cells at a density of 
2x105 in a 6-well plate in either fibroblast growth medium, DMEM 10% FBS or in myoblast 
growth medium containing DMEM F12, 20% FBS, 8ng/ml bFGF and 10µg/ml human insulin 
solution. After 24 hours the cells were dissociated into single cells and stained for 30 
minutes primarily with NCAM monoclonal antibody at a dilution of 1:10 followed by a 
further 30 minutes with Alexa Fluor 488 (AF488) goat anti-mouse secondary antibody at 
1:100. Throughout the process the cells were maintained at 2-8°C. The cells were analysed 
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by flow cytometry and it was found that fibroblasts do not express NCAM however 98% of 
myoblasts positively expressed NCAM (Figure. 5.5A).  
 
To visually illustrate the difference in NCAM and DESMIN expression between fibroblasts, 
myoblasts and myotubes, the cells were subject to high content screening. In separate wells, 
HFFs and myoblasts were plated down as previously described for flow cytometry for 24 
hours. HFFs, myoblasts and myotubes were then fixed with 4% PFA for 15 minutes at room 
temperature. The PFA was then removed and the cells were blocked with PBS containing 
10% FBS for 30 minutes. The cells were then stained with NCAM or DESMIN, washed three 
times and then stained with secondary antibodies AF488 or AF647 respectively. The cells 
were counterstained with Hoescht 33342 during the incubation period with the secondary 
antibody before being washed a further three times. NCAM and DESMIN expression was 
assessed by an INCELL Analyser 2200 and it was clearly visible that fibroblasts do not express 
NCAM or DESMIN yet they are ubiquitously expressed in myoblasts and myotubes (Figure. 
5.5B). DESMIN mRNA levels in HFFs, KM155 myoblasts and differentiated myotubes were 
then analysed by qPCR. DESMIN mRNA levels were found to be 115-fold higher and 223-fold 
higher in myoblasts and myotubes respectively relative to fibroblasts. NCAM and DESMIN 
can therefore be used to distinguish between fibroblasts and proliferating or differentiated 
myoblasts. 
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Figure 5.5. Myoblasts and myotubes but not                                    
fibroblasts express NCAM and DESMIN 
B 
A 
Figure 5.5: Myoblasts and myotubes express NCAM and DESMIN but fibroblasts do not. (A) HFFs and 
KMISS myoblast cells were analysed by flow cytometry for the expression of the cell surface marker, 
NCAM. Staining was performed as described in methods 2.15.1. Flow cytometric analysis showed that 
NCAM was not expressed on fibroblasts but was expressed on 98% of myoblasts. HFFs, KMISS 
myoblasts cells and KMISS myotubes that were differentiated from myoblasts using 
transdifferentiation medium (methods 2.3.5) were then analysed by qPCR for the expression of 
intracellular marker DESMIN. It was found that fibroblasts do not express DESMIN but it is expressed  
~120-fold and ~220-fold higher in myoblasts and myotubes respectively, relative to HFFs. CT values 
were normalised to GAPDH. N=1 (error bars derived from technical triplicates). (B) NCAM and DESMIN 
expression was visualised by analysing HFFs, KMISS myoblasts cells and KMISS myotubes by 
immunofluorescence on the IN Cell Analyser 2200 (GE Healthcare Life Sciences). It was confirmed that 
fibroblasts do not express NCAM or DESMIN however both markers are expressed on myoblasts and 
myotubes derived from KMISS cells. Cells were counterstained with Hoescht at 1:1000. Scale bars = 
200µm (20X), 100µm (40X), 400µm (10X). 
 
HFF passage 14 
(fibroblasts) 
KMISS passage 7 
(myoblasts) 
KMISS passage 7 
(myotubes) 
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5.2.4. NCAM expressing cells transdifferentiated from fibroblasts can be terminally 
differentiated to form multinucleated myotubes confirming they are myoblasts 
 
We have provided a proof-of-concept that mRNAs can be used to direct cell fate by 
successfully transdifferentiating fibroblasts to myoblasts through the repeated addition of 
MYOD1 mRNA. A functional property of myoblasts is the ability to fuse with other 
myoblasts to form multinucleated myotubes. Do the myoblast cells that we have 
converted from fibroblasts possess the functional capacity to form multinucleated 
myotubes?  
 
Myoblasts require close contact with other myoblasts to fuse to form myotubes. Given the 
previous transdifferentiation experiment achieved a conversion frequency of 0.08%, we 
decided to sort the cells following the phase in which mRNAs are added to the cells to enrich 
the population with myoblast-like cells. Re-plating the enriched myoblast-like cell population 
should decrease the space between converted cells and improve the probability of myoblast 
fusion events occurring.  However, cell sorting cannot be performed on cells that have been 
fixed, the purpose of which is to identify the presence of NCAM and DESMIN expressing 
myoblast cells within transdifferentiated cultures. Therefore, transdifferentiation was 
performed in two wells under the same conditions, one to be fixed and analysed in-situ for 
the presence of cells expressing NCAM and DESMIN and the other for sorting cells based on 
NCAM expression.  
 
Myoblast induction was performed as previously described via the repeated addition of 
MYOD1 mRNA albeit the mRNA dose in both wells was increased to 300ng to test whether 
an increased mRNA dose-per-cell ratio would increase the conversion frequency. After four 
days of repeated transfection with MYOD1 mRNA, one well was analysed by high-content 
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screening to determine the number of myoblast-like cells that expressed DESMIN and 
NCAM. On day four it was determined that 0.4% of cells had transdifferentiated to myoblast-
like cells, based on NCAM expression (Figure. 5.6ii). At this point, the second well was sorted 
into NCAM positive and negative fractions containing 4x104 and 2x105 cells respectively 
(Figure. 5.6iii). The positive and negative fractions were re-plated into separate wells of a 6-
well plate at a cell density of 4x104 in myoblast growth medium. On day 7, the cells had 
proliferated to a confluency of ~80% so the media was then changed to transdifferentiation 
medium for a further 72 hours, to day 10. On day 10, the cells were fixed and stained with 
NCAM, DESMIN and Hoescht 33342 as previously described (Figure. 5.6iv). It was 
determined that the NCAM positive fraction contained myoblasts that had fused to form 
multinucleated myotubes. The myotubes had multiple nuclei, stained positive for NCAM and 
morphologically resembled large fibres (Figure. 5.6iv). The cells in the negative fraction did 
not form myotubes or myoblasts and did not express NCAM or DESMIN.  
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  Figure 5.6. In-vitro differentiation of myoblast-like cells 
transdifferentiated from fibroblasts to multinucleated myotubes 
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Figure 5.6. In-vitro differentiation of myoblast-like cells 
transdifferentiated from fibroblasts to multinucleated myotubes 
Figure 5.6: Fibroblasts were transdifferentiated to NCAM expressing myoblast-like cells which can be 
differentiated to form multinucleated myotubes. (i) Schematic of the experimental design. Fibroblasts were 
seeded at a density of 5x103/cm2 on day-1 in to two wells of a 6-well plate in myoblast growth medium 
(methods 2.3.4). A dose of 300ng MYOD1 mRNA was added to both wells daily for four days. (ii) On day 4, 
one well was analysed by the IN Cell Analyser 2200 (GE Healthcare Life Sciences) to assess whether 
fibroblasts had begun to convert to myoblasts. It was found that 0.4% of fibroblasts had converted to NCAM-
expressing myoblast cells. (iii) The second well, also on day 4, was therefore sorted via fluorescent activated 
cell sorting (FACS) for cells that positively expressed NCAM (NCAM+ve) and those that did not express NCAM 
(NCAM-ve). Gating was performed as described in methods 2.15.1.1. FACS analysis isolated 6% of the gated 
population that expressed NCAM (NCAM+ve). Both the NCAM+ve enriched and NCAM-ve cells were plated into 
separate wells containing myoblast growth medium until day 7 and then the medium was switched to 
transdifferentiation medium (methods 2.3.5) for 3 days. (iv) On day 10, immunofluorescence analysis was 
performed to detect NCAM and DESMIN-expressing cells. It was found that in the NCAM+ve fraction, cells had 
fused to form DESMIN-expressing myotube-like fibres containing multiple nuclei (white arrowheads). The 
NCAM-ve cells did not express NCAM, DESMIN or contain multiple nuclei. Scale bars = 200µm (20X), 100µm 
(40X), 400µm (10X). 
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 5.3. Discussion 
 
The successful entry of MYOD1 mRNA into HFFs is evidenced by a 9.7x104-fold increase in 
MYOD1 mRNA levels relative to untreated HFFs that occurs following the single addition of 
mRNA. The large increase in mRNA levels may be attributable to the ability for MYOD1 
protein to activate its own transcription [187]. One mechanism by which MYOD1 reportedly 
achieves this is by increasing p21 expression which represses cyclin dependent kinases 
(CDKs) that inhibit the transcription of MYOD1 [188] thus creating an auto-regulatory loop 
for self-activated transcription. A second mechanism is that MYOD1 increases the expression 
of myogenic transcription factors such as MYOGENIN and MYF5 which subsequently auto- 
and cross-regulate one another’s expression [150, 189]. The combination of these 
mechanisms may explain how MYOD1 can achieve sufficiently high levels of MYOD1 protein 
following a single addition of mRNA. Generating an abundance of protein in a short space of 
time may represent one contributing factor that allows for rapid conversion of fibroblasts to 
a myoblast-like phenotype. 
 
Fibroblasts were converted to myoblasts following the daily addition of MYOD1 mRNA for 
three days. Comparing the kinetics of transdifferentiation to our reprogramming 
experiments on BJ fibroblasts, iPS cells were generated more rapidly in the reprogramming 
experiments that utilised M3O mRNA (Figures 3.12, 3.18), a fusion protein between OCT4 
and the transcriptional activation domain of MYOD1. Conversely, using OCT4 instead of M3O 
increased the time it took to generate iPS cells (Figures 3.6, 3.11). These results complement 
the notion that the conversion of cell states can be enhanced when transcription factors are 
bound to or contain the transcriptional activation domain (TAD) of MYOD1. Our current 
thinking is that the TAD of MYOD1 improves the accessibility of chromatin through the 
recruitment of epigenetic modifiers that facilitate transcription factor binding and activation 
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of genes at target loci, through chromatin remodelling and the erasure and re-establishment 
of epigenetic marks. With respect to myoblast transdifferentiation, the conversion of one 
cell state to another, for example fibroblasts to myoblasts, relies on the activation of an 
endogenous myogenic gene network that is facilitated by an increase in transcriptional 
activity at genes important for myogenesis. Our transdifferentiation experiments suggest 
that an endogenous myogenic gene network had been activated (Figures 5.4, 5.6) in that 
two markers, NCAM and DESMIN that fibroblasts do not express were upregulated following 
the addition of MYOD1 mRNA. It would be beneficial to further these experiments by 
identifying epigenetic and genetic changes that occur in fibroblasts following the 
introduction of MYOD1 mRNA to facilitate our understanding of the mechanisms that 
underlie the conversion of cell states.  
 
Conversion of fibroblasts to myoblasts can be achieved after repeated addition of MYOD1 
mRNA but myogenic transcription factors or cell-surface markers are required to distinguish 
between myoblasts and unconverted fibroblasts. NCAM and DESMIN were found to be good 
markers that can distinguish between myoblasts and fibroblasts [190]. Interestingly DESMIN 
protein expression levels appear higher in myotubes than myoblasts when analysed by high-
content screening. This suggests that increased DESMIN expression levels may be associated 
with a more terminally differentiated myoblastic state as myotubes represent a later 
developmental stage during myogenesis. DESMIN could therefore be used to determine the 
differentiation status of myoblasts during transdifferentiation. 
 
The repeated addition of MYOD1 mRNA into fibroblasts was found to induce 
transdifferentiation towards NCAM-expressing myoblast-like cells. Increasing the MYOD1 
mRNA dose from 200ng to 300ng per 5x103 / cm2 cells increased the myoblast conversion 
frequency that is probably attributable to a more efficient mRNA dose-per-cell ratio. Control 
 
193 
wells of fibroblasts that were left untreated, placed in myoblast and transdifferentiation 
medium or mock transfected with Stemfect transfection reagent and buffer did not contain 
NCAM-expressing cells based on two biological replicates. This confirms that MYOD1 mRNA 
is the causative factor for driving myoblast transdifferentiation and not the components in 
the growth medium, the transfection reagent or due to spontaneous differentiation.  
 
To functionally test whether the NCAM-expressing cells were indeed myoblasts, 
subpopulations of cells that did and did not express NCAM were sorted, through 
Fluorescence Activated Cell Sorting (FACS), into positive and negative fractions respectively 
and replated in myoblast growth medium. This was to done to enrich the population for 
myoblasts and to encourage the cells to proliferate in close proximity to one another. 
Placing the cells in transdifferentiation medium caused the cells plated from the positive 
fraction to fuse together to form multinucleated myotubes. The representative image 
provided (Figure. 5.6iv) verified that myotubes had formed as they expressed both NCAM 
and DESMIN and contained multiple nuclei (six shown) that had co-located within one cell. 
Cells replated from the negative fraction did not fuse nor form myotubes.  
 
This research demonstrates a novel mRNA-mediated strategy for directly converting human 
fibroblasts to myoblasts. It also provides proof of concept that this controlled approach 
could be used to look at the function of a whole range of genes delivered by mRNA. The 
approach enables the study of other differentiation pathways and for the creation of other 
cell types free of genomic integrations.  
 
 
 
 
 
194 
Chapter 6. 
General Discussion. 
 
6.1 mRNA dose ramping enhances existing mRNA reprogramming methods by allowing iPS 
cells to be generated without passaging with accelerated kinetics and improved 
efficiencies  
 
The aim of Chapter 3 was to determine whether we could develop a reprogramming method 
utilising mRNAs that could generate iPS cells from fibroblasts with greater efficiency and 
accelerated kinetics compared to existing methods. With regard to this objective, we 
successfully reprogrammed BJ fibroblasts four times with each successive reprogramming 
taking less time than the previous to generate iPS cells, owing to the modifications to the 
process that were implemented. The implementation of a flexible mRNA dose ramping 
approach to the reprogramming process was a key innovation that improved the 
survivability of cells over the course of reprogramming. This optimised method may benefit 
future reprogramming’s by reducing the probability that cells succumb to apoptosis 
following the repeated daily addition of mRNAs.  
 
Our results show that iPS cells can be generated from fibroblasts through mRNA-mediated 
reprogramming in seven days without passaging, compared to 16 days without passaging 
reported in the original mRNA reprogramming study [76]. This can be attributable to a 
technical improvement to the method regarding the dosing of mRNA into cells over the 
course of reprogramming. Rather than following a strict regime that dictates the mRNA dose 
to be added per day, our method relies on cellular cues to determine the amount of mRNA 
to be added. This means that the cells are introduced to gradually increased amounts of 
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mRNA in line with the rate of proliferation to attenuate cell death from overdosing cells with 
mRNA. This technical improvement helped to improve the kinetics of reprogramming 
compared to previous studies [39, 76, 168], cutting the time taken for mRNA-mediated iPS 
cells to emerge by as much as 11 days. Improving the kinetics of mRNA-mediated 
reprogramming is an important aspect in that it makes the process more high throughput 
and cuts down on the workload requirements. Most studies aim to accelerate the kinetics of 
reprogramming by incorporating a single passaging step in the methodology [39, 76] while 
some studies continuously passage the cells throughout reprogramming [56]. However, 
splitting the cells nullifies the efficiency of reprogramming as iPS cell colonies of 
independent clonal origin cannot be confirmed. It is reported that increasing the rate at 
which cells divide during reprogramming can shorten the time it takes to generate iPS cells 
[56]. That study attributes this to an increased probability for undefined stochastic events to 
occur that are necessary for reprogramming to take place. However, a consequence of 
encouraging cells to divide more rapidly is the diluting effect that cell division has on mRNA 
levels within the cells. This may lower mRNA levels in cells containing exogenous mRNAs to 
insufficient levels required to generate iPS cells, which has been avoided in our approach 
that does not implement a splitting step. Our method, that does not rely on a splitting step, 
may sustain sufficient mRNA levels in the cells for a longer period of time, which may explain 
why our method can generate iPS cells in a shorter timeframe. If splitting the cells is 
desirable then perhaps increasing the mRNA dose or more frequently adding mRNAs to the 
cells will ensure that sufficient levels of mRNA are maintained throughout reprogramming. 
However, increasing the daily dose of mRNAs or the frequency of mRNA additions to 
reprogramming cultures could add to the prevalent cytotoxic and pro-apoptotic pressures 
that cells already face during reprogramming. We focused on generating iPS cells without a 
passaging step and found that mRNA dose ramping efficiently maintains cells in a balance 
between a proliferative and apoptotic state allowing for more optimal control over the 
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mRNA dose per cell ratio. This approach better sustains a consistent concentration of mRNA 
throughout reprogramming, a finding that has been shown to improve the efficiency of 
generating iPS cells [39]. Striking this balance efficiently generated iPS cells with improved 
kinetics and efficiency compared to reprogrammings that did not employ a dose ramping 
regimen. A study by Warren et al [39] employed a strict dose ramping regimen however 
there were three key differences to our method. Firstly, we removed a splitting step, 
secondly the mRNA concentration we used throughout was much lower (200-300ng/ml 
compared to 600ng/ml) and finally our reprogramming cell cultures were maintained in 1ml 
of media, as opposed to 0.5ml, in a 6-well plate format during the early stages of 
reprogramming. This is interesting because even though we used the same BJ fibroblast cell 
line and the 6-factor reprogramming premix mRNA (ABP-SC-6FMRNA) that is referenced in 
their study, I found that the addition of this mRNA to a concentration of 400ng/ml or higher 
would reproducibly induce widespread cell death. This occurred even in the presence of 
increased B18R levels or additional MEFs that act to counteract cytotoxicity. This suggests 
that there are other variables for example cell density, age and viability that impact a cell’s 
ability to tolerate the stresses induced by the addition of mRNA and furthermore its ability 
to be reprogrammed. In essence, reprogrammings can exhibit variations in kinetics and 
efficiencies despite using the same cell line and the same mRNAs highlighting either the 
process is stochastic or that there are potential unconsidered variables that impact the 
process. Our method is more accommodating than existing methods as it considers more of 
these variables such as proliferative capacity and cell viability throughout reprogramming. 
  
While efforts have been made to gain insights in to the mechanisms that drive 
reprogramming including the role of the reprogramming factors OCT4, SOX2, KLF4 and cMYC 
[52, 58, 61-63], basic research is still required that is focused on obtaining detailed, 
molecular insights into the reprogramming process. It has been shown that reprogramming 
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is facilitated when transcription factors are bound to potent transcriptional activation 
domains such as that of MYOD1 [68]. We also found this to be the case and demonstrated 
that the kinetics of reprogramming could be improved when OCT4 was replaced with M3O, 
comprising a fusion protein between OCT4 and the TAD of MYOD1, and thus supports the 
notion that reprogramming can be accelerated via better recruitment of chromatin 
modifying proteins. 
 
In addition to reprogramming kinetics, the efficiency is also important. Low efficiencies 
hinder the ability to study reprogramming intermediates that provide insights into the 
mechanisms that underlie the process. Improving the efficiency of reprogramming is 
important considering that iPS cells exhibit heterogeneity, genetic instability and display 
varying levels of epigenetic reprogramming [191]. In a study that characterised 20 hESC lines 
and 12 iPS cell lines it was found that each cell line contained several genes that were 
expressed at notably different levels [191]. Another study found that heterogeneity could be 
observed in iPS cell lines that had been derived from the same individual [192]. In line with 
these findings, we found that two iPS cell lines we had created displayed notable 
differences. For example, the 5AB PiPS and 7AB PiPS cell lines reproducibly displayed 
differences in the expression of SSEA-3, 75% and 98% respectively despite expressing similar 
levels of SSEA-1. This could suggest that the 7AB PiPS cells are more refractory to 
differentiation or that they may contain a genomic abnormality despite being karyotypically 
normal and not displaying an abnormal copy number for BCL2L1. The 5AB PiPS cell line also 
did not express GATA2, ISL1 or PAX6 when induced to differentiate spontaneously as 
embryoid bodies for ten days highlighting differences regarding their capacity to 
differentiate. Functional heterogeneity amongst iPS cell lines has been previously 
documented [192]. In this study, it was suggested that differences in the functional 
properties of iPS cells may have been caused by epigenetic differences. It is conceivable that 
 
198 
the epigenetic status of the 5AB PiPS and 7AB PiPS cell lines had been erased and 
remodelled to different extents, which may have influenced their characteristic differences. 
Bisulphite sequencing would have helped to evaluate the phenotypic differences observed 
between iPS cell lines. For example, why were there differences in mRNA levels between 
two clonal lines (Figure. 3.9) derived from the same reprogramming? In addition, why did 
the 7AB PiPS cell line express SSEA-3 in 98% of the cells after 5 days in culture – is it less 
susceptible to differentiation? Analysing patterns of DNA methylation in the iPS cell lines 
derived from BJ fibroblasts through bisulphite sequencing would have complemented their 
characterisation. It would allow for the epigenetic status of the iPS cell lines generated to be 
compared between each other and to control pluripotent stem cell lines to provide insights 
into the similarities and differences between their epigenetic landscapes. It may transpire 
that the characteristic differences observed between iPS cell lines is attributable to varying 
levels of epigenetic remodelling that has occurred following reprogramming. 
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6.2 mRNAs can achieve partial reprogramming of neuroblastoma cells while fully 
reprogrammed iPS cells can be generated when the Sendai virus delivery vector is used 
 
Following rounds of mRNA-mediated neuroblastoma reprogramming, neuroblastoma-
derived iPS cells (SeViPS-NB2) were successfully generated using Sendai viral methods. SK-N-
SH cells were sent to Anna Falk’s group at the Karolinska Institute in Sweden to be 
reprogrammed using the Sendai virus as a means for introducing the reprogramming factors: 
OCT4, SOX2, KLF4, cMYC into SK-N-SH cells. The neuroblastoma-derived iPS cells generated 
were sent back to us at passage fifteen. When characterised by qPCR these cells were found 
to endogenously express genes associated with pluripotency, OCT4, SOX2, KLF4, cMYC, 
LIN28 and NANOG. The cells were also capable of tri-lineage differentiation when directly 
differentiated as embryoid bodies for ten days in defined conditions (Table 2.4). The cells 
also expressed SSEA-1, SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 to similar levels expressed in 
undifferentiated hESCs signifying that the SeViPS-NB2 cells were indeed pluripotent. The 
gene expression and cell surface marker expression profile of the SeViPS-NB2 cell line is 
consistent with another study that derived iPS cells from neuroblastoma cell lines [193]. 
 
In addition to reprogramming SK-N-SH cells using Sendai viral vectors, we also tested the 
applicability of using mRNAs to reprogramme SK-N-SH cells and we have demonstrated that 
a population of cells within the cancer cell population can be induced to express TRA-1-60, a 
marker of pluripotent stem cells, following the repeated addition of reprogramming factor 
mRNAs (ABP-SC-SEIPSET). Interestingly, this was achieved when using an mRNA cocktail that 
did not include M3O mRNA, which raises a question over the suitability of using potent 
transcriptional activation domains to open up chromatin when reprogramming SK-N-SH 
cells. Transcription factors bound to TADs improve chromatin accessibility through the 
recruitment of epigenetic modifiers that facilitate the activation of repressed genes, in some 
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cases thousands of genes [194]. However this is somewhat uncontrolled in that the genes 
that are activated are either consistent with the role of the transcription factor that is bound 
to the TAD or through indirect interactions. It is possible that transcription factors bound to 
TADs can activate the transcription of apoptosis-inducing genes in SK-N-SH cells and this may 
inhibit the success of reprogramming. However, the induction of TRA-1-60 expression within 
a subpopulation of SK-N-SH cells indicated that the SK-N-SH cell line may be 
reprogrammable using non-integrating techniques. Despite the induction of TRA-1-60, these 
cells did not form a stable iPS cell line and following continuous passaging reverted back to a 
phenotype indistinguishable from the parental SK-N-SH cells. This suggests that the cells had 
undergone partial reprogramming or that the TRA-1-60 population contained a sub-
population of cells that were incompletely reprogrammed and may have outcompeted any 
bona fide iPS cells that had emerged. The TRA-1-60 population was found to contain a sub-
population of cells that may have been partially reprogrammed. During reprogramming, 
mWASABI mRNA is added in to the cell cultures to monitor the uptake of mRNA into the 
cells and is lost in the cells that convert to a fully reprogrammed state [179, 195]. We found 
that the TRA-1-60+ve cells induced during SK-N-SH reprogramming contained a subpopulation 
of mWASABI+ve cells that may have represented a partially reprogrammed state, which 
contributed to a reduction in reprogramming efficiency. 
 
Another study that sought to reprogramme a set of neuroblastoma cell lines reported 
difficulties in establishing iPS cell lines, reporting only one of four neuroblastoma cell lines 
examined successfully generating iPS cells [193]. There is a possibility that not all cancer cell 
lines possesses the ability to obtain the characteristics of iPS cells, however our work 
suggests that the mechanisms required to execute reprogramming of the SK-N-SH cell line 
are not well understood. Several reports suggest that somatic cell lines that endogenously 
express combinations of the reprogramming factors OCT4, SOX2, KLF4 and cMYC are more 
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susceptible to reprogramming [196-198]. We found that SK-N-SH cells endogenously express 
cMYC but do not express any of the other reprogramming factors and this may contribute in 
part to the difficulties encountered in reprogramming this cell line.   
 
Two reasons why mRNA transfection, unlike Sendai viral delivery of the reprogramming 
factors, was incapable of generating iPS cells from SK-N-SH cells, possibly include 
transfection reagent-related cytotoxicity and the transient nature of mRNAs during the 
transfection procedure. Considering that 200ng/ml of 6-factor premix mRNA (ABP-SC-
6FMRNA) was enough to succumb SK-N-SH cells to apoptosis suggests that perhaps a lower 
mRNA dose-per-cell ratio is more favourable when reprogramming this particular cell line. 
Using a smaller dose however may fail to achieve sufficient mRNA levels required to execute 
reprogramming as discussed previously.  
 
Incomplete reprogramming may occur as a result of cells receiving insufficient levels of 
mRNA [76] that can occur if the mRNA dose is not increased as the cells proliferate. To 
combat this, neuroblastoma reprogramming was initiated on SK-N-SH cells following a 
period of treatment with retinoic acid. We found that retinoic acid induced growth arrest in 
treated cells (Figure. 4.5), an effect observed in both SK-N-SH cells [174] and other 
neuroblastoma cell lines [173]. This allowed for the transfection phase of reprogramming to 
be elongated but this had no positive effect on the outcome of reprogramming. 
Reprogramming could not be achieved in SK-N-SH cells following the addition of the Allele 
Biotech 6-factor reprogramming premix (ABP-SC-6FMRNA), a finding that was shown in our 
work and in agreement with others [39] to enhance the reprogramming of fibroblasts. This 
highlights disparities between fibroblast and neuroblastoma reprogramming in that while 
iPS cell induction from fibroblasts can be enhanced by optimising the mRNA type, cell 
densities and dose ramping, this is not directly translational to neuroblastoma cells.  
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We found that cMYC mRNA levels decreased following the independent or collective 
addition of reprogramming factor mRNAs (OCT4, SOX2, KLF4, cMYC, LIN28 and NANOG) into 
SK-N-SH cells. This finding was consistent between both the Allele biotech 6-factor 
reprogramming premix mRNA (ABP-SC-6FMRNA) and the mRNAs in-vitro transcribed from 
the Allele Biotech IVT templates (ABP-SC-SEIPSET). One report explains that cMYC and MYCN 
expression levels are inversely correlated [199] therefore the repression of endogenous 
cMYC mRNA levels may be as a result of MYCN amplification. It is unknown whether the 
introduction of exogenous mRNAs in SK-N-SH cells results in MYCN amplification although 
this mechanism may explain why cMYC mRNA levels are repressed following the addition of 
exogenous mRNAs. Whether MYCN amplification in SK-N-SH cells inhibits reprogramming, is 
something that requires testing. It has recently been demonstrated that cMYC has a general 
role in amplifying gene expression for genes with an active promoter in tumour cells [200]. 
Overexpressing cMYC in tumour cells may prevent the cells from being reprogrammed by 
encouraging the active transcription of oncogenes [201] that have been reported to 
interfere with mechanisms, such as the mesenchymal to epithelial transition, that are 
necessary for reprogramming to take place. Considering it has been reported in mouse that 
cMyc is dispensable for reprogramming mouse fibroblasts [202], it would be appropriate to 
determine whether reprogramming without cMYC promotes reprogramming of 
neuroblastoma cells. A greater understanding of the complex genetic and epigenetic barriers 
to reprogramming would greatly assist in the generation of mRNA-mediated neuroblastoma-
derived iPS cells. 
 
We showed that reprogramming BJ fibroblasts can be achieved in 7 days following the 
repeated addition of mRNAs encoding the reprogramming factors: M3O, SOX2, KLF4, cMYC, 
LIN28 and NANOG. This increases to ~17 days when the reprogramming factors are 
introduced into BJ fibroblasts using the Sendai virus [203] or 6 weeks when introduced into 
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SK-N-SH cells, a length of time consistent with other reports [193]. One reason why it may 
take longer to reprogramme SK-N-SH cells compared to BJ fibroblasts is due to epigenetic 
differences between the two cell lines. A larger degree of chromatin remodelling is 
necessary in SK-N-SH cells before an endogenous pluripotency network can be activated. 
Therefore it may be beneficial to use an epigenetic modifier, such as 5-azacytidine, during 
the reprogramming of SK-N-SH cells to facilitate the generation of iPS cells. The other option 
would be to reprogramme a neuroblastoma cell line that endogenously expresses one or 
more of the reprogramming factors such as SK-N-AS or SK-N-DZ that express NANOG, KLF4 
and NANOG (SK-N-AS) and OCT4, and KLF4 (SK-N-DZ) respectively [193]. 
 
Overall, our findings support the possibility that mRNA reprogramming can generate iPS cells 
from cell lines other than fibroblasts, such as those with a disease genotype, and this in the 
future may lead to the creation of integration-free iPS cells that provide insights into the 
molecular mechanisms that underlie disease development.    
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6.3 MYOD1 mRNA transdifferentiates fibroblasts to myoblasts that fuse to form multi-
nucleated myotubes 
 
We have provided proof-of-principle that mRNAs can be used to direct cell fate by 
successfully and reproducibly transdifferentiating fibroblasts to myoblasts through the 
repeated addition of MYOD1 mRNA. The resultant myoblasts were functionally 
characterised by their ability to differentiate to form multinucleated myotubes. We have 
also provided a methodology involving cell sorting that facilitates the fusing of myoblasts 
that can be used to validate the differentiation capacity of these cells. Validating the 
formation of myotubes was based on the co-location of multiple nuclei in one cell that 
expressed muscle markers, NCAM and DESMIN. The success of our study warrants the 
exploration of a broader number of mRNAs that may be used to direct cell fate, to facilitate 
a greater understanding of the mechanisms involved during transdifferentiation. 
 
Myotubes are derived from mono-nucleated myoblasts that have fused together and share a 
single cell membrane [204]. This is the only mRNA approach on human fibroblasts that has 
been reported and therefore provides proof of principle that mRNAs can directly convert 
fibroblasts to an alternative somatic cell type. The timescale for this approach was 
consistent with two other reports that used mRNA to transdifferentiate somatic cells to 
myoblasts although these reports used alternative transfection and transdifferentiation 
mediums and did not use human fibroblasts. The first report [76] isolated myoblasts by 
differentiating iPS cells to an unknown cell type(s) before transdifferentiating with MYOD1 
mRNA and the second report [205] transdifferentiated murine fibroblasts. It is impossible to 
determine whether the spontaneously differentiated population in the first report was 
indeed enriched for fibroblasts as no characterisation on this population was performed. 
Another problem is that it is conceivable that the starting population may have contained 
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myoblasts as a result of spontaneous differentiation. Without any characterisation on the 
differentiated population of cells it is difficult to ascertain the somatic cell type(s) that were 
transdifferentiated and therefore it cannot be said that fibroblasts were indeed the cell type 
that converted to myoblasts. The second report was performed on murine fibroblasts 
providing proof of principle for investigating whether the same could be achieved in human 
fibroblasts, the results of which have been shown here. Our results show direct conversion 
of human fibroblasts to myoblasts but also provide proof of concept that mRNAs can be 
used a tool to convert one cell type to another. There is no obvious reason as to why this 
approach could not be used to look at differentiation pathways or the function of other 
genes, particularly when other reports of transdifferentiation, for example to the neural 
crest [93] or cardiomyocytes [91], can be achieved by overexpressing a select few defined 
factors. 
 
Myoblast transdifferentiation has been performed using an inducible system comprising a 
tetracycline-regulated lentiviral delivery vector encoding MYOD1 [194] that allows for the 
timing and magnitude of MYOD1 expression to be controlled. This study tested whether the 
kinetics of transdifferentiation could be improved by using engineered variants of the 
MYOD1 vector containing different transcriptional activation domains (TADs). All constructs 
containing variants of the TAD had improved kinetics compared to wildtype MYOD1 
however the fastest conversion rate was achieved after 10 days. We found that myoblasts 
could be generated from fibroblasts using wildtype MYOD1 mRNA by day 7. The difference 
in kinetics may be attributable to the different delivery mechanisms used to introduce the 
MYOD1 transcription factor into fibroblasts, a finding consistent between delivery methods 
used for reprogramming [206]. 
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In addition to high-content screening, which is typically performed to identify the presence 
of transdifferentiated myoblast-like cells, I extended the characterisation to functionally test 
the myoblast-like cell’s capacity to differentiate in to multinucleated myotubes. This 
presented a problem given the myoblast conversion frequencies from two separate 
experiments were 0.08% and 0.4% based on NCAM+ve expression. This meant that there was 
considerable space between converted myoblasts that limited the number of myoblast 
fusion events that could take place. Two other studies have reported myogenic conversion 
frequencies of 25% using cDNA [148] and 10%-40% using MYOD1 mRNA [76]. In the mRNA 
study, the quantification of efficiency was calculated based on adding the number of nuclei 
that expressed Myogenin to the number of cells that expressed Myosin Heavy Chain, making 
comparison difficult to our work that based efficiency on the number of cells that expressed 
NCAM. In our work, generating myotubes was made possible by sorting the cells for NCAM 
prior to the addition of the transdifferentiation medium to enrich the population for 
myoblasts and therefore increasing the likelihood that myoblasts fusion events would occur. 
Following this strategy gave rise to multinucleated myotubes, presumably because multiple 
myoblasts were now within close proximity to one another. As myoblasts and myotubes 
both express NCAM and DESMIN it would be beneficial to have expanded the panel of 
markers to further distinguish between the two cell phenotypes. Immunostaining with 
myosin heavy chain and Phalloidin would have demonstrated the striated pattern that is 
characteristic of ACTIN-MYOSIN banding found in myotubes [207]. The electrophysiological 
competence of myotubes could be characterised through patch clamping that would test 
whether the myotubes contract when electrically stimulated, a characteristic of functional 
skeletal muscle. Staining the myotubes for Myosin Heavy Chain, a skeletal muscle marker, 
and Phalloidin that binds to filamentous-Actin to highlight the striated pattern characteristic 
of muscle fibres [208], would have further facilitated unambiguous validation.  
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Further alterations to the methodology that we had implemented that are in contrast to the 
reports of other transdifferentiation experiments include the use of different mediums used 
throughout transdifferentiation. The medium we used when mRNAs were added to the cells 
had the composition of a typical myoblast growth medium containing bFGF and human 
insulin solution while the transdifferentiation medium contained only DMEM F12 and 
insulin. These mediums had distinctly different compositions to the DMEM 10% FCS or Opti-
MEM-based mediums that have been used in other studies but were chosen because 
previous attempts to transdifferentiate fibroblasts in DMEM 10% FCS had proven 
unsuccessful. Nevertheless, myoblast conversion did not occur in the absence of MYOD1 
mRNA when fibroblasts were cultured in the myoblast growth medium or 
transdifferentiation mediums alone. Nor did they convert to myoblasts following four, once-
daily mock transfections or as a result of spontaneous differentiation determined by the 
absence of NCAM and DESMIN expressing cells in these conditions. This suggests that 
MYOD1 mRNA is they key component required for myoblast conversion and acts as proof of 
principle for mRNA-mediated transdifferentiation. This opens up the door for further 
transdifferentiation studies to be performed using other differentiation-specific mRNAs to 
direct fibroblasts or other somatic cell types to alternative cell fates. 
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6.4 Concluding Remarks 
 
We have shown that mRNAs are an efficient tool for reprogramming and transdifferentiating 
fibroblasts. Reprogramming can be enhanced by using mRNAs encoding transcription factors 
bound to potent transcriptional activation domains that better facilitate the recruitment of 
chromatin modifying proteins. Reprogramming can also be accelerated by employing a dose 
ramping approach that improves the survivability of cells during the addition of mRNAs by 
reducing the number of cells that succumb to mRNA-induced apoptosis. Further 
improvement to the kinetics and efficiency of reprogramming could be facilitated by 
improving our understanding of the underlying mechanisms, such as the temporal 
requirements of factor expression, required to successfully generate iPS cells. One study 
investigated the temporal requirements of the reprogramming factors required to generate 
iPS cells using lentiviral vectors encoding four reprogramming factors (OCT4, SOX2, KLF4 and 
cMYC) bound to fluorescent proteins [53]. However, the study did not elucidate the timings 
that the reprogramming factors should be added or the length of sustained overexpression 
required for each reprogramming factor. Understanding when the reprogramming factors 
are and are not required will benefit reprogramming in two ways. Firstly, it will mitigate 
mRNA-induced cytotoxicity by lowering the daily dose of mRNA used throughout 
reprogramming as a consequence of removing unnecessary reprogramming factors from the 
mRNA cocktail. Secondly, it will enable us to gain insights into the mechanisms involved in 
the induction of pluripotency that may help to make it easier to reprogramme disease cell 
lines in the future. 
 
Following on from the successful generation of iPS cells derived from the SK-N-SH 
neuroblastoma cell line using the Sendai virus (SeViPS-NB2), it is conceivable that with 
further optimisation, an mRNA approach to reprogramming SK-N-SH cells will be achieved 
 
209 
quickly and efficiently. Neuroblastoma cells appear to be more resistant to cellular 
reprogramming induced by exogenous factors translated from mRNA compared to those 
delivered using Sendai viral vectors. Gaining insight into the mechanisms involved in 
epigenetic reprogramming of cancer cells may reveal underlying mechanisms involved in 
cancer cell resistance to reprogramming when using different delivery methods, such as 
mRNA or the Sendai virus. In addition, it would be interesting to assess the consequences of 
differentiating the SeViPS-NB2 cell line in the context of the neural crest to study the 
behaviour of iPS cells carrying a neuroblastoma genome. Differentiation toward the disease 
cell of origin may help to recreate the developmental conditions required to model aspects 
of neuroblastoma development.    
 
The success of mRNA-mediated transdifferentiation acts as a proof-of-concept for using 
mRNAs as a tool for converting the phenotype of one cell to another. It would be beneficial 
to apply this proof-of-concept to an array of other genes so that further platforms for 
studying the mechanisms that underlie differentiation pathways can be created. Recently it 
has been demonstrated that the overexpression of SOX10 in the presence of epigenetic 
modifiers and growth factors within human fibroblasts is sufficient to induce a neural crest 
phenotype [155]. In line with generating a panel of integration-free iPS cells derived from SK-
N-SH cells, it would seem pertinent to determine whether SOX10 mRNA could be used to 
differentiate SeViPS-NB2 cells toward the neural crest. 
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